



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION


(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/10/16
(87) Date publication PCT/PCT Publication Date: 2019/04/25
(85) Entrée phase nationale/National Entry: 2020/04/14
(86) N° demande PCT/PCT Application No.: EP 2018/078210
(87) N° publication PCT/PCT Publication No.: 2019/076880
(30) Priorité/Priority: 2017/10/16 (US62/572,944)

(51) Cl.Int./Int.Cl. *C12N 15/861* (2006.01),
A61K 39/235 (2006.01)
(71) Demandeur/Applicant:
GLAXOSMITHKLINE BIOLOGICALS SA, BE
(72) Inventeur/Inventor:
COLLOCA, STEFANO, IT
(74) Agent: NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) Titre : VECTEURS ADENOVIRAUX SIMIENS COMPRENANT DEUX CASSETTES D'EXPRESSION
(54) Title: SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES

FIG. 7



(57) **Abrégé/Abstract:**

A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

25 April 2019 (25.04.2019)



(10) International Publication Number

WO 2019/076880 A1

(51) International Patent Classification:

C12N 15/861 (2006.01) A61K 39/235 (2006.01)

(21) International Application Number:

PCT/EP2018/078210

(22) International Filing Date:

16 October 2018 (16.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/572,944 16 October 2017 (16.10.2017) US

(71) Applicant: GLAXOSMITHKLINE BIOLOGICALS

SA [BE/BE]; rue de l'Institut 89, 1330 Rixensart (BE).

(72) Inventor: COLLOCA, Stefano; ReiThera Srl, Via Salaria

73, Rome (IT).

(74) Agent: JENKINSON, Kay; GlaxoSmithKline, Global

Patents (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES

FIG. 7



(57) **Abstract:** A simian adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises a transgene and a promoter, and wherein the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication.



WO 2019/076880 A1

TITLE

SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES

SEQUENCE LISTING

- 5 The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on October 11, 2018, is named VU66441A_WO_SL.txt and is 178,926 bytes in size.

FIELD OF THE INVENTION

- 10 This invention is in the field of recombinant adenoviral vectors. The invention relates to an adenoviral vector comprising two expression cassettes. In particular, the invention relates to a simian adenovirus such as a chimpanzee (chimp) adenovirus comprising two expression cassettes.

15 BACKGROUND OF THE INVENTION

Recombinant adenoviruses are useful in gene therapy and as vaccines.

- Human adenoviruses have been widely used for gene transfer applications due to their large transgene capacity and ability to achieve highly efficient gene transfer in a variety of target
20 tissues.

- However, most humans are exposed to and develop immunity to human adenoviruses. Therefore, there is a demand for vectors which effectively deliver molecules to a target and minimize the effect of pre-existing immunity to human adenovirus serotypes. Simian
25 adenoviruses are effective in this regard; they are sufficiently closely related to human viruses to be effective in inducing immunity to delivered exogenous antigens to which humans have little or no pre-existing immunity. Therefore, viral vectors based on simian adenoviruses can provide an alternative to the use of human derived adenoviral vectors for the development of nucleic acid based vaccines.

30

Replication defective adenoviruses deliver their genome to the interior of a cell and, because they do not replicate, do not amplify the transgene payload. Typically, the E1 gene is replaced with a transgene cassette comprising a promoter of choice and a nucleic acid sequence

corresponding to a gene or genes of interest, resulting in a replication defective recombinant virus.

There is a need in the art for improved recombinant adenoviruses.

5

SUMMARY OF THE INVENTION

The invention relates to a simian adenoviral vector comprising two expression cassettes. In particular, the invention relates to a simian adenovirus such as a chimpanzee (chimp) adenovirus comprising two expression cassettes. Examples of suitable chimp adenoviruses include ChAd155 and ChAd83.

10

The adenoviral vectors of the invention are useful as components of immunogenic compositions for the induction of an immune response in a subject, methods for their use in treatment and processes for manufacture.

15

The term "vector" refers to an agent (such as a plasmid or virus) that contains or carries genetic material and can be used to introduce exogenous genes into an organism. The adenoviral vector of the present invention is derived from a non-human simian adenovirus, also referred to as a "simian adenovirus". Preferably, the simian adenoviral vector of the present invention is a simian adenovirus.

20

Each expression cassette in the adenoviral vector of the invention comprises a transgene and a promoter. A "transgene" is a nucleic acid sequence, heterologous to the vector sequences flanking the transgene, which encodes a polypeptide of interest. The nucleic acid coding sequence is operatively linked to regulatory components in a manner which permits transgene transcription, translation, and/or expression in a host cell. A "promoter" is a nucleotide sequence that permits the binding of RNA polymerase and directs the transcription of a gene. Typically, a promoter is located in a non-coding region of a gene, proximal to the transcriptional start site.

25

30

In adenoviral vectors of the invention, the first expression cassette is inserted in the E1 region of the virus, and the second expression cassette is inserted into a second region of the adenoviral vector.

In a simian adenoviral vector comprising two expression cassettes of the invention, the first expression cassette is inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication. A region of the adenoviral vector genome is considered “compatible with vector replication” if disruption of this region would not affect the ability of the adenoviral vector to replicate.

Preferably, in adenoviral vectors of the invention, the first expression cassette is inserted in the E1 region of the virus, and the second expression cassette is inserted into the E3, HE1 or HE2 region of the adenoviral vector. As is well known in the art, the E3 genes are expressed in the early phase of transduction to prepare the host cell for viral replication. E3 is involved in immune modulation. The term “HE1” is used to describe a site located between the stop codons of L5 and E4. The term “HE2” has been used to define a site located between the end of the ITR and the cap site of E4 mRNA.

For example, in a ChAd155 adenovirus vector:

- HE1 ChAd155: insertion site between bp 34611 and 34612 of SEQ ID NO: 1.
- HE2 ChAd155: insertion site between bp 37662 and 37663 of SEQ ID NO: 1.

In another example, in a ChAd83 adenovirus vector:

- HE1 ChAd83: insertion site between bp 33535 and 33536 of SEQ ID NO: 2.
- HE2 ChAd83: insertion site between bp 36387 and 36388 of SEQ ID NO: 2.

As the first expression cassette is inserted in the E1 region of the adenoviral vector, the native E1 region is deleted. In order to increase the cloning capacity of the vector, the native E3 region can be removed from the adenoviral vector. The native E3 region can be deleted from the adenoviral vector in embodiments of the invention where the second expression cassette is inserted in the E3 region, or in embodiments where the second expression cassette is not inserted into the E3 region. The insertion in HE1 or HE2 site doesn't require deletion of any specific sequence of the vector backbone.

Preferably, the second expression cassette is inserted into the HE1 or HE2 region of the adenoviral vector. Most preferably, the second expression cassette is inserted in the HE2

region of the adenoviral vector. In one embodiment, the native E3 region is deleted from the adenoviral vector to increase the cloning capacity of the vector, and the second expression cassette is inserted in the HE1 or HE2 region of the adenoviral vector.

- 5 In embodiments of the invention, the first expression cassette of the adenoviral vector may comprise a human CMV or an enhanced human CMV promoter, and/or the second expression cassette may comprise a human CMV or an enhanced human CMV promoter.

10 In a preferred embodiment, the first and second expression cassettes comprise different promoters. For example, in one embodiment, the first expression cassette may comprise a human CMV promoter and the second expression cassette an enhanced human CMV promoter (or *vice versa*).

15 In one aspect of the invention, there is provided an adenoviral vector of the invention, wherein the first expression cassette is inserted in the E1 region of the virus, and the second expression cassette is inserted in a region of the adenoviral vector that is compatible with vector replication, wherein at least one of the first and second expression cassette comprises an enhanced CMV promoter. In some embodiments, the enhanced hCMV promoter can include a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 20 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 6. In some embodiments, the promoter comprises or consists of a nucleic acid sequence of SEQ ID NO: 6.

25 Adenoviral vectors of the invention are derived from a simian adenoviral vector, for example, from chimpanzees (*Pan troglodytes*), bonobos (*Pan paniscus*), gorillas (*Gorilla gorilla*) and orangutans (*Pongo abelii* and *Pongo pygmaeus*). Chimpanzee adenoviruses include, but are not limited to AdY25, ChAd3, ChAd19, ChAd25.2, ChAd26, ChAd27, ChAd29, ChAd30, ChAd31, ChAd32, ChAd33, ChAd34, ChAd35, ChAd37, ChAd38, ChAd39, ChAd40, ChAd63, ChAd83, ChAd155, ChAd15, SadV41, sAd4310A, sAd4312, SAdV31, SAdV-A1337, ChAdOx1, 30 ChAdOx2 and ChAd157. Preferably, the simian adenoviral vector of the invention is a ChAd83 or ChAd155 adenovirus vector, most preferably a ChAd155 adenovirus vector.

Preferably, the adenoviral vector of the invention has a seroprevalence of less than 30%, preferably less than 10% in human subjects and, most preferably, no seroprevalence in human subjects.

- 5 In a preferred embodiment, the simian adenoviral vector of the invention is capable of infecting a mammalian cell.

In one embodiment, the first and second expression cassettes of the adenoviral vector of the invention comprise transgenes from respiratory syncytial virus (RSV). For example, in one
10 embodiment, one of the expression cassettes comprises an RSV F antigen, and the other expression cassette comprises RSV M and N antigens. In such embodiments, the vector preferably encodes an RSV F0ΔTM antigen (fusion (F) protein deleted of the transmembrane and cytoplasmic regions), and RSV M2-1 (transcription anti-termination) and N (nucleocapsid)
15 antigens.

The present invention also provides a composition comprising a simian adenoviral vector and a pharmaceutically acceptable excipient.

In addition, the present invention provides a simian adenoviral vector or composition comprising
20 such an adenoviral vector for use as a medicament, a vaccine, and/or for the therapy or prophylaxis of a disease.

The invention also provides a method of inducing an immune response in a subject comprising administering the simian adenoviral vector or composition to the subject.

25

DESCRIPTION OF THE FIGURES

FIG. 1: Simian adenoviral constructs with a single expression cassette. Inverted terminal repeats (ITR) flank the 3' and 5' ends; E1 is the early gene 1; CMV is the cytomegalovirus
30 promoter; CASI is the CASI promoter, RG is a model antigen, WPRE is the Woodchuck Hepatitis Postranscriptional Regulatory Element, ΔE3 denotes that the early gene 3 is deleted; fiber denotes the adenoviral gene encoding the fiber protein and E4 is the early gene 4.

Three different simian adenoviral vectors are shown in FIG. 1. The vector of FIG. 1(i) was constructed by inserting a transgene expression cassette in place of the E3 region of the adenoviral genome ("RC1") (top panel), the vector of FIG. 1(ii) was formed by inserting a transgene expression cassette in the HE1 region, *i.e.*, between the stop codons of the fiber gene and the E4 region ("RC3") (middle panel), and the vector of FIG. 1(iii) was made by inserting a transgene expression cassette in the HE2 region, *i.e.*, between the end of the ITR and the cap site of E4 mRNA ("RC2") (bottom panel).

FIG. 2A: Production of ChAd155 and ChAd83 with transgene cassette inserted in E3 and HE2 sites (RC1 and RC2 vectors of FIG. 1) in a primary human cell line.

FIG. 2B: Production of ChAd83 with transgene cassette inserted in E3, HE1 and HE2 (the RC1, RC2 and RC3 vectors of FIG. 1) in a human MRC5 cell line at two and seven days post-infection. Cells were infected at multiplicities of infection of 250 and 1250.

FIG. 3A: Total viral genome copy number of RC1 and RC2 vector (ChAd155 and ChAd83) of FIG. 1 in a primary human cell line.

FIG. 3B: Total viral genome copy number of RC1, RC2 and RC3 versions of ChAd83 vector of FIG. 1 in a human MRC5 cell line at two and seven days post-infection. Cells were infected at multiplicities of infection of 250 and 1250.

FIG. 4: Total viral genome copy number of ChAd155 RC1 and RC2 and ChAd83 RC1 and RC2 vectors of FIG. 1 in a murine cell line (FIG. 4(a), top panel) and in a non-human primate cell line (FIG. 4(b), bottom panel). Cells were infected at multiplicities of infection of 50 and 250.

FIG. 5: Comparison of the expression levels of ChAd155 RC1 and RC2 vectors expressing a model rabies glycoprotein (RG) transgene in a murine cell line, demonstrated by western blot at two and five days post-infection (FIG. 5(a), top panel). Comparison of the expression levels of ChAd155 RC1 and RC2 vectors with ChAd83 RC1 and RC2 vectors expressing a model rabies glycoprotein (RG) transgene in a murine cell line, demonstrated by western blot at two and five days post-infection (FIG. 5(b), bottom panel). Cells were infected at multiplicities of infection of 50, 250 and 1250.

FIG. 5(c): Comparison of the expression levels of ChAd83 RC1, RC2 and RC3 vectors expressing a model rabies glycoprotein (RG) transgene in a human MRC5 cell line, demonstrated by western blot at two and seven days post-infection. Cells were infected at multiplicities of infection of 250 and 1250.

5

FIG. 6: Another simian adenoviral construct of with a single expression cassette. Inverted terminal repeats (ITR) flank the 3' and 5' ends; human CMV (hCMV) is the cytomegalovirus promoter; F Δ TM (F0DTM) and N.M2-1 are RSV antigens; 2A is a self-cleaving linking sequence; Δ E4 denotes that the early gene 4 is deleted; fiber denotes the adenoviral gene encoding the fiber protein. In the vector of FIG. 6, the transgene expression cassette is inserted in place of the E1 region of the adenoviral genome.

10

FIG. 7: A simian adenoviral construct according to the invention with a dual expression cassette. Inverted terminal repeats (ITR) flank the 3' and 5' ends; human CMV (hCMV) is the cytomegalovirus promoter; Enhanced hCMV is the enhanced cytomegalovirus promoter; N-M2-1 and F Δ TM (F0DTM) are the RSV antigens; WPRE is the Woodchuck Hepatitis Postranscriptional Regulatory Element; Δ E3 denotes that the early gene 3 is deleted; fiber denotes the adenoviral gene encoding the fiber protein; and Ad5E4orf6 is a substitute in the early gene 4 (E4) region.

15

20

The vector of FIG. 7 was constructed by inserting a first transgene expression cassette in place of the E1 region of the adenoviral genome, and a second transgene expression cassette in the HE2 region, *i.e.*, downstream of the right ITR.

25

FIG. 8: Comparison of the expression levels of vectors expressing F0 Δ TM transgene in a MRC5 cell line, demonstrated by western blot at 48 hours and 96 hours post-infection under non-reducing conditions. Cells were infected at multiplicities of infection of 500 and 1250.

30

FIG. 9: Comparison of the expression levels of vectors expressing NM2-1 transgene in a MRC5 cell line, demonstrated by western blot at 48 hours post-infection under reducing conditions. Cells were infected at multiplicities of infection of 250 and 1250.

FIG. 10: Comparison of the immunogenicity from ChAd155 vectors expressing the RSV antigen F0 Δ TM (F Δ Tm). The data was collected at 4 weeks and 8 weeks after vaccination with a dose of 5×10^8 virus particles.

5 FIG. 11: Comparison of the immunogenicity from ChAd155 vectors expressing the M2 RSV antigen. The data was collected at 3 weeks after vaccination with a dose of either 10^7 or 10^6 virus particles.

FIG. 12A and 12B: Illustrate the results from the experiment of Example 9 to investigate the lung
10 T cell responses from ChAd155 vectors. FIG 12A shows the CD4+ response, and FIG 12B shows the CD8+ response.

Figures 13A and 13B: Show the results from the experiment of Example 9 to investigate the peripheral T cell responses from ChAd155 vectors. FIG 13A shows the PBMC CD4+ response,
15 and FIG 13B shows the PBMC CD8+ response.

FIG 14A and 14B: Also show results from Example 9. FIG. 14A shows the RSV neutralising Ab titres, and Figure 14B illustrates the ratio of the nAb from day D90 to D0.

20 FIG. 15A, 15B and 15C: Show the results of the immunogenicity experiment of Example 10.

FIG. 16A and 16B: Western blots obtained using the expression in HeLa cells of the vectors in Example 11.

25 FIG. 17: Illustrates the results of the CRPV experiment of Example 12.

FIG. 18: Shows the results of the HPV dual cassette vector characterisation of Example 13.

ANNOTATION OF THE SEQUENCES

30

SEQ ID NO: 1 – Polynucleotide sequence encoding wild type ChAd155

SEQ ID NO: 2 – Polynucleotide sequence encoding wild type ChAd83

SEQ ID NO: 3 – Polynucleotide sequence encoding the CASI promoter

SEQ ID NO: 4 – Polynucleotide sequence encoding ChAd155/RSV

SEQ ID NO: 5 – RSV F0ΔTM-N-M2-1 amino acid sequence

SEQ ID NO: 6 – Polynucleotide sequence encoding the enhanced hCMV promoter

SEQ ID NO: 7 – Polynucleotide sequence encoding the hCMV NM2 bghpolyA cassette

SEQ ID NO: 8 – NM2 amino acid (protein) sequence

5 SEQ ID NO: 9 – Polynucleotide sequence encoding the hCMV F0 WPRE bghpolyA cassette

SEQ ID NO: 10 – F0 amino acid (protein) sequence

SEQ ID NO: 11 – Amino acid sequence of a flexible linker

SEQ ID NO: 12 – Amino acid sequence of a flexible linker

10 DETAILED DESCRIPTION OF THE INVENTION

Adenoviruses

Adenoviruses are nonenveloped icosahedral viruses with a linear double stranded DNA genome of approximately 36 kb. Adenoviruses can transduce numerous cell types of several
 15 mammalian species, including both dividing and nondividing cells, without integrating into the genome of the host cell. They have been widely used for gene transfer applications due to their proven safety, ability to achieve highly efficient gene transfer in a variety of target tissues, and large transgene capacity. Human adenoviral vectors are currently used in gene therapy and vaccines but have the drawback of a high worldwide prevalence of pre-existing immunity,
 20 following previous exposure to common human adenoviruses.

Adenoviruses have a characteristic morphology with an icosahedral capsid comprising three major proteins, hexon (II), penton base (III) and a knobbed fiber (IV), along with a number of other minor proteins, VI, VIII, IX, IIIa and IVa2. The hexon accounts for the majority of the
 25 structural components of the capsid, which consists of 240 trimeric hexon capsomeres and 12 penton bases. The hexon has three conserved double barrels and the top has three towers, each tower containing a loop from each subunit that forms most of the capsid. The base of the hexon is highly conserved between adenoviral serotypes, while the surface loops are variable. The penton is another adenoviral capsid protein; it forms a pentameric base to which the fiber
 30 attaches. The trimeric fiber protein protrudes from the penton base at each of the 12 vertices of the capsid and is a knobbed rod-like structure. The primary role of the fiber protein is to tether the viral capsid to the cell surface via the interaction of the knob region with a cellular receptor. Variations in the flexible shaft, as well as knob regions of fiber, are characteristic of the different adenoviral serotypes.

The adenoviral genome has been well characterized. The linear, double-stranded DNA is associated with the highly basic protein VII and a small peptide pX (also termed mu). Another protein, V, is packaged with this DNA-protein complex and provides a structural link to the capsid via protein VI. There is general conservation in the overall organization of the adenoviral genome with respect to specific open reading frames being similarly positioned, *e.g.* the location of the E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 and L5 genes of each virus. Each extremity of the adenoviral genome comprises a sequence known as an inverted terminal repeat (ITR), which is necessary for viral replication. The 5' end of the adenoviral genome contains the 5' cis-elements necessary for packaging and replication; *i.e.*, the 5' ITR sequences (which can function as origins of replication) and the native 5' packaging enhancer domains, which contain sequences necessary for packaging linear adenoviral genomes and enhancer elements for the E1 promoter. The 3' end of the adenoviral genome includes 3' cis-elements, including the ITRs, necessary for packaging and encapsidation. The virus also comprises a virus-encoded protease, which is necessary for processing some of the structural proteins required to produce infectious virions.

The structure of the adenoviral genome is described on the basis of the order in which the viral genes are expressed following host cell transduction. More specifically, the viral genes are referred to as early (E) or late (L) genes according to whether transcription occurs prior to or after onset of DNA replication. In the early phase of transduction, the E1A, E1B, E2A, E2B, E3 and E4 genes of adenovirus are expressed to prepare the host cell for viral replication. The E1 gene is considered a master switch, it acts as a transcription activator and is involved in both early and late gene transcription. E2 is involved in DNA replication; E3 is involved in immune modulation and E4 regulates viral mRNA metabolism. During the late phase of infection, expression of the late genes L1-L5, which encode the structural components of the viral particles, is activated. Late genes are transcribed from the Major Late Promoter (MLP) with alternative splicing.

HE1 and HE2 sites were identified as potential insertion sites for a transgene since the insertion in these specific points does not interrupt the coding sequences or important regulatory sequences of a chimp adenovirus, such as a Type C or E chimp adenovirus, for example, ChAd155 and ChAd83. The HE1 and HE2 sites can be identified by sequence alignment in

any chimp adenovirus. Therefore, cloning of expression cassettes in the HE1 and HE2 sites of the ChAd genomes doesn't impact the virus replication cycle.

Adenoviral replication

5 Historically, adenovirus vaccine development has focused on defective, non-replicating vectors. They are rendered replication defective by deletion of the E1 region genes, which are essential for replication. Typically, non-essential E3 region genes are also deleted to make room for exogenous transgenes. An expression cassette comprising the transgene under the control of an exogenous promoter is then inserted. These replication-defective viruses are then produced
10 in E1-complementing cells.

The term "replication-defective " or "replication-incompetent" adenovirus refers to an adenovirus that is incapable of replication because it has been engineered to comprise at least a functional deletion (or "loss-of-function" mutation), *i.e.* a deletion or mutation which impairs the function of
15 a gene without removing it entirely, *e.g.* introduction of artificial stop codons, deletion or mutation of active sites or interaction domains, mutation or deletion of a regulatory sequence of a gene etc, or a complete removal of a gene encoding a gene product that is essential for viral replication, such as one or more of the adenoviral genes selected from E1A, E1B, E2A, E2B, E3 and E4 (such as E3 ORF1, E3 ORF2, E3 ORF3, E3 ORF4, E3 ORF5, E3 ORF6, E3 ORF7, E3
20 ORF8, E3 ORF9, E4 ORF7, E4 ORF6, E4 ORF4, E4 ORF3, E4 ORF2 and/or E4 ORF1). Suitably, E1 and optionally E3 and/or E4 are deleted. If deleted, the aforementioned deleted gene region will suitably not be considered in the alignment when determining percent identity with respect to another sequence.

25 *Vectors of the Invention*

Viral vectors based on non-human simian adenovirus represent an alternative to the use of human derived vectors for gene therapy and genetic vaccines. Certain adenoviruses isolated from non-human simians are closely related to adenoviruses isolated from humans, as demonstrated by their efficient propagation in cells of human origin. As humans develop little or
30 no immunity to simian adenoviruses, they promise to provide an improved alternative to human adenoviral uses.

"Low seroprevalence" may mean having a reduced pre-existing neutralizing antibody level as compared to human adenovirus 5 (Ad5). Similarly or alternatively, "low seroprevalence" may

mean less than about 30% seroprevalence, less than about 20% seroprevalence, less than about 15% seroprevalence, less than about 10% seroprevalence, less than about 5% seroprevalence, less than about 4% seroprevalence, less than about 3% seroprevalence, less than about 2% seroprevalence, less than about 1% seroprevalence or no detectable

5 seroprevalence. Seroprevalence can be measured as the percentage of individuals having a clinically relevant neutralizing titer (defined as a 50% neutralisation titer >200) using methods as described in Hum. Gene Ther. (2004) 15:293.

The adenoviral vector of the present invention is derived from a nonhuman simian adenovirus, also referred to as a "simian adenovirus." Numerous adenoviruses have been isolated from nonhuman simians such as chimpanzees, bonobos, rhesus macaques, orangutans and gorillas. Vectors derived from these adenoviruses can induce strong immune responses to transgenes encoded by these vectors. Certain advantages of vectors based on nonhuman simian adenoviruses include a relative lack of cross-neutralizing antibodies to these adenoviruses in the human target population, thus their use overcomes the pre-existing immunity to human adenoviruses. For example, some simian adenoviruses have no cross reactivity with preexisting human neutralizing antibodies and cross-reaction of certain chimpanzee adenoviruses with pre-existing human neutralizing antibodies is only present in 2% of the target population, compared with 35% in the case of certain candidate human adenovirus vectors (Sci. Transl. Med. (2012) 4:1).

Adenoviral vectors of the invention are derived from a simian adenovirus, e.g., from chimpanzees (*Pan troglodytes*), bonobos (*Pan paniscus*), gorillas (*Gorilla gorilla*) and orangutans (*Pongo abelii* and *Pongo pygmaeus*). They include adenoviruses from Group B, Group C, Group D, Group E and Group G. Chimpanzee adenoviruses include, but are not limited to AdY25, ChAd3, ChAd19, ChAd25.2, ChAd26, ChAd27, ChAd29, ChAd30, ChAd31, ChAd32, ChAd33, ChAd34, ChAd35, ChAd37, ChAd38, ChAd39, ChAd40, ChAd63, ChAd83, ChAd155, ChAd15, SadV41 and ChAd157 ChAd3, ChAd19, ChAd25.2, ChAd26, ChAd27, ChAd29, ChAd30, ChAd31, ChAd32, ChAd33, ChAd34, ChAd35, ChAd37, ChAd38, ChAd39, ChAd40, ChAd63, ChAd83, ChAd155, ChAd15, SadV41, sAd4310A, sAd4312, SAdV31, SAdV-A1337, ChAdOx1, ChAdOx2 and ChAd157. Alternatively, adenoviral vectors may be derived from nonhuman simian adenoviruses isolated from bonobos, such as PanAd1, PanAd2, PanAd3, Pan 5, Pan 6, Pan 7 (also referred to as C7) and Pan 9. Vectors may include, in whole or in part, a nucleotide encoding the fiber, penton or hexon of a non-human adenovirus.

In an embodiment of the adenoviral vectors of the invention, the adenoviral vector has a seroprevalence of less than 30%, less than 20%, less than 10% or less than 5% in human subjects, preferably no seroprevalence in human subjects and more preferably no
5 seroprevalence in human subjects that have not previously been in contact with a chimpanzee adenoviral vector.

In embodiments of the adenoviral vectors of the invention, the adenoviral DNA is capable of entering a mammalian target cell, *i.e.* it is infectious. An infectious recombinant adenoviral
10 vector of the invention can be used as a prophylactic or therapeutic vaccine and for gene therapy. Thus, in an embodiment, the recombinant adenoviral vector comprises an endogenous molecule for delivery into a target cell. The target cell is a mammalian cell, *e.g.* a bovine cell, a canine cell, a caprine cell, a cervine cell, a chimpanzee cell, a chiroptera cell, an equine cell, a feline cell, a human cell, a lupine cell, an ovine cell, a porcine cell, a rodent cell, an ursine cell or
15 a vulpine cell. The endogenous molecule for delivery into a target cell is an expression cassette.

In an embodiment of the invention, the vector comprises a left ITR region, a deleted E1 region, then a deleted E3 region, and, optionally, additional enhancer elements; these are followed by a
20 fiber region, an E4 region and a right ITR. Translation occurs in the rightward and leftward directions. In this embodiment, the first expression cassette is inserted in the deleted E1 region, and the second expression cassette is insertion in the deleted E3 region. In a further embodiment, the promoters of the two expression cassettes are CMV promoters. In a yet further embodiment, the enhancer element is the Hepatitis B Postranslational Regulatory
25 Element (HPRE) or the Woodchuck Hepatitis Postranslational Regulatory Element (WPRE).

In one embodiment of the invention, the vector comprises left and right ITR regions; a deleted E1 region; at least a partially deleted E3 region; a fiber region; an E4 region; two expression cassettes, each comprising: a promoter and at least one an antigen of interest and, optionally,
30 one or more enhancer elements. The first expression cassette is inserted in the deleted E1 region, and the second expression cassette is inserted at the HE1 site, *i.e.*, between the stop codons of the fiber gene and an E4 region ("the HE1 site"). The ChAd155 HE1 insertion site is between bp 34611 and 34612 of the wild type ChAd155 sequence. The ChAd83 HE1 insertion site is between bp 33535 and 33536 of the wild type ChAd83 sequence. Translation occurs in

the rightward and leftward directions. In a further embodiment, the promoters are CMV promoters. In a preferred embodiment, one promoter is a CMV promoter and the other is a eCMV promoter. In a yet further embodiment, the enhancer element is HPRE or WPRE.

- 5 In a further embodiment, the vector comprises left and right ITR regions; a deleted E1 region; at least a partially deleted E3 region; a fiber region; an E4 region; two expression cassettes, each comprising: a promoter, at least one antigen of interest and, optionally, one or more enhancer elements. The first expression cassette is inserted in the deleted E1 region, and the second expression cassette is inserted at the HE2 site, *i.e.*, between the end of the left ITR and the cap
10 site of the E4 mRNA ("the HE2 site"). The ChAd155 HE2 insertion site is between bp 37662 and 37663 of the wild type ChAd155 sequence. The ChAd83 HE2 insertion site is between bp 36387 and 36388 of the wild type ChAd83 sequence. Translation occurs in the rightward and leftward directions. In a further embodiment, the promoters are CMV promoters. In a preferred embodiment, one promoter is a CMV promoter and the other is a eCMV promoter. In a yet
15 further embodiment, the enhancer element is HPRE or WPRE (the enhancer element increases expression of the transgene).

The HE1 and HE2 sites were identified as insertion sites for a transgene, as the insertion in these specific points does not interrupt the coding sequences or regulatory sequences of
20 ChAd155 and ChAd83. Therefore, inserting expression cassettes in the HE1 or HE2 sites of the ChAd genome does not affect the viral replication cycle.

In an embodiment of the invention, the vector is a functional or an immunogenic derivative of an adenoviral vector. By "derivative of an adenoviral vector" is meant a modified version of the
25 vector, *e.g.*, one or more nucleotides of the vector are deleted, inserted, modified or substituted.

Regulatory Elements

Regulatory elements, *i.e.*, expression control sequences, include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such
30 as splicing and polyadenylation (poly A) signals including rabbit beta-globin polyA; tetracycline regulatable systems, microRNAs, posttranscriptional regulatory elements (*e.g.*, WPRE, posttranscriptional regulatory element of woodchuck hepatitis virus); sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*e.g.*, Kozak consensus

sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of an encoded product.

A "promoter" is a nucleotide sequence that permits the binding of RNA polymerase and directs the transcription of a gene. Typically, a promoter is located in a non-coding region of a gene, proximal to the transcriptional start site. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and mammals, including simians and humans. A great number of expression control sequences, including promoters which are internal, native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.

Promoters of the invention will typically be heterologous promoters. Promoters of the invention can be constitutive.

Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and mammals (including humans).

Examples of promoters include, without limitation, the TBG promoter, the retroviral Rous sarcoma virus LTR promoter (optionally with the enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer, see, e.g., Boshart et al, Cell, 41:521-530 (1985)), the CASI promoter, the SV40 promoter, the dihydrofolate reductase promoter, the β -actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1a promoter (Invitrogen).

Suitable promoters include the cytomegalovirus (CMV) promoter and the CASI promoter. The CMV promoter is strong and ubiquitously active. It has the ability to drive high levels of transgene expression in many tissue types and is well known in the art. The CMV promoter can be used in vectors of the invention, either with or without a CMV enhancer.

The CASI promoter is a synthetic promoter described as a combination of the CMV enhancer, the chicken beta-actin promoter, and a splice donor and splice acceptor flanking the ubiquitin (UBC) enhancer (US 8865881).

In some embodiments, the CASI promoter can include a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 3. In some embodiments, the promoter comprises or consists of a nucleic acid sequence of SEQ ID NO: 3.

5

In some embodiments, the enhanced hCMV promoter can include a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 6. In some embodiments, the promoter comprises or consists of a nucleic acid sequence of SEQ ID NO: 6.

10

Optionally, vectors carrying transgenes encoding therapeutically useful or immunogenic products may also include selectable markers or reporter genes. The reporter gene may be chosen from those known in the art. Suitable reporter genes include, but are not limited to enhanced green fluorescent protein, red fluorescent protein, luciferase and secreted embryonic alkaline phosphatase (seAP), which may include sequences encoding geneticin, hygromycin or purimycin resistance, among others. Such selectable reporters or marker genes (which may or may not be located outside the viral genome to be packaged into a viral particle) can be used to signal the presence of the plasmids in bacterial cells, such as ampicillin resistance. Other components of the vector may include an origin of replication.

20

A "posttranscriptional regulatory element," as used herein, is a DNA sequence that, when transcribed, enhances the expression of the transgene(s) or fragments thereof that are delivered by viral vectors of the invention. Postranscriptional regulatory elements include, but are not limited to the Hepatitis B Virus Postranscriptional Regulatory Element (HPRE) and the Woodchuck Hepatitis Postranscriptional Regulatory Element (WPRE). The WPRE is a tripartite cis-acting element that has been demonstrated to enhance transgene expression driven by certain, but not all promoters.

25

In embodiments of the invention, a ChAd155 vector may comprise one or more of a promoter, an enhancer, and a reporter gene. For example, vectors of the invention may comprise ChAd155-enhanced hCMV-SeAP, ChAd155-CASI-seAP and ChAd155-hCMV-seAP, optionally with a tetracycline on/off transcriptional control and ChAd155-CMV-hFerL-chEF1-seAP with a tetracycline on/off transcriptional control.

30

In embodiments of the invention, a ChAd83 vector may comprise one or more of a promoter, an enhancer, and a reporter gene. For example, vectors of the invention may comprise ChAd155-enhanced hCMV-SeAP, ChAd83-enhanced hCMV-SeAP, ChAd155-CASI-seAP and ChAd83-hCMV-seAP, optionally with a tetracycline on/off transcriptional control and ChAd83-CMV-hFerL-chEF1-seAP with a tetracycline on/off transcriptional control.

Vectors of the invention are generated using techniques provided herein, in conjunction with techniques known to those of skill in the art. Such techniques include conventional cloning techniques of cDNA such as those described in texts, use of overlapping oligonucleotide sequences of the adenovirus genomes, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.

Transgenes

A “transgene” is a nucleic acid sequence, heterologous to the vector sequences flanking the transgene, which encodes a polypeptide of interest. The nucleic acid coding sequence is operatively linked to regulatory components in a manner which permits transgene transcription, translation, and/or expression in a host cell. In embodiments of the invention, the vectors express transgenes at a therapeutic or a prophylactic level. A “functional derivative” of a transgenic polypeptide is a modified version of a polypeptide, *e.g.*, wherein one or more amino acids are deleted, inserted, modified or substituted.

The transgene may be used for prophylaxis or treatment, *e.g.*, as a vaccine for inducing an immune response, to correct genetic deficiencies by correcting or replacing a defective or missing gene, or as a cancer therapeutic. As used herein, induction of an immune response refers to the ability of a protein to induce a T cell and/or a humoral antibody immune response to the protein.

The immune response elicited by the transgene may be an antigen specific B cell response, which produces neutralizing antibodies. The elicited immune response may be an antigen specific T cell response, which may be a systemic and/or a local response. The antigen specific T cell response may comprise a CD4+ T cell response, such as a response involving CD4+ T cells expressing cytokines, *e.g.* interferon gamma (IFN gamma), tumor necrosis factor alpha (TNF alpha) and/or interleukin 2 (IL2). Alternatively, or additionally, the antigen specific T cell

response comprises a CD8+ T cell response, such as a response involving CD8+ T cells expressing cytokines, *e.g.*, IFN gamma, TNF alpha and/or IL2.

The composition of the transgene sequence will depend upon the use to which the resulting vector will be put. In an embodiment, the transgene is a sequence encoding a product which is useful in biology and medicine, such as a prophylactic transgene, a therapeutic transgene or an immunogenic transgene, *e.g.*, protein or RNA. Protein transgenes include antigens. Antigenic transgenes of the invention induce an immunogenic response to a disease causing organism.

Transgenes of the invention include, but are not limited to, rabies virus antigens, *e.g.*, rabies glycoprotein (RG), respiratory syncytial virus (RSV) antigens, human immunodeficiency virus (HIV) antigens, or fragments thereof.

As a result of the redundancy in the genetic code, a polypeptide can be encoded by a variety of different nucleic acid sequences. Coding is biased to use some synonymous codons, *i.e.*, codons that encode the same amino acid, more than others. By "codon optimized," it is meant that modifications in the codon composition of a recombinant nucleic acid are made without altering the amino acid sequence. Codon optimization has been used to improve mRNA expression in different organisms by using organism-specific codon-usage frequencies.

In addition to, and independently from, codon bias, some synonymous codon pairs are used more frequently than others. This codon pair bias means that some codon pairs are overrepresented and others are underrepresented. Codon pair deoptimization has been used to reduce viral virulence. For example, it has been reported that polioviruses modified to contain underrepresented codon pairs demonstrated decreased translation efficiency and were attenuated compared to wild type poliovirus (Science (2008) 320:1784). Engineering a synthetic attenuated virus by codon pair deoptimization can produce viruses that encode the same amino acid sequences as wild type but use different pairwise arrangements of synonymous codons. Viruses attenuated by codon pair deoptimization generated up to 1000-fold fewer plaques compared to wild type, produced fewer viral particles and required about 100 times as many viral particles to form a plaque.

In contrast, polioviruses modified to contain codon pairs that are overrepresented in the human genome acted in a manner similar to wild type RNA and generated plaques identical in size to

wild type RNA (Coleman et al. (2008) Science 320:1784). This occurred despite the fact that the virus with overrepresented codon pairs contained a similar number of mutations as the virus with underrepresented codon pairs and demonstrated enhanced translation compared to wild type. This observation suggests that codon pair optimized constructs would be expected to act in a manner similar to their non-codon pair optimized counterparts and would not be expected to provide a functional advantage. Without wishing to be constrained by theory, this may be because natural evolution has optimized codon pairing.

A construct of the invention may comprise a codon optimized nucleic acid sequence.

Alternatively or additionally, a vector of the invention comprises a codon optimized sequence of a transgene or an immunogenic derivative or fragment thereof. A construct of the invention may comprise a codon pair optimized nucleic acid sequence. Alternatively or additionally, a vector of the invention comprises or consists of a codon pair optimized sequence of a transgene or an immunogenic derivative or fragment thereof.

Respiratory Syncytial Virus (RSV) Transgenes

In one embodiment, the present invention provides the use of a recombinant simian-derived adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises an immunogenic transgene derived from human respiratory syncytial virus (RSV), in the treatment or prophylaxis of RSV infection. In one embodiment, the recombinant simian-derived adenoviral vector of the present invention comprises an RSV F antigen in one of the expression cassettes, and another RSV viral antigen in the other expression cassette. Suitable antigens are discussed further below. In one embodiment, the recombinant simian-derived adenoviral vector comprises RSV M and N antigens in the second expression cassette. In such embodiments, the vector preferably encodes an RSV F0ΔTM antigen (fusion (F) protein deleted of the transmembrane and cytoplasmic regions), and RSV M2-1 (transcription anti-termination) and N (nucleocapsid) antigens.

Infection with RSV does not confer full protective immunity. Infection in infancy is followed by symptomatic RSV re-infections which continue throughout adulthood. These re-infections generally go undiagnosed because they usually present as common acute upper respiratory tract infections. In more vulnerable persons (e.g., immunocompromised adults or elderly), re-infections can however also lead to severe disease. Both arms of the immune system (humoral and cellular immunity) are involved in protection from severe disease [Guvanel AK, Chiu C and

Openshaw PJ. Current concepts and progress in RSV vaccine development. *Expert Rev Vaccines*. 2014; 13(3): 333-44.].

The humoral immune response is capable of neutralizing the virus and inhibiting viral replication, thereby playing a major role in protection against lower respiratory RSV infection and severe disease [Piedra PA, Jewell AM, Cron SG, et al., Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. *Vaccine*. 2003; 21(24): 3479-82.]. Passive immunization, in the form of Immunoglobulin G (IgG) RSV-neutralizing monoclonal antibodies (Synagis) given prophylactically, has been shown to prevent RSV disease to some extent in premature infants and newborns with bronchopulmonary dysplasia or underlying cardiopulmonary disease [Cardenas S, Auais A and Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. *Expert Rev Anti Infect Ther*. 2005; 3(5): 719-26].

T cells are also involved in the control of RSV disease. Lethal RSV infections have been described in patients with low CD8 T cells counts, as in the case of severe combined immunodeficiency, bone marrow and lung transplant recipients [Hertz, 1989]. The histopathology of fatal cases of RSV infection of newborns shows that there is a relative paucity of CD8 T cells in the lung infiltrate [Welliver TP, Garofalo RP, Hosakote Y, et al., Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. *J Infect Dis*. 2007. 195(8): 1126-36.]. Moreover, the presence of CD8 T cells producing Interferon-gamma (IFN- γ) has been associated with diminished Th2 responses and reduced eosinophilia in animal models of RSV [Castilow EM and Varga SM. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. *Future Virol*. 2008; 3(5): 445-454; Stevens WW, Sun J, Castillo JP, et al., Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. *Viral Immunol*. 2009; 22(4): 243-51].

Suitable antigens of RSV which are useful as immunogens to immunize a human or non-human animal can be selected from: the fusion protein (F), the attachment protein (G), the matrix protein (M2) and the nucleoprotein (N). The term "F protein" or "fusion protein" or "F protein polypeptide" or "fusion protein polypeptide" refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Fusion protein polypeptide. Similarly, the term "G protein" or "G protein polypeptide" refers to a polypeptide or protein having all or part of an amino acid

sequence of an RSV Attachment protein polypeptide. The term “M protein” or “matrix protein” or “M protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Matrix protein and may include either or both of the M2-1 (which may be written herein as M2.1) and M2-2 gene products. Likewise, the term “N protein” or

5 “Nucleocapsid protein” or “N protein polypeptide” refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Nucleoprotein.

Two groups of human RSV strains have been described, the A and B groups, based mainly on differences in the antigenicity of the G glycoprotein. Numerous strains of RSV have been

10 isolated to date, any of which are suitable in the context of the antigens of the immunogenic combinations disclosed herein. Exemplary strains indicated by GenBank and/or EMBL Accession number can be found in US published application number 2010/0203071 (WO2008114149), which is incorporated herein by reference for the purpose of disclosing the nucleic acid and polypeptide sequences of RSV F and G proteins suitable for use in present

15 invention. In an embodiment, the RSV F protein can be an ectodomain of an RSV F Protein (F0ΔTM).

Exemplary M and N protein nucleic acids and protein sequences can be found, e.g., in US published application number 2014/0141042 (WO2012/089833), which are incorporated herein

20 for purpose of disclosing the nucleic acid and polypeptide sequences of RSV M and N proteins suitable for use in present invention.

Suitably, for use with in present invention, transgene nucleic acids encode an RSV F antigen and RSV, M and N antigens. More specifically, the nucleic acids encode an RSV F0ΔTM

25 antigen (fusion (F) protein deleted of the transmembrane and cytoplasmic regions), and RSV M2-1 (transcription anti-termination) and N (nucleocapsid) antigens.

Fusion (F) protein deleted of the transmembrane and cytoplasmic regions (F0ΔTM)

The RSV F protein is a major surface antigen and mediates viral fusion to target cells. The F

30 protein is an antigen which is highly conserved among RSV subgroups and strains. The F protein is a target for neutralizing antibodies, including the prophylactic RSV-neutralizing monoclonal antibody Synagis. Deletion of the transmembrane region and cytoplasmic tail permits secretion of the F0ΔTM protein. Neutralizing antibodies including Synagis, that recognize this soluble form of the F protein, inhibit RSV infectivity in vitro [Magro M, Andreu D,

Gómez-Puertas P, et al., Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. *J Virol.* 2010; 84(16): 7970-82].

5 Nucleocapsid (N) protein

The N protein is an internal (non-exposed) antigen, highly conserved between RSV strains and known to be a source of many T cell epitopes. The N protein is essential for the replication and transcription of the RSV genome. The primary function of the N protein is to encapsulate the virus genome for the purposes of RNA transcription, replication and packaging and protects it
10 from ribonucleases.

Transcription anti-termination (M2-1) protein

The M2-1 protein is a transcription anti-termination factor that is important for the efficient synthesis of full-length messenger RNAs (mRNAs) as well as for the synthesis of polycistronic
15 readthrough mRNAs, which are characteristic of non-segmented negative-strand RNA viruses. M2-1 is an internal (non-exposed) antigen, which is highly conserved between RSV strains and known to be a source of many T cell epitopes.

N-M2-1 Fusion Protein

20 A polynucleotide encoding a linker is positioned between the polynucleotide encoding an RSV N antigen, or fragment thereof, and the polynucleotide encoding an RSV M2.1 antigen, or fragment thereof. Thus, in certain preferred examples, an expression cassette contains a transgene which encodes a fused RSV viral protein N-linker-M2.1. It is preferred that the linker is a flexible linker, preferably a flexible linker comprising an amino acid sequence according to
25 SEQ ID NO: 11 (Gly-Gly-Gly-Ser-Gly-Gly-Gly) or SEQ ID NO: 12 (Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly).

Papilloma (PV) Transgenes

In one embodiment, the present invention provides the use of a recombinant simian-derived
30 adenoviral vector comprising two expression cassettes, wherein each expression cassette comprises an immunogenic transgene derived from a papilloma virus (PV), in the treatment or prophylaxis of a papilloma virus induced disease. Suitably, the recombinant simian-derived adenoviral vector of the present invention comprises a modified papilloma virus E1 antigen in

one of the expression cassettes, and a modified papilloma virus E2 antigen in the other expression cassette.

Human Papillomavirus (HPV) are small DNA viruses that infect mucosal and/or cutaneous skin and cause multiple disease conditions, including cervical neoplasia, cervical cancer, and other anogenital cancers. There are over 40 types of HPV known to infect the anogenital tract of humans and about 15 high-risk HPV genotypes are causally associated with human cervical cancers. A majority of HPV infections of the cervical epithelium are subclinical and self-resolving within a two years period. However, persistent infection with high risk HPV types may cause lesions and progress to invasive cancer.

Suitable antigens of HPV which are useful as immunogens are described in WO2018060288 and include in particular HPV E1 and E2 proteins.

15 *Rabies (RG) Transgenes*

Lyssavirus is an enveloped, single stranded RNA virus in the *Rhabdoviridae* family. Members of the *Lyssavirus* genus cause rabies and have the highest fatality rate of all known human viral pathogens. Rabies is transmitted via the saliva of infected mammals. A neurotropic virus, it enters the nervous system of its host, causing an encephalomyelitis that is almost invariably fatal. Currently there are about 60,000 rabies deaths worldwide yearly, mostly caused by dog bites in developing countries in Asia and Africa and by wildlife and bats in North America.

Rabies presents either in a furious or a paralytic form. The incubation period varies between about five days and several years but is typically between about 20 and 90 days. Clinical illness most often starts with prodromal complaints of malaise, anorexia, fatigue, headache and fever followed by pain or paresthesia at the site of exposure. Anxiety, agitation or irritability may be prominent during this period, followed by hyperactivity, disorientation, seizures, hydrophobia, hypersalivation and, eventually, paralysis, coma and death.

Rabies antigens may be derived from the rabies viral glycoprotein (RG). For example, rabies glycoprotein may be used as a model antigen.

Delivery of Adenoviral Vectors

In some embodiments, the recombinant adenoviral vector of the invention is administered to a subject by epicutaneous administration, intradermal administration, intramuscular injection, intraperitoneal injection, intravenous injection, nasal administration, oral administration, rectal administration, subcutaneous injection, transdermal administration or intravaginal administration.

In an embodiment of the invention, the vectors can be administered intramuscularly (IM), *i.e.*, injection directly into muscle. Muscles are well vascularized and the uptake is typically rapid.

Adjuvants

Approaches to establishing strong and lasting immunity to specific pathogens include addition of adjuvants to vaccines. By “adjuvant” is meant an agent that augments, stimulates, activates, potentiates or modulates the immune response to an active ingredient of the composition. The adjuvant effect may occur at the cellular or humoral level, or both. Adjuvants stimulate the response of the immune system to the actual antigen but have no immunological effect themselves. Alternatively or additionally, adjuvanted compositions of the invention may comprise one or more immunostimulants. By “immunostimulant” it is meant an agent that induces a general, temporary increase in a subject’s immune response, whether administered with the antigen or separately.

A composition of the invention may be administered with or without an adjuvant. Alternatively, or additionally, the composition may comprise, or be administered in conjunction with, one or more adjuvants (*e.g.* vaccine adjuvants), in particular the composition comprises an immunologically effective amount of a vector of the invention encoding a transgene.

Methods of use/ uses

Methods are provided for inducing an immune response against a disease caused by a pathogen in a subject in need thereof comprising a step of administering an immunologically effective amount of a construct or composition as disclosed herein. In some embodiments are provided the use of the constructs or compositions disclosed herein for inducing an immune response to a transgenic antigen in a subject in need thereof. Vectors of the invention may be applied for the prophylaxis, treatment or amelioration of diseases due to infection.

Methods of the invention include the use of a vector of the invention in medicine. They include the use of a vector of the invention for the treatment of a disease caused by a pathogen. A vector of the invention can be used in the manufacture of a medicament for treating a disease caused by a pathogen. A vector of the invention can be used in the manufacture of a
5 medicament for the prevention or treatment of a disease, for example, a disease caused by respiratory syncytial virus (RSV).

Effective immunization with adenoviral vectors depends on the intrinsic immunomodulatory capability of the adenoviral vector backbone. Immunologically less potent adenoviruses induce
10 less antigen expression. Effective immunization also depends on the ability of the promoter to drive strong and sustained transgene expression. For example, adenoviral vectors driven by the cytomegalovirus immediate-early (CMV-IE) promoter do not sustain long-term transgene expression because they induce cytokines that dampen expression.

15 By "subject" is intended a vertebrate, such as a mammal e.g. a human or a veterinary mammal. In some embodiments the subject is human.

General

20 Vectors of the invention are generated using techniques and sequences provided herein, in conjunction with techniques known to those of skill in the art. Such techniques include conventional cloning techniques of cDNA such as those described in texts, use of overlapping oligonucleotide sequences of the adenovirus genomes, polymerase chain reaction, and any suitable method which provides the desired nucleotide sequence.

25 Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context
30 clearly indicates otherwise. The term "plurality" refers to two or more. Additionally, numerical limitations given with respect to concentrations or levels of a substance, such as solution component concentrations or ratios thereof, and reaction conditions such as temperatures, pressures and cycle times are intended to be approximate. The term "about" used herein is intended to mean the amount $\pm 10\%$.

The present invention will now be further described by means of the following non-limiting examples.

5 EXAMPLES

Example 1: Construction of Chimpanzee Adenoviruses with a Single Expression Cassette

10 Wild type chimpanzee adenoviruses type 155 (ChAd155) (WO 2016/198621) and type 83 (ChAd83) (WO 2010/086189) were isolated from healthy chimpanzees using standard procedures and were constructed as described in Sci Transl Med (2012) 4:1 and WO 2010/086189.

15 In Example 1, the ChAd155 and ChAd 83 vectors were each constructed by inserting a single transgene expression cassette. The expression cassette components used either the classical human CMV promoter or the CASI promoter, rabies glycoprotein as a model antigen and, optionally, a WPRE enhancer. Three different insertion sites were tested for the transgene cassette:

- 20 (i) replacing the E3 region with the transgene cassette,
- (ii) inserting the transgene cassette between the fiber and the E4 region (site HE1), and
- (iii) inserting the transgene cassette downstream of the right ITR (site HE2).

This numbering of these insertion sites corresponds to the illustrations of FIG.1 where:

- 25 (i) the top panel illustrates the RC1 vector, in which a transgene cassette replaced the E3 region,
- (ii) the middle panel illustrates the RC3 vector, in which a transgene cassette is inserted between the stop codons of the fiber gene and the E4 region (site HE1), and
- (iii) the bottom panel illustrates the RC2 vector, in which a transgene cassette is inserted downstream of the right ITR (site HE2).

30

In the vectors shown in Example 1, the E1 region remains intact in all configurations.

The transgene was inserted by homologous recombination techniques in the following positions of the SEQ ID NO: 1 and of the SEQ ID NO: 2:

HE1 ChAd155: insertion site between bp 34611 and 34612 of SEQ ID NO: 1;

HE2 ChAd155: insertion site between bp 37662 and 37663 of SEQ ID NO: 1;

HE1 ChAd83: insertion site between bp 33535 and 33536 of SEQ ID NO: 2;

5 HE2 ChAd83: insertion site between bp 36387 and 36388 of SEQ ID NO: 2.

When the transgene cassette was inserted in site HE1, ChAd155 failed to replicate. However, insertion of a transgene cassette into the HE1 site of ChAd83 produced a viable vector.

10 Example 2: Virus Production, Vector Titer and Expression of Vectors of Example 1

To identify an animal model in which to evaluate vector replication, a type C adenovirus ChAd155 RC2 and a type E adenovirus ChAd83 RC2 vectors of Example 1 were assessed for their ability to replicate, measured by vector titer and genome copy number, in cells of various
15 animal origins. The results are shown in Table 1.

Table 1. Replication and Expression of RC2 ChAd155 and RC2 ChAd83 of Example 1

<u>Cell line:</u> <u>Species</u>	<u>Vector</u>	<u>Vector</u> <u>Titer</u>	<u>Genome</u> <u>Copy</u>	<u>Expression</u>	
				<u>Day 2</u>	<u>Day 7</u>
MRC5: Human	ChAd155	+++	+++	++	++++
	ChAd83	+++++	+++++	+++	+++++
PK15: Swine	ChAd155	+++++	+++++	NA	NA
	ChAd83	+++	++++	NA	NA
NMuLi: Mouse	ChAd155	++	+++	+++	+++
	ChAd83	ND	+	++	++
Vero: Non-human primate	ChAd155	++	++++	+++	+++
	ChAd83	ND	+	+	+

ND = not detected; NA = not available

20 As shown in Table 1, human MRC5 cells and swine PK15 cells produced high vector titers and high genome copy numbers of both ChAd155 and ChAd83. Murine NMuLi and non-human

primate Vero cells also produced RC ChAd155 but to a lesser extent than the human or swine cells. RC ChAd83 failed to grow well in murine NMuLi cells and, surprisingly, in non-human primate Vero cells.

- 5 Human MRC5, mouse NMuLi and non-human primate Vero cells supported the expression of RC ChAd155 through day 7. Human MRC5 cells supported the expression of RC ChAd83 through day 7, as did mouse NMuLi and non-human primate Vero cells, but to a lesser extent than the human cells.

10 *Virus production*

FIG. 2A shows the amount of virus produced by human primary MRC5 cells infected with either ChAd155 or ChAd83, each comprising either the RC1 or RC2 vector construction of Example 1. The cells were harvested seven days post-infection and the vector titer was evaluated in cell lysates obtained following three freeze-thaw cycles. Vector titers were measured by
 15 quantitative PCR (QPCR) analysis with primers designed for the respective promoter regions. The multiplicity of infection (moi) was 1250 virus particles per cell. The virus production is indicated in the number of virus particles per cell (vp/cell) above the bars.

- Human MRC5 cells supported production of ChAd155 comprising either RC1 (2.17×10^3 vp/cell)
 20 or RC2 (4.40×10^3 vp/cell) and also supported production of ChAd83 comprising either RC1 (1.18×10^4 vp/cell) or RC2 (1.06×10^5 vp/cell). As shown in FIG. 2A, ChAd83 was produced at a higher level than ChAd155; the ChAd83 vector comprising RC2 was the most robust of the four viral/vector combinations.

- 25 FIG. 2B shows the amount of virus produced by human primary MRC5 cells infected with ChAd83 comprising the RC1, RC2 or RC3 vector construction of Example 1. The cells were harvested two and seven days post-infection. As with FIG. 2A, vector titers were measured by quantitative PCR (QPCR) analysis with primers designed for the respective promoter regions. The multiplicity of infection (moi) was 250 or 1250 virus particles per cell. The virus production
 30 is indicated in the number of virus particles per cell (vp/cell) above the bars.

Human MRC5 cells supported production of ChAd83 comprising RC1, RC2 or RC3. As shown in FIG. 2B, there was higher virus production for the RC2 and RC3 ChAd83 vectors than for the

RC1 vector. There was also higher virus production for the ChAd83 RC2 HE2 vector than the RC3 HE1 vector.

Vector genome copy number

5 After infection, the vector is replicated in the cell and the vector genome copy number can be measured by QPCR. Vector DNA replication can occur even in cells not fully permissive for viral replication and propagation. QPCR of vector DNA provides a measure of vector replication within the infected cell, independently of the ability of the virus to complete the replication cycle and be released as mature viral progeny. Vector replication can thus be quantified in animal
10 species, tissue types and cell types which are not permissive for ChAd virus replication or propagation.

Vector genome copy number was measured in parallel with vector titer and the results shown in FIG. 3A and FIG. 3B.

15

As with the virus production shown in FIG. 2A, Human MRC5 cells were infected with either ChAd155 or ChAd83, each comprising either the RC1 or RC2 vector construction of Example 1. The cells were harvested seven days post-infection, the total DNA extracted, the viral genome quantified by QPCR and the results expressed as vector genome copy per cell. The multiplicity
20 of infection (moi) was 250 virus particles per cell and the numbers of virus particles per cell are indicated above the bars denoting viral genome copies per cell. The copy number is directly proportional to the level of transgene expression.

As shown in FIG. 3A, the amount of viral DNA replication of RC1 (6.21×10^3 vp/cell) and RC2
25 (6.71×10^3 vp/cell) by ChAd155 was similar. ChAd83 produced more RC1 (2.76×10^4 vp/cell) and RC2 (9.19×10^4 vp/cell) viral DNA than ChAd155. The highest level of viral DNA replication was observed by ChAd83 RC2.

As with the virus production shown in FIG. 2B, Human MRC5 cells were infected with ChAd83,
30 comprising the RC1, RC2 or RC3 vector construction of Example 1. The cells were harvested at two and seven days post-infection, the total DNA extracted, the viral genome quantified by QPCR and the results expressed as vector genome copy per cell. The multiplicity of infection (moi) was 250 or 1250 virus particles per cell and the numbers of virus particles per cell are

indicated above the bars denoting viral genome copies per cell. The copy number is directly proportional to the level of transgene expression.

As shown in FIG. 3B, the amount of viral DNA replication was higher for the RC2 and RC3 ChAd83 vectors than for the RC1 vector. There was comparable viral DNA replication between the RC2 and RC3 ChAd83 vectors.

Example 3: Adenoviral Genome Copy Number of Vectors of Example 1

The efficiency of the replication competent adenoviral vectors with the constructs of Example 1, expressed as vector copies per cell, was evaluated in cell cultures derived from both mice and non-human primates.

FIG. 4(a) shows the genome copy number of replication competent vectors grown in murine hepatic NMuLi cells grown in monolayers and infected with ChAd155 RC1, ChAd155 RC2, ChAd83 RC1 or ChAd83 RC2 at a multiplicity of infection of 250 virus particles per cell. Total DNA was extracted at five days post-infection and the vector replication was measured by QPCR using primers annealing to the vector's promoter region.

The results, expressed as vector copies per cell, are shown in FIG. 4(a). ChAd155 amplified both the RC1 and RC2 vector with high efficiency in NMuLi cells. ChAd155 replicated the RC1 (1.73×10^4) and RC2 (1.92×10^4) vectors to approximately the same degree. ChAd83 was less efficient than ChAd155 in replicating the RC1 and RC2 vectors. ChAd83 replicated the vector DNA only in small amounts in the murine cells. RC1 vector replicated at a level of 5.47×10^2 copies per cell and the RC2 vector at a level of 6.74×10^2 copies per cell.

Non-human primate Vero cells were also grown in monolayers and infected with ChAd155 RC1, ChAd155 RC2, ChAd83 RC1 or ChAd83 RC2 (FIG. 4(b)). Two different multiplicities of infection were used: 50 and 250 virus particles per cell. Total DNA was extracted at five days post-infection and the vector replication was measured by QPCR using primers annealing to the vector's promoter region.

The results, expressed as vector copies per cell, are shown in FIG. 4(b). The Vero primate cell line was permissive for ChAd155 RC1 (3.71×10^3 copies per cell at an moi of 50 and 4.93×10^4

copies per cell at an moi of 250) and ChAd155 RC2 (8.15×10^3 copies per cell at an moi of 50 and 7.05×10^4 copies per cell at an moi of 250). The Vero primate cell line was poorly, if at all, permissive for ChAd83 RC1 or ChAd83 RC2. No ChAd83 RC1 or ChAd83 RC2 vectors were detected to be expressed from Vero cells at an moi of 50. At an moi of 250, ChAd83 replicated the RC1 vector at a level of 1.13×10^2 copies per cell and the RC2 vector at a level of 1.29×10^3 copies per cell.

Example 4: Transgene Expression from Murine and Non-human Primate Cells of Vectors of Example 1

Western blot analysis was performed to compare the level of transgene expression by ChAd155 RC1 and ChAd155 RC2 in murine NMuLi cells (FIG. 5(a)). The cells were infected with ChAd155 RC1 or ChAd155 RC2 at a multiplicity of infection of 50, 250 or 1250 viral particles per cell. The cells were harvested at two and five days post infection, extracts prepared using standard methods and an equivalent amount of total cell extract loaded onto SDS-PAGE gels. Following electrophoretic separation, the proteins were transferred onto nitrocellulose membranes, which were then probed with a commercially available monoclonal antibody to the rabies glycoprotein transgene.

FIG. 5(a) demonstrates that both ChAd155 RC1 and ChAd155 RC2 express a transgene in murine NMuLi cells. Expression was observed at both two and five days post infection, indicated by the band of about 51 kDa, which corresponds to the expected molecular weight of the rabies glycoprotein (RG). The ChAd155 RC2 vector produced a higher level of transgene expression than the ChAd155 RC1 vector at both two and five days post-infection.

Western blot analysis was then performed to compare the level of transgene expression by ChAd155 RC1, ChAd155 RC2, ChAd83 RC1 and ChAd83 RC2 in murine NMuLi cells (FIG. 5(b)). The cells were infected with ChAd155 RC1, ChAd155 RC2, ChAd83 RC1 or ChAd83 RC2 at a multiplicity of infection of 50, 250 or 1250 viral particles per cell (250 and 1250 for ChAd83 RC1). The cells were processed for western blot. The cells were harvested at two and seven days post infection, extracts prepared using standard methods and an equivalent amount of extract loaded onto SDS-PAGE gels. Following electrophoretic separation, the proteins were transferred onto nitrocellulose membranes, which were then probed with a commercially available monoclonal antibody to the rabies glycoprotein transgene.

FIG. 5(b) demonstrates that ChAd155 RC1, ChAd155 RC2, ChAd83 RC1 and ChAd83 RC2 express a transgene in murine NMuLi cells. Expression was observed at both two and five days post infection, indicated by the band of about 51 kDa, which corresponds to the expected molecular weight of the rabies glycoprotein (RG). ChAd155 demonstrated more efficient expression of the transgene than ChAd83. At two days post-infection, robust transgene expression by ChAd155 RC2 was observed even at the low multiplicity of 50 vp/cell, whereas robust transgene expression by ChAd155 RC1 was first observed at higher mois. Also, RC2 demonstrated more efficient transgene expression than RC1 in both ChAd155 and ChAd83 viral serotypes. RC2 was more robustly expressed than RC1 in each of the direct comparisons.

Western blot analysis was performed to compare the level of transgene expression by ChAd83 RC1, RC2 and RC3 in MRC5 cells (FIG. 5(c)). The cells were infected with ChAd83 RC1, RC2 or RC3 at a multiplicity of infection of 250 or 1250 viral particles per cell. The cells were harvested at two and seven days post infection, extracts prepared using standard methods and an equivalent amount of total cell extract loaded onto SDS-PAGE gels. Following electrophoretic separation, the proteins were transferred onto nitrocellulose membranes, which were then probed with a commercially available monoclonal antibody to the rabies glycoprotein transgene.

FIG. 5(c) demonstrates that all of ChAd83 RC1, RC2 and RC3 express a transgene in MRC5 cells. Expression was observed at both two and seven days post infection, indicated by the band of about 51 kDa, which corresponds to the expected molecular weight of the rabies glycoprotein (RG). The ChAd83 RC2 vector produced a higher level of transgene expression than the ChAd83 RC1 and RC3 vectors at both two and seven days post-infection. There was no rabies glycoprotein detection for the RC1 and RC3 vectors at 7days.

Example 5: Construction of Alternative Chimpanzee Adenoviruses with a Single Expression Cassette

As in Example 1, wild type chimpanzee adenoviruses type 155 (ChAd155) (WO 2016/198621) isolated from healthy chimpanzees using standard procedures were constructed as replication defective viruses as described in Sci Transl Med (2012) 4:1 and WO 2010/086189.

In Example 5, the ChAd155 is constructed by inserting a single transgene expression cassette. This expression cassette comprises the classical human CMV (hCMV) promoter, F0ΔTM, N and M2-1 RSV antigens and, optionally, a WPRE enhancer. This vector is shown in FIG. 6. The expression cassette is inserted into the E1 region of the adeno virus (after the E1 region has been deleted).

The ChAd155 shown in FIG. 6 comprises a transgene encoding all of the RSV F0ΔTM, M2-1 and N antigens, wherein a self-cleavage site ("2A") is included between the RSV F0ΔTM antigen and the composite RSV N.M2-1 antigen, in which a flexible linker is included between the RSV M2-1 and N antigens.

The ChAd155 RSV vector of Example 5 comprises the polynucleotide of SEQ ID NO: 4 and encodes the polypeptide of SEQ ID NO: 5.

Example 6: Construction of a Chimpanzee Adenoviruses with a Dual Expression Cassette

Again, wild type chimpanzee adenoviruses type 155 (ChAd155) (WO 2016/198621) isolated from healthy chimpanzees using standard procedures were constructed as replication defective viruses as described in Sci Transl Med (2012) 4:1 and WO 2010/086189.

The ChAd155 of Example 6 is constructed by inserting two transgene expression cassettes into two different locations in the adenovirus:

(1) The first expression cassette components comprise the classical human CMV (hCMV) promoter and N.M2-1 RSV composite antigen. This first expression cassette is inserted into the E1 region of the adenovirus (after the E1 region has been deleted).

(2) The second expression cassette comprises an enhanced classical human CMV (enhanced hCMV) promoter, the F0ΔTM RSV antigen and a WPRE enhancer. This first expression cassette is inserted into the HE2 region of the adenovirus (after the HE2 region has been deleted).

This vector comprising a dual expression cassette is shown in FIG. 7.

In the construct of FIG. 7, Ad5E4orf6 has been substituted into the early gene 4 (E4) region. The substitution is necessary to increase the productivity in HEK 293 cells.

Example 7: Transgene expression from the Dual Expression Cassette of Example 6

5

Western blot analysis was performed to compare the level of transgene expression in the ChAd155 vector of Example 6 (labelled "Dual" or "Dual cassette" in the figures) in MRC5 cells with:

- 10 (i) a vector comprising a single F expression cassette (ChAd155-F0ΔTM, labelled "F0ΔTm"),
- (ii) a vector comprising a single NM2 expression cassette (ChAd155-NM2, labelled "NM2-1"), and
- (iii) the vector of Example 5 comprising a single expression cassette containing the F
- 15 and N.M2-1 RSV antigens (ChAd155-F0ΔTM.NM2, also labelled "RSV")

The western blot analysis is shown in FIG. 8 and FIG. 9.

As shown in FIG. 8, the cells were infected with ChAd155-F0ΔTM, ChAd155-F0ΔTM.NM2 ("RSV") or the ChAd155 dual cassette of Example 6 at a multiplicity of infection of 500 viral particles per cell. In addition, cells were infected with ChAd155-F0ΔTM.NM2 ("RSV") at a multiplicity of infection of 500 or 1250 viral particles per cell. The cells were harvested at 48 hours and 96 hours post infection, extracts prepared using standard methods and an equivalent amount of total cell extract loaded onto SDS-PAGE gels.

25

FIG. 8 shows that the ChAd155 dual cassette provides an expression level of the F antigen which is comparable to ChAd155F0ΔTM and higher than ChAd155-FΔTM.NM2 in MRC5 cells.

As shown in FIG. 9, the cells were infected with ChAd155-NM2, ChAd155-F0ΔTM.NM2 ("RSV") or the ChAd155 dual cassette of Example 6 at a multiplicity of infection of 250 and 1250 viral particles per cell. The cells were harvested at 48 hours post infection, extracts prepared using standard methods and an equivalent amount of total cell extract loaded onto SDS-PAGE gels.

30

In FIG. 9, the ChAd155 dual cassette provides NM2-1 expression level at least comparable to the ChAd155-NM2 single vector and higher than ChAd155-F Δ TM.NM2 ("RSV") in MRC5 cells.

Example 8: Immunogenicity of the Dual Expression Cassette of Example 6

5

The immunogenicity of the dual expression cassette of Example 6 was evaluated in CD1 outbred mice (10 per group). The experiment was performed by injecting 5×10^8 viral particles intramuscularly into the mice. The B-cell response was measured at 4 and 8 weeks after the immunization by measuring the RSV neutralising titres. Each dot represents the response in a single mouse, and the line corresponds to the mean for each dose group. The results of this analysis are shown in FIG. 10.

10

FIG. 10 shows that the ChAd155 dual cassette provides a B-cell response comparable to ChAd155F0 Δ TM and higher than that produced by ChAd155-F0 Δ TM.NM2 ("RSV").

15

The immunogenicity of the dual expression cassette of Example 6 was also evaluated in BALB/c inbred mice (48, 11 or 8 per group). The experiment was performed by injecting 10^7 or 10^6 viral particles intramuscularly. The T-cell response was measured 3 weeks after the immunization by ex vivo IFN-gamma enzyme-linked immunospot (ELISpot) using a M2 peptide T cell epitope mapped in BALB/c mice. The results are shown in Figure 11, expressed as IFN-gamma Spot Forming Cells (SFC) per million splenocytes. Each dot represents the response in a single mouse, and the line corresponds to the mean for each dose group. Injected dose in number of virus particles are shown on the x axis. The results are shown in FIG. 11.

20

FIG. 11 shows that the ChAd155 dual cassette provides a T-cell response higher than that produced by the single cassette ChAd155-F0 Δ TM.NM2 ("triple RSV", the results for which are obtained from historical data). This difference in response is greater for the 10^6 vp dose.

25

FIG. 11 refers to "#positive mice", i.e. the number of mice which responded to the vaccine.

Example 9: Immunogenicity of the Dual Expression Cassette of Example 6 in cows

30

The study design is detailed in Table 2 below:

<u>Group</u>	<u>No. Cows</u>	<u>Vaccine</u>	<u>Route</u>	<u>Dose</u>	<u>Immunization</u>	<u>End of Study</u>
Gp1	4	ChAd155 single RSV	Intramuscular (IM)	1×10^{11}	D0	D90
Gp2	4	ChAd155 dual RSV	Intramuscular (IM)	1×10^{11}	D0	D90
Gp3	4	Saline	Intramuscular (IM)	N/A	D0	D90

The “ChAd155 single RSV” is the ChAd155 of Example 5, and the “ChAd155 dual RSV” is the ChAd155 of Example 6.

- 5 A total of 12 adult cows were enrolled in the study. The cows ranged in age from 2.7 years to 7.8 years and had a mean range of 4.8 years.

Before they were enrolled in the study, the cows were pre-screened for bovine RSV (BRVS) antibodies by ELISA. This allowed study groups to be established that had a similar distribution and mean BRVS Ab titer (so as to not bias any of the groups).

10 Samples were collected from the cows before vaccination (D-5 or D0) and after vaccination (D7,10,14,28,60,90). In this study, the cows were vaccinated with 1×10^{11} viral particles of one of the two vaccines or with saline on day zero (D0).

15 A Bronchoalveolar lavage (BAL) was performed at day -5, 7, 10 or 28 after vaccination to isolate T cells in the lungs of the cow. Then IFN-gamma cytokine production of the CD4+ and CD8+ T cells upon stimulation with RSV antigens (in the form of peptide pools) encoded in the vaccines was detected using intracellular cytokine staining (ICS) (i.e. IFN γ ICS was used to detect the lung T cell responses in the animals). The results of this experiment are shown in Figures 12A and 12B. It can be concluded from this experiment that the ChAd155-dual RSV induces consistent RSV-specific CD4+ and CD8+ responses in Bronchoalveolar lavage (BAL).

25 Blood samples were also taken from the cows on day 0, 14, 28, 60 and 90 after vaccination in order for IFN-gamma cytokine production of the RSV-specific CD4+ and CD8+ responses of the peripheral blood mononuclear cells (PBMC) to be detected using intracellular cytokine staining

(ICS) (i.e. IFN γ ICS was used to detect the peripheral T cell responses). The results of this experiment are shown in Figures 13A and 13B. Based on these results, it can be concluded that the ChAd155-dual RSV consistently expand the pre-existing RSV-specific CD4+ and CD8+ responses in PBMC.

5

The blood samples were also used to detect neutralising antibodies (nAbs) for RSV in the serum (i.e. the peripheral humoral response was detected). The results of this experiment are shown in Figures 14A and 14B. These results show that the ChAd155-dual RSV boosts RSV nAbs in serum which are maintained at levels higher than baseline 3 months after vaccination.

10

Example 10: Immunogenicity of ChAd155 dual encoding rabies G and RSV NM2 proteins

Three different ChAd155 vectors used constructed in this experiment:

- 15
- ChAd155 encoding both rabies G (RG) and RSV NM2 proteins (called “ChAd155 dual” in this example, and ChAd155 dual hCMV NM 2-1 – CASI RG WPRE);
 - ChAd155 encoding just the rabies G (RG) protein (called “ChAd155 RG” in this example, and ChAd155(Δ E4)CASI RG WPRE); and
 - The ChAd155 vector shown in FIG. 6, i.e. the vector with transgene encoding all of the
- 20 RSV F0 Δ TM, M2-1 and N antigens (called “ChAd155 RSV”).

Three different doses of the ChAd155 dual adenovirus were administered to mice: a highest dose of 10^7 viral particles, and a middle dose of 10^6 viral particles, and a lowest dose of 10^5 viral particles.

25

Two different doses of the ChAd155 RG and ChAd155 RSV vectors were administered to mice. For the ChAd155 RSV, this was a higher dose of 10^7 vaccine particles, and a lower dose of 10^6 vaccine particles. For the ChAd155 RG, this was a higher dose of 10^6 vaccine particles, and a lower dose of 10^5 vaccine particles. Mice were sacrificed 3 weeks later and splenocytes tested

30 by IFN γ ELISpot for T cell response to the vaccine encoded antigens.

The results of this experiment are shown in FIG. 15A, 15B and 15C. As can be seen from FIG. 15A, 15B and 15C, the ChAd155 dual RG-NM2 vector shows overall comparable immune responses to the vectors encoding each of the RG and NM2 antigens alone.

FIG. 15C compares the cumulative response to all encoded antigens at the common 10^6 vp dosage used for all three different vectors. The rabies G protein is listed twice (G1 and G2) as two pools of overlapping peptides were used to cover the whole sequence of the protein

5

Therefore, placing the two antigens in the same vector still produces a comparable immune response while allowing antigens for different pathogens to be provided in the same vector.

Example 11: Expression of ChAd155 dual encoding rabies G and RSV NM2 proteins in HeLa cells

10

In the experiments of Example 11, HeLa cells were infected with the purified "ChAd155 dual", "ChAd155 RG" and "ChAd155 RSV" used in Example 10.

15

Multiplicities of infection (MOI) of 50, 250 and 1250 were used in this experiment.

In order to obtain the Western Blot shown in FIG. 16A (obtained under reducing conditions), the cell lysate was harvested 48 hours post-infection. The estimated size of the NM2-1 is 65 kDa. FIG. 16A shows a comparable expression level for ChAd155 dual cassette and ChAd155 NM2-1. In addition, the NM2-1 expression level was higher for the ChAd155 dual cassette than the ChAd155 RSV vector.

20

To obtain the Western Blot shown in FIG. 16B, the supernatant was harvested 48 hours post-infection. The estimated size of the rabies glycoprotein is 57.6 kDa. FIG. 16B shows a comparable expression level for the ChAd155 dual and ChAd155 RG adenoviruses.

25

In addition, infectivity data was also collected using the four different vectors. The infectivity of purified virus was evaluated in adherent Procell 92 cells by Hexon Immunostaining. The results are given in Table 3 below (vp = virus particle, ifu = infectious unit, and R is the ratio between these two numbers). The infectivity results indicate that all of the vectors have similar infectivity. In addition, as all of the R values were below 300, the infectivity of all vectors was deemed to be within the range of acceptability.

30

Table 3:

	Vp/ml	Ifu/ml	R (vp/ifu)
ChAd155 hCMV NM 2-1 – CASI RG WPRE	5,51E+11	4,53E+09	122
ChAd155(Δ E4)hCMV-RSV	1.12E+11	1.05E+09	107
ChAd155(Δ E4)hCMV NM2-1	5.68E+11	4.26E+09	133
ChAd155(Δ E4)CASI RG WPRE	3.48E+11	3.35E+09	104

Example 12: Immunogenicity of ChAd155 dual encoding CRPV E2 and E1 proteins

5

Two different ChAd155 vectors were constructed in this experiment:

- ChAd155 encoding a modified CRPV E2 protein in a first expression cassette, and a modified CRPV E1 protein in a second expression cassette (called “CRPV Dual”); and
- ChAd155 encoding a fusion of the modified CRPV E2 and E1 proteins in a single expression cassette (called “CRPV Fusion”)

10

15

20

Two different doses of the two adeno vectors were administered to mice: a higher dose of 10^7 viral particles, and a lower dose of 10^6 viral particles. The results of this experiment are shown in FIG. 17. FIG. 17 is a IFN γ ELISpot on splenocytes 3 weeks post vaccination. A statistical analysis was performed on the results and the differences between the response from the different vectors was not deemed to be statistically significant. However, as can be seen from FIG. 17, the ChAd155 CRPV Dual vectors show increased frequency of responding mice at lowest dosage than the CRPV Fusion vectors (6/6 positive responding mice for the 10^6 dose of the CRPV dual vector, but only 4/6 positive responding mice for the 10^6 dose of the CRPV fusion vector).

Example 13: Expression of ChAd155 dual encoding CRPV E2 and E1 proteins

The two different ChAd155 vectors used in Example 12 were also used in Example 13.

5

Multiplicities of infection (MOI) of 250 and 1250 were used in this experiment. The cell lysate was harvested 48 hours post-infection. The estimated size of the modified E1 protein is 48 kDa, the modified E2 protein is 35 kDa, and the fusion protein containing both the modified E1 and E2 proteins is 88 kDa.

10

FIG. 18 shows a Western blot (obtained under reducing conditions) illustrating that there was better expression of the modified E1 and E2 proteins by the CRPV dual vector than the CRPV fusion vector. The “Pvj” columns shown in FIG. 18 are the controls used.

15

In addition, infectivity data was collected using the two different vectors. The infectivity of purified virus was evaluated in adherent Procell 92 cells by Hexon Immunostaining. The results are given in Table 4 below (vp = virus particle, ifu = infectious unit, and R is the ratio between these two numbers). The infectivity results indicate that the two vectors have similar infectivity. In addition, as all of the R values were below 300, the infectivity of all vectors was deemed to be within the

20

Table 4:

	Vp/ml	Ifu/ml	R (vp/ifu)
ChAd155 hCMV CRPV DE2DE1 Fusion HA WPRE “CRPV Fusion”	4.52E+11	2.97E+09	153
ChAd155 hCMV CRPV DE2 HA WPRE – Enh.CMV CRPV DE1 HA WPRE “CRPV Dual”	6.20E+11	4.39E+09	143

25

DESCRIPTION OF THE SEQUENCES

SEQ ID NO: 1 Polynucleotide sequence encoding wild type ChAd155

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGATGGGCGGCGCGGGGCGGGAG
 5 GCGGGTCCGGGGGCGGGCCGGCGGGGCGGGGCGGTGTGGCGGAAGTGGACTTTGTAAGTGTGGCGGATGTGACTTGCT
 AGTGCCGGGCGCGGTAAAAGTGACGTTTTCCGTGCGCGACAACGCCACGGGAAGTGACATTTTCCCGCGGTTTTT
 ACCGGATGTTGTAGTGAATTTGGGCGTAACCAAGTAAGATTTGGCCATTTTCGCGGGAACCTGAAACGGGGAAGTG
 AAATCTGATTAATTTTCGCGTTAGTCATACCGCGTAATATTTGTCGAGGGCCGAGGGACTTTGGCCGATTACGTGGAG
 GACTCGCCAGGTGTTTTTTGAGGTGAATTTCCGCGTTCCGGGTCAAAGTCTCCGTTTTATTATTATAGTCAGCTGA
 10 CGCGGAGTGATTTATACCTCTGATCTCGTCAAGTGGCCACTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCTGC
 CGCTCTCCGCTCCGCTCCGCTCGGCTCTGACACCGGGGAAAAAATGAGACATTTACCTACGATGGCGGTGTGCTCA
 CCGGCCAGCTGGCTGCTGAAGTCTTGACACCTGATCGAGGAGGTATTGGCCGATAATTATCCTCCCTCGACTCCT
 TTTGAGCCACCTACACTTCACGAACCTTACGATCTGGATGTGGTGGGGCCAGCGATCCGAACGAGCAGGCGGTTTC
 CAGTTTTTTTCCAGAGTCCATGTTGTTGGCCAGCCAGGAGGGGGTCAACTTGAGACCCCTCCTCCGATCGTGGATT
 15 CCCCCGATCCGCCGAGCTGACTAGGCAGCCGAGCGCTGTGCGGGACCTGAGACTATGCCCCAGCTGCTACCTGAG
 GTGATCGATCTCACCTGTAATGAGTCTGGTTTTTCCACCCAGCGAGGATGAGGACGAAGAGGGTGAGCAGTTTGTGTT
 AGATTCTGTGGAACAACCCGGGCGAGGATGCAGGTCTTGTCAATATCACCGGAAAAACACAGGAGACTCCAGATTA
 TGTGTTCTCTGTGTTATATGAAGATGACCTGTATGTTTATTTACAGTAAGTTTATCATCTGTGGGCAGGTGGGCTAT
 AGTGTGGGTGGTGGTCTTTGGGGGGTTTTTTAATATATGTGAGGGGTTATGCTGAAGACTTTTTTTATTGTGATTTTT
 20 AAAGGTCCAGTGTCTGAGCCCGAGCAAGAACCTGAACCGGAGCCTGAGCCTTCTCGCCCCAGGAGAAAGCCTGTAAT
 CTTAACTAGACCCAGCGCACCCGGTAGCGAGAGGCCTCAGCAGCGCGGAGACCACCGACTCCGGTGCTTCCCTCATCAC
 CCCCCGAGATTACCCCCCTGGTGCCCCCTGTGTCCCGTTAAGCCCGTTGCCGTGAGAGTCAGTGGGCGGCGGTCTGCT
 GTGGAGTGCATTGAGGACTTGCTTTTTTGATTCACAGGAACCTTTGGACTTGAGCTTGAAACGCCCCAGGCATTAAAC
 CTGGTCACCTGGACTGAATGAGTTGACGCCTATGTTTGCTTTTGAATGACTTAATGTGTATAGATAATAAAGAGTGA
 25 GATAATGTTTTAATTGCATGGTGTGTTAACTTGGGCGGAGTCTGCTGGGTATATAAGCTTCCCTGGGCTAAACTTG
 GTTACACTTGACCTCATGGAGGCCTGGGAGTGTTTGGAGAACTTTGCCGAGTTCTGTCCTTGCTGGACGAGAGCTC
 TAACAATACCTCTTGGTGGTGGAGGTATTTGTGGGGCTCTCCCCAGGGCAAGTTAGTTTGTAGAATCAAGGAGGATT
 ACAAGTGGGAATTTGAAGAGCTTTTGAAATCCTGTGGTGAGCTATTGGATTCTTTGAATCTAGGCCACCAGGCTCTC
 TTCCAGGAGAAGGTATCAGGACTTTGGATTTTTCCACACCGGGGCGCATTGCAGCCGCGGTTGCTTTTCTAGCTTT
 30 TTTGAAGGATAGATGGAGCGAAGAGACCCACTTGAGTTCGGGCTACGTCCTGGATTTTCTGGCCATGCAACTGTGGA
 GAGCATGGATCAGACACAAGAACAGGCTGCAACTGTTGTCTTCCGTCCGCCCGTTGCTGATTCCGGCGGAGGAGCAA
 CAGGCCGGGTGAGGACCGGGCCCGTCGGGATCCGGAGGAGAGGGCACCGAGGCCGGGCGAGAGGAGCGCGCTGAA
 CCTGGGAACCGGGCTGAGCGGCCATCCACATCGGGAGTGAATGTCGGGCAGGTGGTGGATCTTTTTCCAGAACTGCG
 GCGGATTTTGACTATTAGGGAGGATGGGCAATTTGTTAAGGGTCTTAAGAGGGAGAGGGGGGCTTCTGAGCATAACG
 35 AGGAGGCCAGTAATTTAGCTTTTAGCTTGATGACCAGACACCGTCCAGAGTGCATCACTTTTACAGCAGATTAAGGAC
 AATTGTGCCAATGAGTTGGATCTGTTGGGTGAGAAGTATAGCATAGAGCAGCTGACCATTACTGGCTGCAGCCGGG
 TGATGATCTGGAGGAAGCTATTAGGGTGTATGCTAAGGTGGCCCTGCGGCCCGATTGCAAGTACAAGCTCAAGGGGC
 TGGTGAATATCAGGAATTGTTGCTACATTTCTGGCAACGGGGCGGAGGTGGAGATAGAGACCGAAGACAGGGTGGCT
 TTCAGATGCAGCATGATGAATATGTGGCCGGGGGTGCTGGGCATGGACGGGGTGGTGATTATGAATGTGAGGTTTAC

GGGGCCCAACTTTAACGGCACGGTGTTTTTGGGGAACACCAACCTGGTCCTGCACGGGGTGAGCTTCTATGGGTTTA
 ACAACACCTGTGTGGAGGCCTGGACCGATGTGAAGGTCCGCGGTTGCGCCTTTTATGGATGTTGGAAGGCCATAGTG
 AGCCGCCCTAAGAGCAGGAGTTCCATTAAGAAATGCTTGTGTTGAGAGGTGCACCTTGGGGATCCTGGCCGAGGGCAA
 CTGCAGGGTGCGCCACAATGTGGCCTCCGAGTGCGGTTGCTTCATGCTAGTCAAGAGCGTGGCGGTAAATCAAGCATA
 5 ATATGGTGTGCGGCAACAGCGAGGACAAGGCCTCACAGATGCTGACCTGCACGGATGGCAACTGCCACTTGCTGAAG
 ACCATCCATGTAACCAGCCACAGCCGGAAGGCCTGGCCCCGTGTTTCGAGCACAACTTGCTGACCCGCTGCTCCTTGCA
 TCTGGGCAACAGCGGGGGGTGTTCTGCCCCTATCAATGCAACTTTAGTCACACCAAGATCTTGCTAGAGCCCGAGA
 GCATGTCCAAGGTGAACTTGAACGGGGTGTTTGACATGACCATGAAGATCTGGAAGGTGCTGAGGTACGACGAGACC
 AGGTCCCGGTGACAGCCCTGCGAGTGCGGGGGCAAGCATATGAGGAACCAGCCCGTGATGCTGGATGTGACCGAGGA
 10 GCTGAGGACAGACCACTTGGTCTGTCCTGCACAGGGCCGAGTTTGGTTCTAGCGATGAAGACACAGATTGAGGTG
 GGTGAGTGGGCGTGGCTGGGGTGGTCATGAAAATATATAAGTTGGGGTCTTAGGGTCTCTTTATTTGTGTTGCAG
 AGACCGCCGGAGCCATGAGCGGGAGCAGCAGCAGCAGTAGCAGCAGCGCCTTGGATGGCAGCATCGTGAGCCCT
 TATTTGACGACGCGGATGCCCCACTGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATCGACGGCCGACCCGT
 CCTGCCCCGAAATTCCGCCACGCTGACCTATGCGACCGTCGCGGGGACGCCGTTGGACGCCACCGCCGCCGCCGCCG
 15 CCACCGCAGCCGCTCGGCCGTGCGCAGCCTGGCCACGGACTTTGCATTCTGGGACCACTGGCGACAGGGGCTACT
 TCTCGGGCCGCTGCTGCCGCCGTTTCGCGATGACAAGCTGACCGCCCTGCTGGCGCAGTTGGATGCGCTTACTCGGGA
 ACTGGGTGACCTTTCTCAGCAGGTGATGGCCCTGCGCCAGCAGGTCTCTCCCTGCAAGCTGGCGGGAATGCTTCTC
 CCACAAATGCCGTTTAAAGATAAAATAAACAGACTCTGTTTGGATTAAAGAAAAGTAGCAAGTGCAATTGCTCTCTTT
 ATTTTCATAATTTTCCGCGCGCGATAGGCCCTAGACCAGCGTTCTCGGTGCTTGAGGGTGCGGTGATCTTCTCCAGG
 20 ACGTGGTAGAGGTGGCTCTGGACGTTGAGATACATGGGCATGAGCCCGTCCCGGGGGTGGAGGTAGCACCCTGCAG
 AGCTTCATGCTCCGGGGTGGTGTGTGTAGATGATCCAGTCGTAGCAGGAGCGCTGGGCATGGTGCTAAAAATGTCCT
 TCAGCAGCAGGCCGATGGCCAGGGGGAGGCCCTTGGTGTAAGTGTTTACAAAACGGTTAAGTTGGGAAGGGTGCAAT
 CGGGGAGAGATGATGTGCATCTTGACTGTATTTTTAGATTGGCGATGTTTCCGCCCAGATCCCTTCTGGGATTCA
 GTTGTGCAGGACCACAGTACAGTGTATCCGGTGCCTTGGGGAATTTGTGATGCAGCTTAGAGGGAAAAAGCGTGGA
 25 AGAATTGGAGACGCCTTTGTGGCCTCCCAGATTTTCCATGCATTCTGTCATGATGATGGCAATGGGCCCCGCGGAG
 GCAGCTTGGGCAAAGATATTTCTGGGGTTCGTGACGTCGTAGTTGTGTTCCAGGGTGAGGTGCTCATAGGCCATTTT
 TACAAAGCGCGGGCGGAGGGTGCCCGACTGGGGGATGATGGTCCCCTCTGGCCCTGGGGCGTAGTTGCCCTCGCAGA
 TCTGCATTTCCCAGGCCTTAATCTCGGAGGGGGGAATCATATCCACCTGCGGGCGATGAAGAAAACGGTTTCCGGA
 GCCGGGGAGATTAACTGGGATGAGAGCAGGTTTCTAAGCAGCTGTGATTTTCCACAACCGGTGGGCCCCATAAAATAAC
 30 ACCTATAACCGGTTGCAGCTGGTAGTTTAGAGAGCTGCAGCTGCCGTCGTCCCGGAGGAGGGGGGCCACCTCGTTGA
 GCATGTCCCTGACGCGCATGTTCTCCCCGACCAGATCCGCCAGAAGGCGCTCGCCGCCAGGGACAGCAGCTCTTGC
 AAGGAAGCAAAGTTTTTTCAGCGGCTTGAGGCCGTCCGCCGTGGGCATGTTTTTCAGGGTCTGGCTCAGCAGCTCCAG
 GCGGTCCCAGAGCTCGGTGACGTGCTCTACGGCATCTCTATCCAGCATATCTCCTCGTTTCGCGGGTTGGGGCGACT
 TTCGCTGTAGGGCACCAAGCGGTGGTCTGTCAGCGGGGCCAGAGTCATGTCCTTCCATGGGCGCAGGGTCTCGTCA
 35 GGGTGGTCTGGGTACGGTGAAGGGGTGCGCTCCGGGCTGAGCGCTTGCCAAGGTGCGCTTGAGGCTGGTCTGCTG
 GTGCTGAAGCGCTGCCGGTCTTCGCCCTGCGCGTGGGCCAGGTAGCATTTGACCATGGTGTGATAGTCCAGCCCCCTC
 CGCGGCGTGTCCCTTGGCGCGCAGCTTGCCCTTGGAGGTGGCGCCGCACGAGGGGCAGAGCAGGCTCTTGAGCGCGT
 AGAGCTTGGGGGCGAGGAAGACCGATTGCGGGGAGTAGGCGTCCGCGCCGACAGCCCCGCACACGGTCTCGCACTCC
 ACCAGCCAGGTGAGCTCGGGGCGCGCCGGGTCAAAAACAGGTTTCCCCCATGCTTTTTGATGCGTTTCTTACCTCG
 40 GGTCTCCATGAGGTGGTGTCCCCGCTCGGTGACGAAGAGGCTGTCCGTGCTCCGTAGACCGACTTGAGGGGTCTTT

TCTCCAGGGGGTCCCTCGGTCTTCTCGTAGAGGAAC TCGGACCACTCTGAGACGAAGGCCCGCTCCAGGCCAGG
 ACGAAGGAGGCTATGTGGGAGGGGTAGCGGTCTGTTGTCCACTAGGGGGTCCACCTTCTCCAAGGTGTGAAGACACAT
 GTCGCCTTCTCGGCGTCCAGGAAGGTGATTGGCTTGTAGGTGTAGGCCACGTGACCGGGGGTTCCTGACGGGGGG
 TATAAAAGGGGGTGGGGGCGCGCTCGTCTGCTACTCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTGCTGGGGTGTAG
 5 TATTCCCTCTCGAAGGCGGGCATGACCTCCGCGCTGAGGTGTGTCAGTTTCCAAAAACGAGGAGGATTTGATGTTTAC
 CTGTCCCGAGGTGATACCTTTGAGGGTACCCGCGTCCATCTGGTCAGAAAACACGATCTTTTTATTGTCCAGCTTGG
 TGGCGAACGACCCGTAGAGGGCGTTGGAGAGCAGCTTGGCGATGGAGCGCAGGGTCTGGTTCTTGTCCCTGTGCGCG
 CGCTCCTTGGCCGCGATGTTGAGCTGCACGTA TCTGCGCGCGACGCAGCGCCACTCGGGGAAGACGGTGGTGCCTC
 GTCGGGCACCAAGCGCACGCGCCAGCCGCGGTGTTGTGCAGGGTGACCAGGTCCACGCTGGTGGCGACCTCGCCGCGCA
 10 GGCCTCGTTGGTCCAGCAGAGACGGCCGCCCTTGCGCGAGCAGAAGGGGGGCAGGGGTGAGCTGGGTCTCTGTCC
 GGGGGTCCGCGTCCACGGTGAAAACCCCGGGGCGCAGGCGCGCTCGAAGTAGTCTATCTTGCAACCTTGCATGTC
 CAGCGCTGCTGCCAGTCGCGGGCGGCGAGCGCGCTCGTAGGGTTGAGCGGCGGGCCCCAGGGCATGGGGTGGG
 TGAGTGCAGGAGCGTACATGCCGAGATGT CATAGACGTAGAGGGGTCCCAGGACCCCGATGTAGGTGGGGTAG
 CAGCGGCCGCCGCGGATGCTGGCGCGCACGTAGTCATACAGCTCGTGCAGGGGGCGAGGAGGTGGGGCCCCAGGTT
 15 GGTGCGGGCGGGGCGCTCCGCGCGGAAGACGATCTGCCTGAAGATGGCATGCGAGTTGGAAGAGATGGTGGGGCGCT
 GGAAGACGTTGAAGCTGGCGTCTTGCAGGCCGACGGCGTCGCGCACGAAGGAGGCGTAGGAGTCGCGCAGCTTGTGT
 ACCAGCTCGGCGGTGACCTGCACGTCGAGCGCGCAGTAGTCGAGGGTCTCGCGGATGATGTCATATTTAGCTGCC
 CTTCTTTTTCCACAGCTCGCGGTTGAGGACAACTCTTCGCGGTCTTTCCAGTACTCTTGATCGGGAAACCGTCCG
 GTTCCGAACGGTAAGAGCCTAGCATGTAGAACTGGTTGACGGCCTGGTAGGCGCAGCAGCCCTTCTCCACGGGGAGG
 20 GCGTAGGCCTGCGCGGCTTGCAGGAGCGAGGTGTGGGTGAGGGCGAAGGTGTCCCTGACCATGACTTTGAGGTACTG
 GTGCTTGAAGTCGGAGTCGTCGAGCCGCCCGCTCCAGAGCGAGAAGTCGGTGCCTTCTTGAGCGGGGGTTGG
 GCAGAGCGAAGGTGACATCGTTGAAGAGGATTTTGCCGCGCGGGGCATGAAGTTGCGGGTGATGCGGAAGGGCCCC
 GGCAC TTCAGAGCGTTGTTGATGACCTGGGCGGCGAGCACGATCTCGTCAAGCCGTTGATGTTGTGGCCACGAT
 GTAGAGTTCCAGGAAGCGGGGCCGCGCTTTACGGTGGGCGAGCTTCTTTAGCTCTTCGTAGGTGAGCTCCTCGGGCG
 25 AGGCGAGGCCGTGCTCGGCCAGGGCCCAGTCCGCGAGGTGCGGGTTGTCTCTGAGGAAGGACTTCCAGAGGTGCGCG
 GCCAGGAGGGTCTGCAGCGGTCTCTGAAGGTCTTGAAGTGGCGGGCCACGGCCATTTTTTCGGGGGTGATGCAGTA
 GAAGGTGAGGGGGTCTTGTGCCAGCGGTCCAGTCGAGCTGCAGGGCGAGGTGCGCGCGGGCGGTGACCAGGCGCT
 CGTCGCCCCGAATTTTCATGACCAGCATGAAGGGCACGAGCTGCTTTCCGAAGGCCCCCATCCAAGTGTAGGTCTCT
 ACATCGTAGGTGACAAAAGAGGCGCTCCGTGCGAGGATGCGAGCCGATCGGAAGAAGTGGATCTCCCGCCACCAGTT
 30 GGAGGAGTGGCTGTTGATGTGGTGGAAGTAGAAGTCCCGTGC CGGGGCCGAACACTCGTGTGGCTTTTGTAAGC
 GAGCGCAGTACTGGCAGCGCTGCACGGGTGTACCTCATGCACGAGATGCACCTTTCGCGCGGCACGAGGAAGCCG
 AGGGGAAATCTGAGCCCCCGCTGGCTCGCGGCATGGCTGGTTCTTCTACTTTGGATGCGTGTCCGTCTCCGTCT
 TGGCTCCTCGAGGGGTGTTACGGTGGAGCGGACCACACGCCGCGGAGCCGAGGTCCAGATATCGGCGCGCGGCG
 GTCGGAGTTTGATGACGACATCGCGCAGCTGGGAGCTGTCCATGGTCTGGAGCTCCCGCGGCGGCGGCGAGGTGAGCC
 35 GGGAGTTCTTGCAAGTTACCTCGCAGAGTCGGGCCAGGGCGCGGGGCAGGTCTAGGTGGTACCTGATCTCTAGGGG
 CGTGTGGTGGCGGCGTCGATGGCTTG CAGGAGCCCGCAGCCCCGGGGGGCGACGACGGTCCCCCGGGGGTGGTGG
 TGGTGGTGGCGGTGACGCTCAGAAGCGGTGCCGCGGGCGGGCCCCCGAGGTAGGGGGGGTCCGGTCCCGCGGGCA
 GGGGCGGCAGCGGCACGTCGGCGTGGAGCGCGGGCAGGAGTTGGTGTGTGCCCGGAGGTTGCTGGCGAAGGCGACG
 ACGCGGCGGTTGATCTCCTGGATCTGGCGCTCTGCGTGAAGACGACGGGCCGGTGAGCTTGAACCTGAAAAGAGAG
 40 TTCGACAGAATCAATCTCGGTGTCATTGACCGCGGCTGGCGCAGGATCTCCTGCACGTCTCCCGAGTTGTCTTGGT

AGGCGATCTCGGCCATGAACTGCTCGATCTCTTCCTCCTGGAGGTCTCCGCGTCCGGCGCGTTCACGGTGGCCGCC
 AGGTCGTTGGAGATGCGCCCCATGAGCTGCGAGAAGGCGTTGAGTCCGCCCTCGTTCCAGACTCGGCTGTAGACCAC
 GCCCCCTGGTCATCGCGGGCGCGCATGACCACCTGCGCGAGGTTGAGTCCACGTGCCGCGCGAAGACGGCGTAGT
 TGCGCAGACGCTGGAAGAGGTAGTTGAGGGTGGTGGCGGTGTGCTCGGCCACGAAGAAGTTCATGACCAGCGGCGC
 5 AACGTGGATTTCGTTGATGTCCCCAAGGCCTCCAGCCGTTCCATGGCCTCGTAGAAGTCCACGGCGAAGTTGAAAAA
 CTGGGAGTTGCGCGCCGACACGGTCAACTCCTCCTCCAGAAGACGGATGAGCTCGGCGACGGTGTGCGCGACCTCGC
 GCTCGAAGGCTATGGGGATCTCTTCCTCCGCTAGCATCACCACCTCCTCCTCTTCCTCCTCTTCTGGCACTTCCATG
 ATGGCTTCCTCCTCTTCGGGGGTGGCGGCGGCGGCGGTGGGGGAGGGGGCGCTCTGCGCCGGCGGCGGCGCACCGG
 GAGGCGGTCCACGAAGCGCGCATCTCTCCCGCGGCGGCGGCGCATGGTCTCGGTGACGGCGCGCCGTTCTCCC
 10 GGGGGCGCAGTTGGAAGACGCCGCCGACATCTGGTGTGGGGCGGTGGCCGTGAGGCAGCGAGACGGCGCTGACG
 ATGCATCTCAACAATTGCTGCGTAGGTACGCCGCCGAGGGACCTGAGGGAGTCCATATCCACCGGATCCGAAAACCT
 TTCGAGGAAGGCGTCTAACCAGTCGCGAGTCGCAAGGTAGGCTGAGCACCGTGGCGGGCGGCGGGGGGTGGGGGGAGT
 GTCTGGCGGAGGTGCTGCTGATGATGTAATTGAAGTAGGCGGACTTGACACGGCGGATGGTCGACAGGAGCACCATG
 TCCTTGGGTCCGGCTGCTGGATGCGGAGGCGGTGCGCTATGCCCCAGGCTTCGTTCTGGCATCGGCGCAGGTTCCTT
 15 GTAGTAGTCTTGATGAGCCTTTCACCGGCACCTCTTCTCCTTCCTCTTCTGCTTCTTCCATGTCTGCTTCGGCCC
 TGGGGCGGCGCGCGCCCCCTGCCCCCATGCGCGTGACCCCGAACCCCTGAGCGGTTGGAGCAGGGCCAGGTGCG
 GCGACGACGCGCTCGGCCAGGATGGCTGCTGCACCTGCGTGAGGGTGGTTTGAAGTCATCCAAGTCCACGAAGCG
 GTGGTAGGCGCCCGTGTGATGGTGTAGGTGCAGTTGGCCATGACGGACAGTTGACGGTCTGGTGGCCCGGTTGCG
 ACATCTCGGTGTACCTGAGTCGCGAGTAGGCGCGGAGTCGAAGACGTAGTCGTTGCAAGTCCGCACCAGGTACTGG
 20 TAGCCACACAGGAAGTGGCGGCGGCTGGCGGTAGAGGGGCCAGCGCAGGGTGGCGGGGGCTCCGGGGGCCAGGTC
 TTCCAGCATGAGGCGGTGGTAGGCGTAGATGTACCTGGACATCCAGGTGATACCCGCGGCGGTGGTGGAGGCGCGCG
 GGAAGTCGCGCACCCGGTTCCAGATGTTGCGCAGGGGCAGAAAGTGTCCATGGTAGGCGTGCTCTGTCCAGTCAGA
 CGCGCGCAGTCGTTGATACTCTAGACCAGGGAAAACGAAAGCCGGTCAGCGGGCACTCTTCCGTGGTCTGGTGAATA
 GATCGCAAGGGTATCATGGCGGAGGGCCTCGGTTTCGAGCCCCGGTCCGGGCCGGACGGTCCGCCATGATCCACGCG
 25 GTTACCGCCCGCGTGTGCAACCCAGGTGTGCGACGTGAGACAACGGTGGAGTGTTCCTTTTGGCGTTTTTCTGGCCG
 GGCGCCGGCGCCGCTAAGAGACTAAGCCGCGAAAGCGAAAGCAGTAAGTGGCTCGCTCCCCGTAGCCGAGGGATC
 CTTGCTAAGGGTTGCGTTGCGGCGAACCCCGGTTTGAATCCCGTACTCGGGCCGGCCGACCCGCGGCTAAGGTGTT
 GGATTGGCCTCCCCCTCGTATAAAGACCCCGCTTGCGGATTGACTCCGGACACGGGGACGAGCCCCTTTATTTTTG
 CTTTCCCCAGATGCATCCGGTGTGCGGCAGATGCGCCCCCGCCCCAGCAGCAGCAACAACACCAGCAAGAGCGGC
 30 AGCAACAGCAGCGGAGTCATGCAGGGCCCCCTCACCCACCTCGGCGGGCCGGCCACCTCGGCGTCCGCGGCCGTG
 TCTGGCGCCTGCGGCGGCGGCGGGGGGCCGCTGACGACCCGAGGAGCCCCGCGGCGCAGGGCCAGACACTACCT
 GGACCTGGAGGAGGCGAGGGCCTGGCGCGGCTGGGGGCGCCGTCTCCCAGCGCCACCCGCGGGTGCAGCTGAAGC
 GCGACTCGCGCGAGGCGTACGTGCCTCGGCAGAACCTGTTTCAGGGACCGCGGGCGAGGAGCCCAGGAGATGCGG
 GACAGGAGGTTACGCGAGGGCGGGAGCTGCGGCAGGGGCTGAACCGCGAGCGGCTGCTGCGCGAGGAGGACTTTGA
 35 GCCCCACGCGCGGACGGGGATCAGCCCCGCGCGCGCACGTGGCGGCCCGCCGACCTGGTGACGGCGTACGAGCAGA
 CGGTGAACCAGGAGATCAACTTCCAAAAGAGTTTCAACAACCACGTGCGCACGTGGTGGCGCGCGAGGAGGTGACC
 ATCGGGCTGATGCACCTGTGGGACTTTGTAAGCGCGCTGGTGCAGAACCCCAACAGCAAGCCTCTGACGGCGCAGCT
 GTTCCTGATAGTGCAGCACAGCAGGGACAACGAGGCGTTTAGGGACGCGCTGCTGAACATCACCGAGCCCAGGGTC
 GGTGGCTGCTGGACCTGATTAACATCCTGCAGAGCATAGTGGTGCAGGAGCGCAGCCTGAGCCTGGCCGACAAGGTG
 40 GCGGCCATCAACTACTCGATGCTGAGCCTGGGCAAGTTTTACGCGCGCAAGATCTACCAGACGCCGTACGTGCCCAT

AGACAAGGAGGTGAAGATCGACGGTTTTTACATGCGCATGGCGCTGAAGGTGCTCACCTGAGCGACGACCTGGGCG
 TGTACCGCAACGAGCGCATCCACAAGGCCGTGAGCGTGAGCCGGCGGCGGAGCTGAGCGACCGCGAGCTGATGCAC
 AGCCTGCAGCGGGCGCTGGCGGGCGCCGGCAGCGGCGACAGGGAGGCGGAGTCTTACTTCGATGCGGGGGCGGACCT
 GCGCTGGGCGCCAGCCGGCGGGCCCTGGAGGCCGCGGGGTCCGCGAGGACTATGACGAGGACGGCGAGGAGGATG
 5 AGGAGTACGAGCTAGAGGAGGGCGAGTACCTGGACTAAACCGCGGGTGGTGTTCGGTAGATGCAAGACCCGAACG
 TGGTGGACCCGGCGCTGCGGGCGGCTCTGCAGAGCCAGCCGTCCGGCCTTAACCTCCTCAGACGACTGGCGACAGGTC
 ATGGACCGCATCATGTCGTGACGGCGGTAAACCGGACGCGTTCCGGCAGCAGCCGAGGCCAACAGGCTCTCCGC
 CATCTGGAGGCGGTGGTGCTGCGCGCTCGAACCCACGCACGAGAAGGTGCTGGCCATAGTGAACGCGCTGGCCG
 AGAACAGGGCCATCCGCCCCGACGAGGCCGGGTGGTGTACGACGCGCTGCTGCAGCGCGTGGCCCCGTACAACAGC
 10 GGCAACGTGCAGACCAACCTGGACCGGCTGGTGGGGGACGTGCGCGAGGCGGTGGCGCAGCGGAGCGCGCGGATCG
 GCAGGGCAACCTGGGCTCCATGGTGGCGCTGAATGCCTTCTGAGCACGCAGCCGGCCAACGTGCCGCGGGGCGAGG
 AAGACTACACCAACTTTGTGAGCGCGCTGCGGCTGATGGTGACCGAGACCCCCAGAGCGAGGTGTACCAGTCGGGC
 CCGGACTACTTCTTCCAGACCAGCAGACAGGGCCTGCAGACGGTGAACCTGAGCCAGGCTTTCAAGAACCTGCGGGG
 GCTGTGGGGCGTGAAGCGCCACCGGCGACCGGGCGACGGTGTCCAGCCTGCTGACGCCAACTCGCGCCTGCTGC
 15 TGCTGCTGATCGCGCCGTTACGGACAGCGGCAGCGTGTCCCGGACACCTACCTGGGGCACCTGCTGACCCTGTAC
 CGCGAGGCCATCGGGCAGGCGCAGGTGGACGAGCACACCTTCCAGGAGATCACCAGCGTGAGCCGCGCGCTGGGGCA
 GGAGGACACGAGCAGCTTGAGGGCGACTCTGAACTACCTGCTGACCAACCGGCGGCAGAAGATTCCCTCGCTGCACA
 GCCTGACCTCCGAGGAGGAGCGCATCTTGCGCTACGTGCAGCAGAGCGTGAGCCTGAACCTGATGCGCGACGGGGTG
 ACGCCCAGCGTGCGCTGGACATGACCGCGCGCAACATGGAACCGGGCATGTACGCCGCGCACCGGCCCTTACATCAA
 20 CCGCCTGATGGACTACCTGCATCGCGCGGCGGCCGTGAACCCCGAGTACTTTACCAACGCCATCCTGAACCCGCACT
 GGCTCCCGCCGCCCGGGTTCTACAGCGGGGGCTTCGAGGTCCCGGAGACCAACGATGGCTTCTGTGGGACGACATG
 GACGACAGCGTGTCTCCCCGCGGCCGAGGCGCTGGCGGAAGCGTCCCTGCTGCGTCCCAAGAAGGAGGAGGAGGA
 GGAGGCGAGTCGCCGCCGCGGCAGCAGCGGCGTGGCTTCTGTCCGAGCTGGGGGCGGCAGCCGCCGCGCGCCCCG
 GGTCCCTGGGCGGCAGCCCCCTTCCGAGCCTGGTGGGGTCTCTGCACAGCGAGCGCACCAACCGCCCTCGGCTGCTG
 25 GGCGAGGACGAGTACCTGAATAACTCCCTGCTGCAGCCGGTGCGGGAGAAAAACCTGCCTCCCGCCTTCCCCAACAA
 CGGGATAGAGAGCCTGGTGGACAAGATGAGCAGATGGAAGACCTATGCGCAGGAGCACAGGGACGCGCCTGCGCTCC
 GGCCGCCACGCGGCGCCAGCGCCACGACCGGCAGCGGGGGTGGTGTGGGATGACGAGGACTCCGCGGACGATAGC
 AGCGTGCTGGACCTGGGAGGGAGCGGCAACCCGTTGCGGCACCTGCGCCCCGCTGGGGAGGATGTTTTAAAAAAA
 AAAAAAAAAAGCAAGAGCATGATGCAAAAATTAAATAAACTACCAAGGCCATGGCGACCGAGCGTTGGTTTTCTT
 30 GTGTTCCCTTTCAGTATGCGGCGCGCGGCGATGTACCAGGAGGGACCTCCTCCCTCTTACGAGAGCGTGGTGGGCGCG
 GCGGCGGCGGCGCCCTCTTCTCCCTTTGCGTGCAGCTGCTGGAGCCGCCGTACGTGCCTCCGCGCTACCTGCGGCC
 TACGGGGGGGAGAAACAGCATCCGTTACTCGGAGCTGGCGCCCCTGTTTCGACACCACCGGGTGTACCTGGTGGACA
 ACAAGTCGGCGGACGTGGCCTCCCTGAACTACCAGAACGACCACAGCAATTTTTTGACCACGGTCATCCAGAACAAT
 GACTACAGCCCAGCGAGGCCAGCACCCAGACCATCAATCTGGATGACCGGTCGCACTGGGGCGGCGACCTGAAAAAC
 35 CATCTGCACACCAACATGCCAACGTGAACGAGTTCATGTTACCAATAAGTTCAAGGCGCGGGTGTGTTGTCGC
 GCTCGCACACCAAGGAAGACCGGGTGGAGCTGAAGTACGAGTGGGTGGAGTTCGAGCTGCCAGAGGGCAACTACTCC
 GAGACCATGACCATTGACCTGATGAACAACGCGATCGTGAGCACTATCTGAAAGTGGGCAGGCAGAACGGGGTCTCT
 GGAGAGCGACATCGGGGTCAAGTTCGACACCAGGAACCTCCGCCTGGGGCTGGACCCCGTGACCGGGCTGGTTATGC
 CCGGGGTGTACACCAACGAGGCCCTTCCATCCCGACATCATCTGCTGCCCCGCTGCGGGGTGGACTTCACTTACAGC
 40 CGCCTGAGCAACCTCCTGGGCATCCGCAAGCGGCAGCCCTTCCAGGAGGGCTTCAGGATCACCTACGAGGACCTGGA

GGGGGGCAACATCCCCGCGCTCCTCGATGTGGAGGCCCTACCAGGATAGCTTGAAGGAAAATGAGGCGGGACAGGAGG
 ATACCGCCCCCGCCGCTCCGCGCCGCGGAGCAGGGCGAGGATGCTGCTGACACCGCGGCCGCGGACGGGGCAGAG
 GCCGACCCCGCTATGGTGGTGGAGGCTCCCGAGCAGGAGGAGGACATGAATGACAGTGCGGTGCGCGGAGACACCTT
 CGTCACCCGGGGGAGGAAAAGCAAGCGGAGGCCGAGGCCGCGGCCGAGGAAAAGCAACTGGCGGCAGCAGCGGCGG
 5 CGGCGGCGTTGGCCGCGGCGGAGGCTGAGTCTGAGGGGACCAAGCCCGCCAAGGAGCCCGTGATTAAAGCCCTGACC
 GAAGATAGCAAGAAGCGCAGTTACAACCTGCTCAAGGACAGCACCAACACCGCGTACCGCAGCTGGTACCTGGCCTA
 CAACTACGGCGACCCGTCGACGGGGGTGCGCTCCTGGACCCTGCTGTGCACGCCGGACGTGACCTGCGGCTCGGAGC
 AGGTGTACTGGTCGCTGCCGACATGATGCAAGACCCCGTGACCTTCCGCTCCACGCGGCAGGTCAGCAACTTCCCG
 GTGGTGGGCGCCGAGCTGCTGCCCCGTGCACTCCAAGAGCTTCTACAACGACCAGGCCGTCTACTCCGAGCTCATCCG
 10 CCAGTTCACCTCTCTGACCCACGTGTTCAATCGCTTTCTTGAGAACCAGATTCTGGCGCGCCCGCCCGCCCCACCA
 TCACCACCGTCAGTGAAAACGTTCTTGCTCTCACAGATCACGGGACGCTACCGCTGCGCAACAGCATCGGAGGAGTC
 CAGCGAGTGACCGTTACTGACGCCAGACGCCGCACCTGCCCTACGTTTACAAGGCCCTTGGGCATAGTCTCGCCGCG
 CGTCTTTTCCAGCCGCACTTTTGTAGCAACACCACCATCATGTCCATCTTGATCTCACCAGCAATAACTCCGGCTG
 GGGACTGCTGCGCGCGCCAGCAAGATGTTTCGAGGGGCGAGGAAGCGTTCCGAGCAGCACCCCGTGCGCGTGCGCG
 15 GGCAC TTCCGCGCCCCCTGGGGAGCGCACAAACGCGGCCGCGCGGGGCGCACCAACCGTGACGACGCCATCGACTCG
 GTGGTGGAGCAGGCGCGCAACTACAGGCCCGCGGTCTCTACCGTGACGCGGCCATCCAGACCGTGGTGCGGGGCGC
 GCGGCGGTACGCCAAGCTGAAGAGCCGCCGAAGCGCGTGGCCCGCCGCCACCGCCGCCGACCCGGGGCCGCCGCCA
 AACGCGCCGCCGCGGCCCTGCTTCGCCGGGCCAAGCGCACGGGCCGCCGCGCCGCCATGAGGGCCGCGCGCCGCTTG
 GCCGCCGGCATCACCGCCGCCACCATGGCCCCCGTACCCGAAGACGCGCGGCCGCCGCCGCCGCCGCCGCCATCAG
 20 TGACATGGCCAGCAGGCGCCGGGCAACGTGTACTGGGTGCGGACTCGGTGACCGGCACGCGCGTGCCCGTGCGCT
 TCCGCCCCCGCGGACTTGAGATGATGTGAAAAACAACACTGAGTCTCCTGCTGTTGTGTGTATCCAGCGGCGGC
 GCGCGCGCAGCGTCATGTCCAAGCGCAAAATCAAAGAAGAGATGCTCCAGGTCGTGCGCCGAGATCTATGGGCC
 CCCGAAGAAGGAAGAGCAGGATTCGAAGCCCCGCAAGATAAAGCGGGTCAAAAAGAAAAAGAAAGATGATGACGATG
 CCGATGGGGAGGTGGAGTTCTGCGCGCCACGGCGCCAGGCGCCCGGTGCAGTGGAAGGGCCGGCGCGTAAAGCGC
 25 GTCTGCGCCCCGGCACCGCGGTGGTCTTCACGCCCCGGCAGCGCTCCACCCGGACTTTCAAGCGCGTCTATGACGA
 GGTGTACGGCGACGAAGACCTGCTGGAGCAGGCCAACGAGCGCTTCGGAGAGTTTGCTTACGGGAAGCGTCAGCGGG
 CGCTGGGGAAGGAGGACCTGCTGGCGCTGCCGCTGGACCAGGGCAACCCACCCCGAGTCTGAAGCCCGTGACCTTG
 CAGCAGGTGCTGCCGAGCAGCGCACCCCTCCGAGGCGAAGCGGGTCTGAAGCGCGAGGGCGGCGACCTGGCGCCAC
 CGTGACGTCATGGTGCCCAAGCGGCAGAGGCTGGAGGATGTGCTGGAGAAAATGAAAGTAGACCCCGGTCTGCAGC
 30 CGGACATCAGGTTCCGCCCCATCAAGCAGGTGGCGCCGGGCCCTCGGCGTGACAGACCGTGACGTGGTTCATCCCCACC
 GGCAACTCCCCCGCCGCCGCCACCACTACCGCTGCCTCCACGGACATGGAGACACAGACCGATCCCGCCGAGCCGC
 AGCCGCAGCCGCCGCCGCGACCTCCTCGGCGGAGGTGCAGACGGACCCCTGGCTGCCGCCGGCGATGTCAGCTCCCC
 GCGCGCGTGCAGGGCGCAGGAAGTACGGCGCCGCCAACGCGCTCCTGCCCGAGTACGCCTTGATCCTTCCATCGCG
 CCCACCCCGGCTACCGAGGCTATACCTACCGCCCGCAAGAGCCAAGGGTTCCACCCGCCGTCCCCGCCGACGCGC
 35 CGCCGCCACCACCCGCCGCCGCCGCCGAGACGCCAGCCCGCACTGGCTCCAGTCTCCGTGAGGAAAGTGGCGCGCG
 ACGGACACACCCCTGGTGCTGCCCAGGGCGCGCTACCACCCAGCATCGTTTAAAAGCCTGTTGTGGTTCTTGAGAT
 ATGGCCCTCACTTGCCGCTCCGTTTCCCGGTGCCGGGATACCGAGGAGGAAGATCGCGCCGAGGAGGGGTCTGGC
 CGGCCGCGGCTGAGCGGAGGCAGCCGCCGCGCGCACCGGCGGCGACGCGCCACCAGCCGACGCATGCGCGGCGGGG
 TGCTGCCCCGTGTTAATCCCCCTGATCGCCGCGGCGATCGGCGCCGTGCCCGGATCGCTCCGTGGCTTGCAAGCG
 40 TCCCAGAGGCATTGACAGACTTGCAAACCTTGCAAATATGGAATAAATAAAGTCTAGACTCTCACG

CTCGCTTGGTCCTGTGACTATTTTGTAGAATGGAAGACATCAACTTTGCGTCGCTGGCCCCGCGTCACGGCTCGCGC
 CCGTTCCCTGGGACACTGGAACGATATCGGCACCAGCAACATGAGCGGTGGCGCCTTCAGTTGGGGCTCTCTGTGGAG
 CGGCATTAAAAGTATCGGGTCTGCCGTTAAAAATTACGGCTCCCGGGCCTGGAACAGCAGCACGGGCCAGATGTTGA
 GAGACAAGTTGAAAGAGCAGAAGTTCCAGCAGAAGGTGGTGGAGGGCCTGGCCTCCGGCATCAACGGGGTGGTGGAC
 5 CTGGCCAACCAGGCCGTGCAGAATAAGATCAACAGCAGACTGGACCCCCGGCCGCCGGTGGAGGAGGTGCCGCCGGC
 GCTGGAGACGGTGTCCCCGATGGGCGTGGCGAGAAGCGCCCGCGGCCGATAGGGAAGAGACCACTCTGGTCCACGC
 AGACCGATGAGCCGCCCCCGTATGAGGAGGCCCTGAAGCAAGGTCTGCCACCACGCGGGCCATCGCGCCCATGGCC
 ACCGGGGTGGTGGGCCGCCACACCCCCGCCACGCTGGACTTGCCTCCGCCCGCCGATGTGCCGCAGCAGCAGAAGGC
 GGCACAGCCGGGCCCCGCCCGCGACCGCCTCCCGTTCTCCGCCGGTCTCTGCGCCGCGCGGCCAGCGCCCCCGCG
 10 GGGGGGTGCGGAGGCACGGCAACTGGCAGAGCACGCTGAACAGCATCGTGGGTCTGGGGGTGCGGTCCGTGAAGCGC
 CGCCGATGCTACTGAATAGCTTAGCTAACGTGTTGTATGTGTGTATGCGCCCTATGTCGCCGCCAGAGGAGCTGCTG
 AGTCGCCGCCGTTTCGCGCGCCACCACCACCGCCACTCCGCCCTCAAGATGGCGACCCCATCGATGATGCCGCAGT
 GGTCTGATACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCCCGGGCTGGTGCAGTTCGCCCGCGCCACC
 GAGAGCTACTTCAGCCTGAGTAACAAGTTTAGGAACCCACGGTGGCGCCACGCACGATGTGACCACCGACCGGTC
 15 TCAGCGCTGACGCTGCGGTTTCATTCCCGTGGACCGCGAGGACACCGCGTACTCGTACAAGGCGCGGTTACCCCTGG
 CCGTGGGCGACAACCGCGTGTCTGGACATGGCCTCCACCTACTTTGACATCCGCGGGGTGCTGGACCGGGGTCCCACT
 TTCAAGCCCTACTCTGGCACCGCCTACAACCTCCCTGGCCCCAAGGGCGTCCCAACTCCTGCGAGTGGGAGCAAGA
 GGAACTCAGGCAGTTGAAGAAGCAGCAGAAGAGGAAGAAGAAGATGCTGACGGTCAAGCTGAGGAAGAGCAAGCAG
 CTACCAAAAAGACTCATGTATATGCTCAGGCTCCCCCTTTCTGGCGAAAAAATTAGTAAAGATGGTCTGCAAAATAGGA
 20 ACGGACGCTACAGCTACAGAACAAAAACCTATTTATGCAGACCCTACATTCCAGCCCGAACCCCAAATCGGGGAGTC
 CCAGTGGAAATGAGGCAGATGCTACAGTCGCCGGCGGTAGAGTGCTAAAGAAATCTACTCCCATGAAACCATGCTATG
 GTTCCATGCAAGACCCACAAATGCTAATGGAGGTCAGGGTGTACTAACGGCAAATGCCAGGGACAGCTAGAATCT
 CAGGTTGAAATGCAATTCTTTTCAACTTCTGAAAACGCCCCGTAACGAGGCTAACAACTTCAGCCCAAATTTGGTGT
 GTATAGTGAGGATGTGCACATGGAGACCCCGGATACGCACCTTTCTTACAAGCCCGCAAAAAGCGATGACAATTCAA
 25 AAATCATGCTGGGTGAGCAGTCCATGCCCAACAGACCTAATTACATCGGCTTCAGAGACAACTTTATCGGCCTCATG
 TATTACAATAGCACTGGCAACATGGGAGTGCTTGCAGGTGAGGCTCTCAGTTGAATGCAGTGGTGGACTTGCAAGA
 CAGAAACACAGAAGTGTCTTACCAGCTCTTGCTTGATTCCATGGGTGACAGAACCAGATACTTTTCCATGTGGAATC
 AGGCAGTGGACAGTTATGACCCAGATGTTAGAATTATTGAAAATCATGGAACGAAGACGAGCTCCCCAACTATTGT
 TTCCCTCTGGGTGGCATAGGGGTAAGTACACTTACCAGGCTGTAAAACCAACAATGGCAATAACGGGGGCCAGGT
 30 GACTTGGACAAAAGATGAAACTTTTGCAGATCGCAATGAAATAGGGGTGGGAAACAATTTGCTATGGAGATCAACC
 TCAGTGCCAACCTGTGGAGAACTTCTGTACTCCAACGTGGCGCTGTACCTACCAGACAAGCTTAAGTACAACCCC
 TCCAATGTGGACATCTCTGACAACCCCCAACACCTACGATTACATGAACAAGCGAGTGGTGGCCCCGGGGCTGGTGGGA
 CTGCTACATCAACCTGGGCGCGCGCTGGTTCGCTGGACTACATGGACAACGTCAACCCCTTCAACCAACACCGCAATG
 CGGGCTGCGCTACCGCTCCATGCTCTGGGCAACGGGCGCTACGTGCCCTTCCACATCCAGGTGCCCCAGAAAGTTC
 35 TTTGCCATCAAGAACCTCCTCCTCTGCCGGCTCCTACACCTACGAGTGGAACTTCAGGAAGGATGTCAACATGGT
 CCTCCAGAGCTCTCTGGGTAACGATCTCAGGGTGGACGGGGCCAGCATCAAGTTCGAGAGCATCTGCCTCTACGCCA
 CCTTCTTCCCCATGGCCACAACACGGCTCCACGCTCGAGGCCATGCTCAGGAACGACACCAACGACCACTCTCCATCCCCCTC
 AATGACTACCTCTCCGCCGCCAACATGCTCTACCCCATACCCGCCAACGCCACCAACGTCCCCATCTCCATCCCCCTC
 GCGCAACTGGGCGGCCTTCCGCGGCTGGGCTTACCCGCTCAAGACCAAGGAGACCCCTCCCTGGGCTCGGGAT
 40 TCGACCCCTACTACACCTACTCGGGCTCCATTCCCTACCTGGACGGCACCTTCTACCTCAACCACACTTTCAAGAAG

GTCTCGGTACCTTCGACTCCTCGGTGCTGAGCTGGCCGGGCAACGACCGTCTGCTCACCCCCAACGAGTTCGAGATCAA
 GCGCTCGGTTCGACGGGGAGGGCTACAACGTGGCCAGTGCAACATGACCAAGGACTGGTTCTGGTCCAGATGCTGG
 CCAACTACAACATCGGCTACCAGGGCTTCTACATCCCAGAGAGCTACAAGGACAGGATGTACTCCTTCTTCAGGAAC
 TTCCAGCCCATGAGCCGGCAGGTGGTGGACCAGACCAAGTACAAGGACTACCAGGAGGTGGGCATCATCCACCAGCA
 5 CAACAACTCGGGCTTCGTGGGCTACCTCGCCCCACCATGCGCGAGGGACAGGCCTACCCCGCCAACTTCCCCTATC
 CGCTCATAGGCAAGACCGCGGTGACAGCATCACCCAGAAAAAGTTCTCTGCGACCGCACCCCTCTGGCGCATCCCC
 TTCTCCAGCAACTTCATGTCCATGGGTGCGCTCTCGGACCTGGGCCAGAACTTGCTCTACGCCAACTCCGCCACGC
 CCTCGACATGACCTTCGAGGTGACCCCATGGACGAGCCACCCCTTCTCTATGTTCTGTTTGAAGTCTTTGACGTGG
 TCCGGGTCCACCAGCCGACCGCGGGCGTTCGAGACCGTGTACCTGCGTACGCCCTTCTCGGCCGGCAACGCCACC
 10 ACCTAAAGAAGCAAGCCGAGTCATCGCCGCTGCATGCCGTGCGGTTCCACCAGCAAGAGCTCAGGGCCATCGTC
 AGAGACCTGGGATGCGGGCCCTATTTTTTGGGCACCTTCGACAAGCGCTTCCCTGGCTTTGTCTCCCCACACAAGCT
 GGCTGCGCCATCGTCAACACGGCCGGCCGCGAGACCGGGGGCGTGCCTGGCTGGCTTCGCCGGAACCCGCGCT
 CAAAACATGCTTCTCTTTGACCCCTTCGGCTTTTCGGACAGCGGCTCAAGCAAATCTACGAGTTCGAGTACGAG
 GGCTTGCTGCGTCGCGAGCGCCATCGCTCCTCGCCGACCGTGCCTCACCCCTCGAAAAGTCCACCCAGACCGTGCA
 15 GGGGCCCCGACTCGGCCGCTGCGGTCTCTTCTGCTGCATGTTTCTGCACGCCTTTGTGCACTGGCCTCAGAGTCCCA
 TGGACCGCAACCCACCATGAACTTGCTGACGGGGGTGCCAACTCCATGCTCCAGAGCCCCAGGTGAGCCCCACC
 CTGCGCCGCAACCAGGAGCAGCTCTACAGCTTCTGAGCGCCACTCGCCTTACTTCCGCCGCCACAGCGCACAGAT
 CAGGAGGGCCACCTCCTTCTGCCACTTGCAAGAGATGCAAGAAGGGTAATAACGATGTACACACTTTTTTTCTCAAT
 AAATGGCATCTTTTTATTTATACAAAGCTCTCTGGGGTATTCAATTTCCACCACCACCCGCCGTTGTCGCCATCTGGC
 20 TCTATTTAGAAATCGAAAGGGTCTGCGGGGAGTGCCTGCGCCACGGGCAGGGACACGTTGCGATACTGGTAGCG
 GGTGCCCCACTTGAACTCGGGCACCACCAGGCGAGGCAGCTCGGGGAAGTTTTCTGCTCCACAGGCTGCGGGTACGA
 CCAGCGCGTTTCATCAGGTGCGGCGCCGAGATCTTGAAGTCGCAGTTGGGGCCGCCGCCCTGCGCGCGCGAGTTGCGG
 TACACCGGGTTGCGCACTGGAACACCAACAGCGCCGGGTGCTTCACGCTGGCCAGCACGCTGCGGTGCGAGATCAG
 CTCGGCGTCCAGGTCTCCGCGTTGCTCAGCGCGAACGGGGTATCTTGGGCATTGCGGCCCCAGGAAGGGCGCGT
 25 GCCCCGGTTTCGAGTTGCAGTCGCGAGCGCAGCGGGATCAGCAGGTGCCCGTGCCCGGACTCGGCGTTGGGGTACAGC
 GCGCGCATGAAGGCTGCATCTGGCGGAAGGCCATCTGGGCCTTGGCGCCCTCCGAGAAGAACATGCCGAGGACTT
 GCCCCGAACTGGTTTTCGGGGCAGCTGGCGTCTGTCAGGCAGCAGCGCGCTCGGTGTTGGCGATCTGCACCACGT
 TGCGCCCCACCGGTTCTTCACGATCTTGGCCTTGGACGATTGCTCCTTCAGCGCGCGCTGCCCGTTCTCGCTGGTC
 ACATCCATCTCGATCACATGTTTCTTACCATGCTGCTGCCGTGCGACACTTCAGCTCGCCCTCCGTCTCGGT
 30 GCAGCGGTGCTGCCACAGCGCGCAGCCGTGGGCTCGAAAGACTTGTAGGTACCTCCGCGAAGGACTGCAGGTACC
 CCTGCAAAAAGCGGCCCATCATGGTTCAGAAAGTCTTGTGCTGCTGAAGGTCAGCTGCAGCCCGCGGTGCTCCTCG
 TTCAGCCAGGTCTTGACACGGCCGCCAGCGCCTCCACCTGGTCGGGCAGCATCTTGAAGTTCACCTTCAGCTCATT
 CTCCACGTGGTACTTGTCCATCAGCGTGCAGCGCCGCTCCATGCCCTTCTCCAGGCCGACACCAGCGGCAGGCTCA
 CGGGGTTCTTCACCATCACCGTGGCCGCCGCTCCGCGCGCTTTTCGCTTTCCGCCCGCTGTTCTCTTCTCTTCC
 35 TCCTCTTCTCGCCGCCGCCACTTCGAGCCCCCGCACACGGGGTGTCTTCTGCGAGGCGCTGCACCTTGCCTT
 GCCGTTGCGCCCCGCTTGATGCGCACGGGCGGGTTGCTGAAGCCACCATCACAGCGCGGCTCTTCTTGTCTCGT
 CCTCGCTGTCCAGAAATGACCTCCGGGGAGGGGGGTTGGTCATCTCAGTACCGAGGCACGCTTCTTTTTCTTCTTG
 GGGGCGTTGCGCAGCTCCGCGGCTGCGGCCGCTGCCGAGGTGCAAGGCCAGGGCTGGGCGTGCGGGCACACGCGC
 GTCCTGCGAGCCGTCTCGTCTCTCTCGGACTCGAGACGGAGGCGGGCCGCTTCTTCGGGGGCGCGGGGGCGGCG
 40 GAGGCGGCGGCGGCGACGAGACGGGGACGAGACATCGTCCAGGTGGGTGGACGGCGGGCCGCGCCGCTCCGCGC

TCGGGGGTGGTCTCGCGCTGGTCCCTCTTCCCGACTGGCCATCTCCCACTGCTCCTTCTCCTATAGGCAGAAAGAGAT
 CATGGAGTCTCTCATGCGAGTCGAGAAGGAGGAGGACAGCCTAACCGCCCCCTCTGAGCCCTCCACCACCGCCGCCA
 CCACCGCCAATGCCGCCGCGGACGACGCGCCACCGAGACCACCGCCAGTACCACCCTCCCCAGCGACGCACCCCCG
 CTCGAGAATGAAGTGCTGATCGAGCAGGACCCGGGTTTTGTGAGCGGAGAGGAGGATGAGGTGGATGAGAAGGAGAA
 5 GGAGGAGGTGCGCCGCTCAGTGCCAAAAGAGGATAAAAAGCAAGACCAGGACGACGCAGATAAGGATGAGACAGCAG
 TCGGGCGGGGGAACGGAAGCCATGATGCTGATGACGGCTACCTAGACGTGGGAGACGACGTGCTGCTTAAGCACCTG
 CACCGCCAGTGCCTCATCGTCTGCGACGCGCTGCAGGAGCGCTGCGAAGTGCCCTGGACGTGGCGGAGGTGAGCCG
 CGCCTACGAGCGGCACCTCTTCGCGCCGCACGTGCCCCCAAGCGCCGGGAGAACGGCACCTGCGAGCCCAACCCGC
 GTCTCAACTTCTACCCGGTCTTCGCGGTACCCGAGGTGCTGGCCACCTACCACATCTTTTTCCAAAAGTGCAAGATC
 10 CCCCTCTCCTGCCGCGCAACCGCACCCGCGCCGACAAAACCTGACCCTGCGGCAGGGCGCCACATACCTGATAT
 CGCCTCTCTGGAGGAAGTGCCCAAGATCTTCGAGGGTCTCGGTGCGACGAGAAACGGGCGGCGAACGCTCTGCACG
 GAGACAGCGAAACGAGAGTCACTCGGGGGTGTGGTGGAGCTCGAGGGCGACAACGCGCGCCTGGCCGTACTCAAG
 CGCAGCATAGAGGTACCCACTTTGCTACCCGGCGCTCAACCTGCCCCCAAGGTCATGAGTGTGGTCAATGGGCGA
 GCTCATCATGCGCCGCGCCAGCCCCCTGGCCGCGGATGCAAACTTGCAAGAGTCCTCCGAGGAAGGCTGCCCGCGG
 15 TCAGCGACGAGCAGCTGGCGCGCTGGCTGGAGACCCGCGACCCCGCGCAGCTGGAGGAGCGGCGCAAGCTCATGATG
 GCCGCGGTGCTGGTCACCGTGGAGCTCGAGTGTCTGCAGCGCTTCTTCGCGGACCCCGAGATGCAGCGCAAGCTCGA
 GGAGACCCGCACTACACCTTCCGCCAGGGCTACGTGCGCCAGGCCTGCAAGATCTCCAACGTGGAGCTCTGCAACC
 TGGTCTCCTACCTGGGCATCCTGCACGAGAACCGCCTCGGGCAGAACGTCTGCACTCCACCCTCAAAGGGGAGGCG
 CGCCGCGACTACATCCGCGACTGCGCCTACCTCTTCTCTGCTACACCTGGCAGACGGCCATGGGGGTCTGGCAGCA
 20 GTGCTGGAGGAGCGCAACCTCAAGGAGCTGGAAAAGCTCCTCAAGCGCACCCCTCAGGGACCTCTGGACGGGCTTCA
 ACGAGCGCTCGGTGGCCGCCGCGCTGGCGGACATCATCTTTCCGAGCGCCTGCTCAAGACCCCTGCAGCAGGGCCTG
 CCCGACTTCACCGCCAGAGCATGCTGCAGAACTTCAGGACTTTCATCCTGGAGCGCTCGGGCATCCTGCCGGCCAC
 TTGCTGCGCGCTGCCACGCACTTCGTGCCCATCAAGTACAGGGAGTGCCCGCCGCGCTCTGGGGCCACTGCTACC
 TCTTCCAGCTGGCCAACCTACCTCGCCTACCACTCGGACCTCATGGAAGACGTGAGCGGCGAGGGCTGCTCGAGTGC
 25 CACTGCCGCTGCAACCTCTGCACGCCCCACCGCTCTCTAGTCTGCAACCCGCAGCTGCTCAGCGAGAGTCAGATTAT
 CGGTACCTTCGAGCTGCAGGGTCCCTCGCCTGACGAGAAGTCCGCGGCTCCAGGGCTGAAACTCACTCCGGGGCTGT
 GGACTTCCGCCCTACCTACGCAAAATTTGTACCTGAGGACTACCACGCCCACGAGATCAGGTTCTACGAAGACCAATCC
 CGCCCGCCCAAGGCGGAGCTCACCGCCTGCGTCATCACCCAGGGGCACATCCTGGGCCAATTGCAAGCCATCAACAA
 AGCCCGCCGAGAGTTCTTGCTGAAAAAGGGTCGGGGGGTGTACCTGGACCCCCAGTCCGGCGAGGAGCTAAACCCGC
 30 TACCCCGCCGCCGCCAGCAGCGGGACCTTGCTTCCCAGGATGGCACCCAGAAAGAAGCAGCAGCCGCCGCCGCC
 GCCGCGAGCCATACATGCTTCTGGAGGAAGAGGAGGAGGACTGGGACAGTCAGGCAGAGGAGGTTTCGGACGAGGAGC
 AGGAGGAGATGATGGAAGACTGGGAGGAGGACAGCAGCCTAGACGAGGAAGCTTCAGAGGCCGAAGAGGTGGCAGAC
 GCAACACCATCGCCCTCGGTGCGAGCCCCCTCGCCGGGGCCCCCTGAAATCCTCCGAACCCAGCACCAGCGCTATAAC
 CTCCGCTCCTCCGGCGCCGGCGCCACCCGCCGCGAGACCCAACCGTAGATGGGACACCACAGGAACCGGGGTGCGTA
 35 AGTCCAAGTGCCCGCCGCCGCCACCCGAGCAGCAGCAGCAGCAGCGCCAGGGCTACCGCTCGTGGCGCGGGCACAAG
 AACGCCATAGTCGCTTGCAAGACTGCGGGGGCAACATCTCTTTCGCCCCGCGCTTCTGCTATTCCACCACGG
 GGTGCTCTTTCCCGCAATGTCTGCAATTACTACCGTCTATCTTACAGCCCCCTACTGCAGCGGCGACCCAGAGGCGG
 CAGCGGCAGCCACAGCGGCGACCAACCTAGGAAGATATCCTCCGCGGGCAAGACAGCGGCAGCAGCGGCCAGGAG
 ACCCGCGGCAGCAGCGGCGGGAGCGGTGGGCGCACTGCGCCTCTCGCCCAACGAACCCCTCTCGACCCGGGAGCTCA
 40 GACACAGGATCTTCCCACTTTGTATGCCATCTTCCAACAGAGCAGAGGCCAGGAGCAGGAGCTGAAAATAAAAAAC

50

ACTCTTCTTCTTTTGCCACTCCCGAATACCCTCCCGATTCTACTTTCCACATCACGGGTACCAAAGACCCCTAACCTC
 TCTTTCTACCTGATGCTGCTGCTCTGTATCTCTGTGGTCTCTTCCGCGCTGATGTTACTGGGGATGTTCTGCTGCCT
 GATCTGCCGCAGAAAAGAGAAAAGCTCGCTCTCAGGGCCAACCACTGATGCCCTTCCCCTACCCCCGGATTTTGCAG
 ATAACAAGATATGAGCTCGCTGCTGACACTAACCGCTTTACTAGCCTGCGCTCTAACCCTTGTGCTTGCAGACTCGA
 5 GATTCCACAATGTCACAGCTGTGGCAGGAGAAAATGTTACTTTCAACTCCACGGCCGATACCCAGTGGTCTGAGAGT
 GGCTCAGGTAGCTACTTAACCTATCTGCAATAGCTCCACTTCCCCCGGCATATCCCCAACCAAGTACCAATGCAATGC
 CAGCCTGTTTACCCTCATCAACGCTTCCACCCTGGACAATGGACTCTATGTAGGCTATGTACCCCTTGGTGGGCAAG
 GAAAGACCCACGCTTACAACCTGGAAGTTCGCCAGCCGAGAACCCTACCCAAGCTTCTCCACCACCACCACCACC
 ACCACCATCACCAGCAGCAGCAGCAGCAGCAGCCACAGCAGCAGCAGCAGATTATTGACTTTTGGTTTTGGCCAGCTC
 10 ATCTGCCGCTACCCAGGCCATCTACAGCTCTGTGCCGAAACCACTCAGATCCACGCCCAGAAACGACCACCGCCA
 CCACCCTACACACCTCCAGCGATCAGATGCCGACCAACATCACCCCTTGGCTCTTCAAATGGGACTTACAAGCCCC
 ACTCCAAAACCAAGTGATGCGGCCGAGGTCTCCGCCCTCGTCAATGACTGGGCGGGGCTGGGAATGTGGTGGTTCGC
 CATAGGCATGATGGCGCTCTGCCTGCTTCTGCTCTGGCTCATCTGCTGCCTCCACGCGAGGCGAGCCAGACCCCCCA
 TCTATAGACCCATCATTTGTCTGAACCCCGATAATGATGGGATCCATAGATTGGATGGCCTGAAAAACCTACTTTTTT
 15 TCTTTTACAGTATGATAAATTGAGACATGCCTCGCATTTTCTTGTACATGTTCTTCTCCACCTTTTCTGGGGTGT
 TCTACGCTGGCCGCTGTGTCTCACCTGGAGGTAGACTGCCTCTCACCTTCACTGTCTACCTGCTTACGGATTGGT
 CACCCTCACTCTCATCTGCAGCCTAATCACAGTAATCATCGCCTTCATCCAGTGCATTGATTACATCTGTGTGCGCC
 TCGCATACTTCAGACACCACCCGCGAGTACCGAGACAGGAACATTGCCCAACTTCTAAGACTGCTCTAATCATGCATA
 AGACTGTGATCTGCCTTCTGATCCTCTGCATCCTGCCACCCCTCACCTCCTGCCAGTACACCACAAAAATCTCCGCGC
 20 AAAAGACATGCCTCCTGCCGCTTCAACCAACTGTGGAATATACCCAAATGCTACAACGAAAAGAGCGAGCTCTCCGA
 AGCTTGGCTGTATGGGGTCATCTGTGTCTTAGTTTTCTGCAGCACTGTCTTTGCCCTCATAATCTACCCCTACTTTG
 ATTTGGGATGGAACGCGATCGATGCCATGAATTACCCACCTTTCCCGCACCCGAGATAATTCCACTGCGACAAGTT
 GTACCCGTTGTGCTTAATCAACGCCCCCATCCCTACGCCCCTGAAATCAGCTACTTTAACCTAACAGGCGGAGA
 TGAAGTACGCCCCTAGATCTAGAAAATGGACGGCATCAGTACCGAGCAGCGTCTCCTAGAGAGGCGCAGGCAGGCGGCT
 25 GAGCAAGAGCGCCTCAATCAGGAGCTCCGAGATCTCGTTAACCTGCACCAGTGCAAAAGAGGCATCTTTTGTCTGGT
 AAAGCAGGCCAAAGTCACTTACGAGAAGACCGGCAACAGCCACCGCCTCAGTTACAAATTGCCACCCAGCGCCAGA
 AGCTGGTGTCTATGGTGGGTGAGAATCCCATCACCGTCAACCCAGCACTCGGTAGAGACCGAGGGGTGTCTGCACTCC
 CCCTGTGCGGGTCCAGAAGACCTCTGCACCCTGGTAAAGACCTGTGCGGTCTCAGAGATTTAGTCCCTTTAACTA
 ATCAAACACTGGAATCAATAAAAAAGAACTACTTACTTAAATCAGACAGCAGGTCTCTGTCCAGTTTATTACAGCAGC
 30 ACCTCCTTCCCTCTCCCAACTCTGGTACTCCAAACGCCTTCTGGCGGCAAACTTCCTCCACACCCTGAAGGGAAT
 GTCAGATTCTTGTCTCTGTCCCTCCGCACCCACTATCTTCATGTTGTTGCAGATGAAGCGCACCAAAACGTCTGACG
 AGAGCTTCAACCCCGTGTACCCCTATGACACGGAAAGCGGCCCTCCCTCCGTCCCTTTCTCACCCCTCCCTTCGTG
 TCTCCCGATGGATTCCAAGAAAGTCCCCCGGGTCTGTCTCTGAACCTGGCCGAGCCCTGGTCACTTCCACCGG
 CATGCTCGCCCTGAAAAATGGGAAGTGGCCTCTCCCTGGACGACGCTGGCAACCTCACCTCTCAAGATATCACCAACG
 35 CTAGCCCTCCCTCAAAAAACCAAGACCAACCTCAGCCTAGAAACCTCATCCCCCTAACTGTGAGCACCTCAGGC
 GCCCTCACCGTAGCAGCCGCCGCTCCCTGGCGGTGGCCGGCACCTCCCTCACCATGCAATCAGAGGCCCCCTGAC
 AGTACAGGATGCAAAACTCACCTGGCCACCAAGGCCCTTGACCGTGTCTGAAGGCAAACTGGCCTTGCAACAT
 CGGCCCCGCTGACGGCCGCTGACAGCAGCACCCCTCACAGTCAGTGCCACACCACCCCTTAGCACAAAGCAATGGCAGC
 TTGGGTATTGACATGCAAGCCCCATTTACACCACCAATGGAAAACCTAGGACTTAACCTTTGGCGCTCCCTTCATGT
 40 GGTAGACAGCCTAAATGCACTGACTGTAGTTACTGGCCAAGGTCTTACGATAAACGGAACAGCCCTACAAACTAGAG

TCTCAGGTGCCCTCAACTATGACACATCAGGAAACCTAGAATTGAGAGCTGCAGGGGGTATGCGAGTTGATGCAAAT
 GGTCAACTTATCCTTGATGTAGCTTACCCATTTGATGCACAAAACAATCTCAGCCTTAGGCTTGGACAGGGACCCCT
 GTTTGTTAACTCTGCCACAACCTGGATGTAACTACAACAGAGGCCCTCTACCTGTTACATCTGGAAATACCAAAA
 AGCTAGAAGTTAATATCAAAAACAGCCAAGGGTCTCATTTATGATGACACTGCTATAGCAATCAATGCGGGTGATGGG
 5 CTACAGTTTGAAGTCAAGGCTCAGATACAAATCCATTAAAACTAAACTTGGATTAGGACTGGATTATGACTCCAGCAG
 AGCCATAATTGCTAAACTGGGAACCTGGCCTAAGCTTTGACAACACAGGTGCCATCACAGTAGGCAACAAAAATGATG
 ACAAGCTTACCTTGTGGACCACACCAGACCCATCCCCTAACTGTAGAATCTATTTCAGAGAAAGATGCTAAATTCACA
 CTTGTTTTGACTAAATGCGGCAGTCAGGTGTTGGCCAGCGTTTCTGTTTTATCTGTAAAAGGTAGCCTTGCGCCCAT
 CAGTGGCACAGTAACTAGTCTCAGATTGTCCTCAGATTTGATGAAAATGGAGTTCTACTAAGCAATTCTTCCCTTG
 10 ACCCTCAATACTGGAACACAGAAAAGGTGACCTTACAGAGGGCACTGCATATACCAACGCAGTGGGATTTATGCCC
 AACCTCACAGCATACCCAAAAACACAGAGCCAACTGCTAAAAGCAACATTGTAAGTCAGGTTTACTTGAATGGGGA
 CAAATCCAAACCCATGACCCTCACCATTACCCTCAATGGAACATAATGAAACAGGAGATGCCACAGTAAGCACTTACT
 CCATGTCATTCTCATGGAACCTGGAATGGAAGTAATTACATTAATGAAACGTTCCAAACCAACTCCTTCACCTTCTCC
 TACATCGCCCAAGAATAAAAAAGCATGACGCTGTTGATTTGATTCAATGTGTTTTCTGTTTTATTTTCAAGCACAACAA
 15 AATCATTCAAGTCATTCTTCCATCTTAGCTTAATAGACACAGTAGCTTAATAGACCCAGTAGTGCAAAGCCCCATTC
 TAGCTTATAGATCAGACAGTGATAATTAACCACCACCACCACCATACCTTTTGATTTCAGGAAATCATGATCATCACA
 GGATCCTAGTCTTCAGGCCGCCCCCTCCCTCCCAAGACACAGAATACACAGTCTCTCCCCCGACTGGCTTTAAAT
 AACACCATCTGGTTGGTCACAGACATGTTCTTAGGGGTTATATTCCACACGGTCTCCTGCCGCGCCAGGCGCTCGTC
 GGTGATGTTGATAAACTCTCCCGGCAGCTCGCTCAAGTTCACGTGCTGTCCAGCGGTGAACCTCCGGCTGACGCG
 20 ATAACGTGTCGACCGGCTGCTGGACGAACGGAGGCCGCGCTACAAGGGGGTAGAGTCATAATCCTCGGTCAGGATA
 GGGCGGTGATGCAGCAGCAGCGAGCGAAACATCTGCTGCCGCGCGCGCTCCGTCCGGCAGGAAAACAACACGCCCGGT
 GGTCTCCTCCGCGATAATCCGCACCGCCCGCAGCATCAGCTTCTCGTTCTCCGCGCGCAGCACCTCACCTTATCT
 CGCTCAAATCGGCGCAGTAGGTACAGCACAGCACCACGATGTTATTTCATGATCCACAGTGCAGGGCGCTGTATCCA
 AAGCTCATGCCGGGAACCAACCGCCCCACGTGGCCATCGTACCACAAGCGCACGTAAATCAAGTGTGACCCCTCAT
 25 GAACGCGCTGGACACAAACATTACTTCTTGGGCATGTTGTAATTCACCACCTCCCGGTACCAGATAAACCTCTGGT
 TGAACAGGGCACCTTCCACCACCATCTGAAACCAAGAGGCCAGAACCTGCCACCGGCTATGCACTGCAGGGAACCC
 GGGTTGGAACAATGACAATGCAGACTCCAAGGCTCGTAACCGTGGATCATCCGGCTGCTGAAGGCATCGATGTTGGC
 ACAACACAGACACACGTGCATGCACTTTCTCATGATTAGCAGCTCTTCCCTCGTCAGGATCATATCCCAAGGAATAA
 CCCATTCTTGAATCAACGTAAACCCACACAGCAGGGAAGGCCTCGCACATAACTCACGTTGTGCATGGTCAGCGTG
 30 TTGCATTCCGAAACAGCGGATGATCCTCCAGTATCGAGGCGCGGGTCTCCTTCTCACAGGGAGGTAAAGGGTCCCT
 GCTGTACGGACTGCGCCGGGACGACCGAGATCGTGTTGAGCGTAGTGTCATGGAAAAGGGAACGCCGGACGTGGTCA
 TACTTCTTGAAGCAGAACCAGGTTTCGCGCGTGGCAGGCCTCCTTGCGTCTGCGGTCTCGCCGTCTAGCTCGCTCCGT
 GTGATAGTTGTAGTACAGCCACTCCCGCAGAGCGTCGAGGCGCACCTGGCTTCCGGATCTATGTAGACTCCGTCTT
 GCACCGCGGCCCTGATAATATCCACCACCGTAGAATAAGCAACACCCAGCCAAGCAATACACTCGCTCTGCGAGCGG
 35 CAGACAGGAGGAGCGGGCAGAGATGGGAGAACCATGATAAAAACTTTTTTTAAAGAATATTTTCCAATTCTTCGAA
 AGTAAGATCTATCAAGTGGCAGCGCTCCCCCTCCACTGGCGCGGTCAAACCTCTACGGCCAAAGCACAGACAACGGCAT
 TTCTAAGATGTTCTTAATGGCGTCCAAAAGACACACCGCTCTCAAGTTGCAGTAAACTATGAATGAAAACCCATCC
 GGCTGATTTTCCAATATAGACGCGCCGGCAGCGTCCACCAAACCCAGATAATTTTCTTCTCTCCAGCGGTTTACGAT
 CTGCTAAGCAAATCCCTTATATCAAGTCCGACCATGCCAAAATCTGCTCAAGAGCGCCCTCCACCTTCATGTACA
 40 AGCAGCGCATCATGATTGCAAAAATTCAGGTTCTTCAGAGACCTGTATAAGATTCAAATGGGAACATTAACAAAAA

TTCTCTGTCGCGCAGATCCCTTCGCAGGGCAAGCTGAACATAATCAGACAGGTCCGAACGGACCAGTGAGGCCAAA
 TCCCCACCAGGAACCAGATCCAGAGACCTATACTGATTATGACGCGCATACTCGGGGTATGCTGACCAGCGTAGC
 GCCGATGTAGGCGTGCTGCATGGGCGGCGAGATAAAATGCAAAGTGCTGGTTAAAAAATCAGGCAAAGCCTCGCGCA
 AAAAAGCTAACACATCATAATCATGCTCATGCAGGTAGTTGCAGGTAAGCTCAGGAACCAAAACGGAATAACACACG
 5 ATTTTCTCTCAAACATGACTTCGCGGATACTGCGTAAAACAAAAAATTATAAATAAAAAATTAATTAAATAACTTA
 AACATTGGAAGCCTGTCTCACAACAGGAAAAACCACTTTAATCAACATAAGACGGGCCACGGGCATGCCGGCATAGC
 CGTAAAAAAATTGGTCCCCGTGATTAACAAGTACCACAGACAGCTCCCCGGTCATGTCGGGGGTTCATCATGTGAGAC
 TCTGTATACACGTCTGGATTGTGAACATCAGACAAACAAAGAAATCGAGCCACGTAGCCCGGAGGTATAATCACCCG
 CAGGCGGAGGTACAGCAAAACGACCCCCATAGGAGGAATCACAAAATTAGTAGGAGAAAAAATACATAAAACACCAG
 10 AAAAACCCTGTTGCTGAGGCAAAATAGCGCCCTCCCGATCCAAAACAACATAAAGCGCTTCCACAGGAGCAGCCATA
 ACAAAGACCCGAGTCTTACCAGTAAAAGAAAAAAGATCTCTCAACGCAGCACCAGCACCAACACTTCGCAGTGTA
 AGGCCAAGTGCCGAGAGAGTATATATAGGAATAAAAAGTGACGTAAACGGGCAAAGTCCAAAAACGCCAGAAAAA
 CCGCACGCGAACCTACGCCCCGAAACGAAAGCCAAAAACACTAGACACTCCCTTCCGGCGTCAACTTCCGCTTTCC
 CACGCTACGTCACTTCCCCCGGTCAAACAAACTACATATCCCGAATTCCAAGTCGCCACGCCCCAAACACCGCCTA
 15 CACCTCCCCGCCCGCCGGCCCCGCCCGGACCCGCCTCCCGCCCCGCGCCGCCCATCTCATTATCATATTGGCTTCA
 ATCCAAAATAAGGTATATTATTGATGATG

SEQ ID NO: 2 Polynucleotide sequence encoding wild type ChAd83

CATCATCAATAATATACCTCAAACCTTTTGGTGCGCGTTAATATGCAAATGAGCTGTTTGAATTTGGGGAT
 20 GCGGGGCGCTGATTGGCTGCGGGAGCGGCGACCGTTAGGGGCGGGGCGGGTGACGTTTTGATGACGTGGC
 CGTGAGGCGGAGCCGGTTTGAAGTTCTCGTGGGAAAAGTGACGTCAAACGAGGTGTGGTTTGAACACGG
 AAATACTCAATTTTCCGCGCTCTCTGACAGGAAATGAGGTGTTTCTGGGCGGATGCAAGTGAAAACGGG
 CCATTTTTCGCGCGAAACTGAATGAGGAAGTGAAAATCTGAGTAATTTTCGCGTTTATGGCAGGGAGGAGT
 ATTTGCCGAGGGCCGAGTAGACTTTGACCGATTACGTGGGGGTTTCGATTACCGTATTTTTCACCTAAAT
 25 TTCCGCGTACGGTGTCAAAGTCCGGTGTTTTTACGTAGGCGTCAGCTGATCGCCAGGGTATTTAAACCTG
 CGCTCACTAGTCAAGAGGCCACTCTTGAGTGCCAGCGAGTAGAGTTTTCTCCTCCGCGCCGCGAGTCAGA
 TCTACACTTTGAAAGATGAGGCACTTGAGAGACCTGCCCGGTAATGTTTTCTGGCTACTGGGAACGAGA
 TTCTGGAATTGGTGGTGGACGCCATGATGGGTGACGACCCTCCCGAGCCCCCTACCCCATTTGAGGCGCC
 TTCGCTGTACGATTTGTATGATCTGGAGGTGGATGTGCCCCGAGAACGACCCCAACGAGGAGGCGGTGAAT
 30 GATTTGTTTAGCGATGCCGCGCTGCTGGCTGCCGAGCAGGCTAATACGGACTTTGGCTCAGACAGCGATT
 CTTCTCTCCATACCCCGAGACCCGGCAGAGGTGAGAAAAAGATCCCCGAGCTTAAAGGGGAAGAGCTCGA
 CCTGCGCTGCTATGAGGAATGCTTGCCCTCCGAGCGATGATGAGGAGGACGAGGAGGCGATTTCGAGCTGCA
 GCGAACCAGGGAGTGAAAGCTGCGGGCGAAAGCTTTAGCCTGGACTGTCTACTCTGCCCGGACACGGCT
 GTAAGTCTTGTGAATTTTCATCGCATGAATACTGGAGATAAGAATGTGATGTGTGCCCTGTGCTATATGAG
 35 AGCTTACAACCATTTGTGTTTACAGTAAGTGTGATTAACTTTAGTTGGGAAGGCAGAGGGTGACTGGGTGC
 TGAAGTGGTTTATTTATGTATATGTTTTTTATGTGTAGGTCCCGTCTCTGACGCGAGATGAGACCCCCACTT
 CAGAGTGCATTTTCATCACCCCCAGAAATTGGCGAGGAACCGCCGAAGATATTATTCATAGACCAGTTGC
 AGTGAGAGTCACCGGGCGGAGAGCAGCTGTGGAGAGTTTGGATGACTTGCTACAGGGGTGGGGATGAACCT
 TTGGACTTGTGTACCCGGAAACGCCCCAGGCACCTAAGTGCCACACATGTGTGTTTACTTAAGGTGATGTC
 40 AGTATTTATAGGGTGTGGAGTGCAATAAAATCCGTGTTGACTTTAAGTGCGTGGTTTATGACTCAGGGGT

GGGGACTGTGGGTATATAAGCAGGTGCAGACCTGTGTGGTCAGTTCAGAGCAGGACTCATGGAGATCTGG
 ACGGTCTTGGAAGACTTTCACCAGACTAGACAGCTGCTAGAGAACTCATCGGAGGGAGTCTCTTACCTGT
 GGAGATTCTGCTTCGGTGGGCCTCTAGCTAAGCTAGTCTATAGGGCCAAGCAGGATTATAAGGATCAATT
 TGAGGATATTTTGAGAGAGTGTCTTGGTATTTTGGACTCTCTCAACTTGGGCCATCAGTCTCACTTTAAC
 5 CAGAGTATTCTGAGAGCCCTTGACTTTTCCACTCCTGGCAGAACTACCGCCGCGGTAGCCTTTTTTGCCT
 TTATCCTTGACAAATGGAGTCAAGAAACCCATTTTCAGCAGGGATTACCGTCTGGACTGCTTAGCAGTAGC
 TTTGTGGAGAACATGGAGGTGCCAGCGCCTGAATGCAATCTCCGGCTACTTGCCAGTACAGCCGGTAGAC
 ACGCTGAGGATCCTGAGTCTCCAGTCACCCAGGAACACCAACGCCGCCAGCAGCCGCAGCAGGAGCAGC
 AGCAAGAGGAGGACCGAGAAGAGAACCCGAGAGCCGGTCTGGACCTCCGGTGGCGGAGGAGGAGGAGTA
 10 GCTGACTTGTTTTCCCGAGCTGCGCCGGGTGCTGACTAGGTCTTCCAGTGGACGGGAGAGGGGGATTAAGC
 GGGAGAGGCATGAGGAGACTAGTCACAGAACTGAACTGACTGTCAGTCTGATGAGCCGCAGCGCCCAGA
 ATCGGTGTGGTGGCATGAGGTGCAGTCGCAGGGGATAGATGAGGTCTCGGTGATGCATGAGAAATATTCC
 CTAGAACAAGTCAAGACTTGTTGGTTGGAGCCTGAGGATGATTGGGAGGTAGCCATCAGGAATTATGCCA
 AGCTAGCTCTGAAGCCAGACAAGAAGTACAAGATTACCAAAGTATTAATATCAGAAATTCCTGCTACAT
 15 TTCAGGGAATGGGGCCGAGGTGGAGATCAGTACCCAGGAGAGGGTGGCCTTCAGATGCTGCATGATGAAT
 ATGTACCCGGGGGTGGTGGGCATGGAGGGAGTCACTTTTATGAACGCGAGGTTTCAGGGGCGATGGGTATA
 ATGGGGTGGTCTTTATGGCCAACACCAAGCTGACAGTGCACGGATGCTCCTTCTTTGGCTTCAATAACAT
 GTGCATCGAGGCCTGGGGCAGTGTTTCAGTGAGGGGATGCAGTTTTTTCAGCCAACTGGATGGGGGTCTGTG
 GGCAGAACCAAGAGCAAGGTGTCAGTGAAGAAATGCCTGTTTCGAGAGGTGCCACCTGGGGGTGATGAGCG
 20 AGGGCGAAGCCAAAGTCAAACACTGCGCCTCTACTGAGACGGGCTGCTTTGTGCTGATCAAGGGCAATGC
 CCAAGTCAAGCATAACATGATCTGTGGGGCCTCGGATGAGCGCGGCTACCAGATGCTGACCTGCGCCGGT
 GGGAACAGCCATATGCTGGCCACCGTGCATGTGACCTCGCACCCCGCAAGACATGGCCCGAGTTCGAGC
 ACAACGTCATGACCCGCTGCAATGTGCACCTGGGCTCCCGCCGAGGCATGTTTCATGCCCTACCAGTGCAA
 CATGCAATTTGTGAAGGTGCTGCTGGAGCCCGATGCCATGTCCAGAGTGAGCCTGACGGGGGTGTTTGAC
 25 ATGAATGTGGAGATGTGGAAAATTCTGAGATATGATGAATCCAAGACCAGGTGCCGGGCCTGCCAATGCG
 GAGGCAAGCAGCCAGGCTTCAGCCCGTGTGTGTGGAGGTGACGGAGGACCTGCGACCCGATCATTTGGT
 GTTGTCTTCAACGGGACGGAGTTTCGGCTCCAGCGGGGAAGAATCTGACTAGAGTGAGTAGTGTGTTGGGG
 GAGGTGGAGGGCCTGGATGAGGGGCAGAATGACTAAAATCTGTGTTTTTCTGCGCAGCAGCATGAGCGGA
 AGCGCCTCCTTTGAGGGAGGGGTATTTCAGCCCTTATCTGACGGGGCGTCTCCCCTCCTGGGCGGGAGTGC
 30 GTCAGAATGTGATGGGATCCACGGTGGACGGCCGGCCCGTGCAGCCCGCGAACTCTTCAACCCTGACCTA
 CGCGACCTGAGCTCCTCGTCCGTGGACGCAGCTGCCGCCGAGCTGCTGCTTCCGCCGCCAGCGCCGTG
 CGCGGAATGGCCCTGGGCGCCGGCTACTACAGCTCTCTGGTGGCCAACTCGAGTTCCACCAATAATCCCG
 CCAGCCTGAACGAGGAGAAGCTGCTGCTGCTGATGGCCAGCTCGAGGCCCTGACCCAGCGCCTGGGCGA
 GCTGACCCAGCAGGTTGCTCAGCTGCAGGCGGAGACGCGGGCCGCGGTTGCCACGGTGAAAACCAATAA
 35 AAAATGAATCAATAAATAAACGGAGACGGTTGTTGATTTTAACACAGAGTCTTGAATCTTTATTTGATTT
 TTCGCGCGCGGTAGGCCCTGGACCACCGGTCTCGATCATTGAGCACCCGGTGGATCTTTTCCAGGACCCG
 GTAGAGGTGGGCTTGATGTTGAGGTACATGGGCATGAGCCCGTCCCGGGGGTGGAGGTAGCTCCATTGC
 AGGGCCTCGTGCTCGGGGGTGGTGTGTAATCACCAGTCATAGCAGGGGCGCAGGGCGTGGTGCTGCA
 CGATGTCTTGAGGAGGAGACTGATGGCCACGGGCAGCCCTTGGTGAGGTGTTGACGAACCTGTTGAG
 40 CTGGGAGGGATGCATGCGGGGGGAGATGAGATGCATCTTGGCCTGGATCTTGAGATTGGCGATGTTCCCG

CCCAGATCCCGCCGGGGTTCATGTTGTGCAGGACCACCAGCACGGTGTATCCGGTGCACCTTGGGGAATT
 TGTTCATGCAACTTGAAGGGAAGGCGTGAAAGAATTTGGAGACGCCCTTGTGGCCGCCAGGTTTTCCAT
 GCACTCATCCATGATGATGGCGATGGGCCCCGTGGGCGGGCCCTGGGCAAAGACGTTTCGGGGGTTCGGAC
 ACATCGTAGTTGTGGTCCTGGGTGAGCTCGTCATAGGCCATTTTAATGAATTTGGGGCGGAGGGTGCCCC
 5 ACTGGGGGACGAAGGTGCCCTCGATCCCGGGGGCGTAGTTGCCCTCGCAGATCTGCATCTCCCAGGCCTT
 GAGCTCGGAGGGGGGATCATGTCCACCTGCGGGGCGATGAAAAAACGGTTTCGGGGCGGGGAGATG
 AGCTGCGCCGAAAGCAGGTTCCGGAGCAGCTGGGACTTGCCGCAGCCGGTGGGGCCGTAGATGACCCCGA
 TGACCGGCTGCAGGTGGTAGTTGAGGGAGAGACAGCTGCCGTCTCGCGGAGGAGGGGGGCCACCTCGTT
 CATCATCTCGCGCACATGCATGTTCTCGCGCACGAGTTCCGCCAGGAGGCGCTCGCCCCCAGCGAGAGG
 10 AGCTCTTGACGCGAGGCGAAGTTTTTCAGCGGCTTGAGCCCGTCGGCCATGGGCATTTTGAGAGAGGGTCT
 GTTGCAAGAGTTCCAGACGGTCCCAGAGCTCGGTGATGTGCTCTAGGGCATCTCGATCCAGCAGACCTCC
 TCGTTTTCGCGGGTTGGGGCGACTGCGGGAGTAGGGCACCAGGCGATGGGCGTCCAGCGAGGCCAGGGTCC
 GGTCTTCCAGGGTTCGAGGGTCCGCGTCAGCGTGGTCTCCGTACGGTGAAGGGGTGCGCGCCGGGCTG
 GCGCTTGCGAGGGTGCGCTTCAGGCTCATCCGGCTGGTCGAGAACCGTCCCGGTGCGCGCCCTGTGCG
 15 TCGGCCAGGTAGCAATTGAGCATGAGTTCGTAGTTGAGCGCCTCGGCCGCGTGGCCCTTGCGCGGAGCT
 TACCTTTGGAAGTGTGTCCGCAGACGGGACAGAGGAGGGACTTGAGGGCGTAGAGCTTGGGGGCGAGGAA
 GACGGAATCGGGGGCGTAGGCGTCCGCGCCGCAGCTGGCGCAGACGGTCTCGCACTCCACGAGCCAGGTG
 AGGTGCGGGGCGGTGCGGGTCAAAAACGAGGTTTCCTCCGTGCTTTTTTGATGCGTTTCTTACCTCTGGTCT
 CCATGAGCTCGTGTCCCCGCTGGGTGACAAAGAGGCTGTCCGTGTCCCCGTAGACCGACTTTATGGGCCG
 20 GTCCTCGAGCGGGGTGCCGCGTCTCGTCGTAGAGGAACCCCGCCACTCCGAGACGAAGCCCCGGGTC
 CAGGCCAGCACGAAGGAGGCCACGTGGGAGGGGTAGCGGTGCTGTGCCACCAGCGGGTCCACCTTCTCCA
 GGGTATGCAAGCACATGTCCCCCTCGTCCACATCCAGGAAGGTGATTGGCTTGTAAGTGTAGGCCACGTG
 ACCGGGGGTCCCGGCCGGGGGGGTATAAAAGGGGGCGGGCCCTGCTCGTCCTCACTGTCTTCCGGATCG
 CTGTCCAGGAGCGCCAGCTGTGGGGTAGGTATTCCTCTCGAAGGCGGGCATGACCTCGGCACTCAGGT
 25 TGTCAGTTTCTAGAAACGAGGAGGATTTGATATTGACGGTGCCGTTGGAGACGCCTTTCATGAGCCCCTC
 GTCCATCTGGTCAGAAAAGACGATCTTTTTGTTGTCGAGCTTGGTGGCGAAGGAGCCGTAGAGGGCGTTG
 GAGAGCAGCTTGGCGATGGAGCGCATGGTCTGGTCTTTTTCTTGTGCGCGCTCCTTGGCGGCATGT
 TGAGCTGCACGTACTCGCGCGCCACGCACTTCCATTCGGGGAAGACGGTGGTGAGCTCGTCGGGCACGAT
 TCTGACCCGCCAGCCGCGGTTGTGCAGGGTGATGAGGTCCACGCTGGTGGCCACCTCGCCGCGCAGGGGC
 30 TCGTTGGTCCAGCAGAGGCGCCCGCCCTTGC GCGAGCAGAAGGGGGGAGCGGGTCCAGCATGAGCTCGT
 CGGGGGGGTCGGCGTCCACGGTGAAGATGCCGGGCAGGAGCTCGGGGTCGAAGTAGCTGATGCAGGTGCC
 CAGATCGTCCAGCGCCGCTTGCCAGTCGCGCACGGCCAGCGCGCGCTCGTAGGGGCTGAGGGGCGTGCCC
 CAGGGCATGGGGTGCGTGAGCGCGGAGGCGTACATGCCGCAGATGTGCTAGACGTAGAGGGGCTCCTCGA
 GGACGCCGATGTAGGTGGGGTAGCAGCGCCCCCGCGGATGCTGGCGCGCACGTAGTCGTACAGCTCGTG
 35 CGAGGGCGCGAGGAGCCCCGTGCCAGGTTGGAGCGTTGCGGCTTTTCGGCGCGGTAGACGATCTGGCGG
 AAGATGGCGTGGGAGTTGGAGGAGATGGTGGGCCCTCTGGAAGATGTTGAAGTGGGCGTGGGGCAGGCCGA
 CCGAGTCCCTGATGAAGTGGGCGTAGGAGTCTGCAGCTTGCGCACGAGCTCGGCGGTGACGAGGACGTC
 CAGGGCGCAGTAGTCGAGGGTCTCTTGATGATGTCGTACTTGAGCTGGCCCTTCTGCTTCCACAGCTCG
 CGGTTGAGAAGGAACCTTCGCGGTCTTCCAGTACTCTTCGAGGGGGAACCCGTCTGATCGGCACGGT
 40 AAGAGCCCACCATGTAGAACTGGTTGACGGCCTTGTAGGCGCAGCAGCCCTTCTCCACGGGGAGGGCGTA

AGCTTGCGCGGCCCTTGCGCAGGGAGGTGTGGGTGAGGGCGAAGGTGTCGCGCACCATGACTTTGAGGAAC
 TGGTGCTTGAAGTCGAGGTCGTCGCAGCCGCCCTGCTCCCAGAGTTGGAAGTCCGTGCGCTTCTTGTAGG
 CGGGGTTGGGCAAAGCGAAAGTAACATCGTTGAAGAGGATCTTGCCCGCGCGGGGCATGAAGTTGCGAGT
 GATGCGGAAAAGGCTGGGGCACCTCGGCCCGGTTGTTGATGACCTGGGCGGCGAGGACGATCTCGTCGAAG
 5 CCGTTGATGTTGTGCCCCACGATGTAGAGTTCCACGAATCGCGGGCAGCCCTTGACGTGGGGCAGCTTCT
 TGAGCTCGTCGTAGGTGAGCTCGGCGGGGTGCTGAGCCCGTGCTGCTCGAGGGCCAGTCGGCGACGTG
 GGGGTTGGCGCTGAGGAAGGAAGTCCAGAGATCCACGGCCAGGGCGGTCTGCAAGCGGTCCCGGTACTGA
 CGGAAC TGCTGGCCACGGCCATTTTTTCGGGGGTGACGCAGTAGAAGGTGCGGGGGTTCGCCGTGCCAGC
 GGTCCCACCTTGAGTTGGAGGGCGAGGTGCTGGGCGAGCTCGACGAGCGGCGGGTCCCCGAGAGTTTCAT
 10 GACCAGCATGAAGGGGACGAGCTGCTTGCCGAAGGACCCCATCCAGGTGTAGGTTTCCACATCGTAGGTG
 AGGAAGAGCCTTTCGGTGCGAGGATGCGAGCCGATGGGAAGAACTGGATCTCCTGCCACCAGTTGGAGG
 AATGGCTGTTGATGTGATGGAAGTAGAAATGCCGACGGCGCGCCGAGCACTCGTGCTTGTGTTTATACAA
 GCGTCCGCAGTGCTCGCAACGCTGCACGGGATGCACGTGCTGCACGAGCTGTACCTGGGTTCCCTTTGACG
 AGGAATTTCACTGGGCGAGTGAGCGCTGGCGGCTGCATCTGGTGCTGTACTACGTCTGGCCATCGGCGT
 15 GGCCATCGTCTGCCTCGATGGTGGTCATGCTGACGAGCCCGCGCGGGAGGCAGGTCCAGACCTCGGCTCG
 GACGGGTCGGAGAGCGAGGACGAGGGCGCGCAGGCCGAGCTGTCCAGGGTCCTGAGACGCTGCGGAGTC
 AGGTCACTGGGCGAGCGGCGGCGCGGTTGACTTGACGAGGCTTTTCCAGGGCGCGCGGGAGGTCCAGAT
 GGTACTTGATCTCCACGGCGCCGTTGGTGGCGACGTCCACGGCTTGACAGGGTCCCGTGCCCCCTGGGGCGC
 CACCACCGTGCCCCGTTTCTTCTTGGGCGGCGGCGGCTCCATGCTTAGAAGCGGCGGCGAGGACGCGCGC
 20 CGGGCGGCAGGGGCGGCTCGGGGCCCGAGGCAGGGGCGGCAGGGGCACGTGCGCGCCGCGCGGGGCGAG
 GTTCTGGTACTGCGCCCCGAGAAGACTGGCGTGAGCGACGACGCGACGGTTGACGTCTGGATCTGACGC
 CTCTGGGTGAAGGCCACGGGACCCGTGAGTTTGAACCTGAAAGAGAGTTTCGACAGAATCAATTTCCGTAT
 CGTTGACGGCGGCCTGCCGACGATCTCTTGACGTCGCCCCGAGTTGTCCTGGTAGGCGATCTCGGTCTAT
 GAACTGCTCGATCTCCTCCTCCTGAAGGTCTCCGCGGCGGCGCGCTCGACGGTGGCCGCGAGGTCTGTTG
 25 GAGATGCGGCCCATGAGCTGCGAGAAGGCGTTCATGCCGGCCTCGTTCCAGACGCGGCTGTAGACCACGG
 CTCCGTTGGGGTCGCGCGCGCGCATGACCACCTGGGCGAGGTTAAGCTCGACGTGGCGGTGAAGACCGC
 GTAGTTGACAGGGCGCTGGTAGAGGTAGTTGAGCGTGGTGGCGATGTGCTCGGTGACGAAGAAGTACATG
 ATCCAGCGGCGGAGCGGCATCTCGCTGACGTGCCCCAGGGCTTCCAAGCGCTCCATGGTCTCGTAGAAGT
 CCACGGCGAAGTTGAAAACTGGGAGTTGCGCGCCGAGACGGTCAACTCCTCCTCCAGAAGACGGATGAG
 30 CTCGGCGATGGTGGCGCGCACCTCGCGCTCGAAGGCCCGGGGGGCTCCTCTTCTTCCATCTCCTCCTCC
 TCTTCTCCTCCACTAACATCTCTTCTACTTCTCCTCCTCAGGAGGCGGCGGGGAGGGGCCCTGCGTC
 GCCGGCGGCGCACGGGACAGCGTTCGATGAAGCGCTCGATGGTCTCCCCGCGCGGCGACGCATGGTCTC
 GGTGACGGCGCGCCCGTCTCGCGGGGCCGACGCTGAAGACGCCCGCGCATCTCCAGGTGGCCGCCG
 GGGGGTCTCCGTTGGGCGAGGAGAGGGCGCTGACGATGCATCTTATCAATTGGCCCGTAGGGACTCCGC
 35 GCAAGGACCTGAGCGTCTCGAGATCCACGGGATCCGAAAACCGCTGAACGAAGGCTTCGAGCCAGTCGCA
 GTCGCAAGGTAGGCTGAGCCCGGTTTCTTGTCTTCGGGTATTTGGTTCGGGAGGCGGGCGGGCGATGCTG
 CTGGTGATGAAGTTGAAGTAGGCGGTCTGAGACGGCGGATGGTGGCGAGGAGCACCAGGTCTTGGGCC
 CGGCTTGCTGGATGCGCAGACGGTCGGCCATGCCCCAGGCGTGGTCTGACACCTGGCGAGGTCTTGTGA
 GTAGTCTGTCATGAGCCGCTCTACGGGACGTCCTCCTCGCCCGCGCGGCGGCGTGCATGCGCGTGAGCCCG
 40 AACCCGCGCTGCGGCTGGACGAGCGCCAGGTGCGCGACGACGCGCTCGGCGAGGATGGCCTGCTGGATCT

GGGTGAGGGTGGTCTGGAAGTCGTCGAAGTCGACGAAGCGGTGGTAGGCTCCGGTGTTGATGGTGTAGGA
 GCAGTTGGCCATGACGGACCAGTTGACGGTCTGGTGGCCGGGGCGCACGAGCTCGTGGTACTTGAGGCGC
 GAGTAGGCGCGCGTGTCTGAAGATGTAGTCGTTGCAGGTGCGCACGAGGTACTGGTATCCGACGAGGAAGT
 GCGGCGGGCGGTGGCGGTAGAGCGGCCATCGCTCGGTGGCGGGGGCGCCGGGCGCGAGGTCCTCGAGCAT
 5 GAGGCGGTGGTAGCCGTAGATGTACCTGGACATCCAGGTGATGCCGGCGGCGGTGGTGGAGGCGCGCGGG
 AACTCGCGGACGCGGTTCCAGATGTTGCGCAGCGGCAGGAAGTAGTTTCATGGTGGCCGCGGTCTGGCCCCG
 TGAGGCGCGCGCAGTCGTGGATGCTCTAGACATACGGGCAAAAACGAAAGCGGTCAGCGGCTCGACTCCG
 TGGCCTGGAGGCTAAGCGAACGGGTTGGGCTGCGCGTGTACCCCGGTTTCAATCTCGAATCAGGCTGGAG
 CCGCAGCTAACGTGGTACTGGCACTCCCGTCTCGACCCAAGCCTGCTAACGAAACCTCCAGGATACGGAG
 10 GCGGGTCGTTTTTTGGCCTTGGTCGCTGGTCATGAAAACTAGTAAGCGCGGAAAGCGGCCGCCCGCGCAT
 GGCTCGCTGCCGTAGTCTGGAGAAAGAATCGCCAGGGTTGCGTTGCGGTGTGCCCCGGTTCGAGCCTCAG
 CGCTCGGTGCCGGCCGGATTCCGCGGCTAACGTGGGCGTGGCTGCCCCGTCGTTTCCAAGACCCCTTAGC
 CAGCCGACTTCTCCAGTTACGGAGCGAGCCCCCTCTTTTTCTTGTGTTTTTGCCAGATGCATCCCGTACTG
 CGGCAGATGCGCCCCACCCTCCACCACAACCGCCCCCTACCGCAGCAGCAGCAACAGCCGGCGCTTCTGC
 15 CCCCCCCCCAGCAGCAGCAGCCAGCCACTACCGCGGCGGCCGCCGTGAGCGGAGCCGGCGTTTCACTATGA
 CCTGGCCTTGGAAAGAGGGCGAGGGGCTGGCGCGGCTGGGGGCGTTCGTCGCCGAGCGGCACCCGCGCGTG
 CAGATGAAAAGGGACGCTCGCGAGGCCTACGTGCCAAGCAGAACCTGTTTCAAGACAGGAGCGGCGAGG
 AGCCCGAGGAGATGCGCGCCTCCCGCTTCCACGCGGGGCGGGAGCTGCGGCGCGGCCTGGACCGAAAGCG
 GGTGCTGAGGGACGAGGATTTTCGAGGCGGACGAGCTGACGGGGATCAGCCCCGCGCGCGCGCACGTGGCC
 20 GCGGCCAACCTGGTCACGGCGTACGAGCAGACCGTGAAGGAGGAGAGCAACTTTCAAAAATCCTTCAACA
 ACCACGTGCGCACGCTGATCGCGCGCAGGAGGTGACCCTGGGCGTATGCACCTGTGGGACCTGCTGGA
 GGCCATCGTGCAAGACCCACGAGCAAGCCGCTGACGGCGCAGCTGTTTCTGGTGGTGCAGCACAGTCGG
 GACAACGAGACGTTTCAAGGAGGCGCTGCTGAATATCACCGAGCCCCGAGGGCCGCTGGCTCCTGGACCTGG
 TGAACATTCTGCAGAGCATCGTGGTGCAGGAGCGCGGGCTGCCGCTGTCCGAGAAGCTGGCGGCCATCAA
 25 CTTCTCGGTGCTGAGCCTGGGCAAGTACTACGCTAGGAAGATCTACAAGACCCCGTACGTGCCCATAGAC
 AAGGAGGTGAAGATCGACGGGTTTTACATGCGCATGACCCTGAAAGTGCTGACCCTGAGCGACGATCTGG
 GGGTGTACCGCAACGACAGGATGCACCGCGCGGTGAGCGCCAGCCGCCGGCGCGAGCTGAGCGACCAGGA
 GCTGATGCACAGCCTGCAGCGGGCCCTGACCGGGGCCGGGACCGAGGGGGAGAGCTACTTTGACATGGGC
 GCGGACCTGCGCTGGCAGCCCAGCCGCCGGGCTTGGAAAGCTGCCGGCGGCGTGCCCTACGTGGAGGAGG
 30 TGGACGATGAGGAGGAGGAGGGCGAGTACCTGGAAGACTGATGGCGCGACCGTATTTTTGCTAGATGCAG
 CAACAGCCACCGCCGCTCCTGATCCCGCATGCGGGCGGCGCTGCAGAGCCAGCCGTCCGGCATTAACCT
 CCTCGGACGATTGGACCCAGGCCATGCAACGCATCATGGCGCTGACGACCCGCAATCCCGAAGCCTTTAG
 ACAGCAGCCTCAGGCCAACCGGCTCTCGGCCATCCTGGAGGCCGTGGTGCCCTCGCGCTCGAACCCACG
 CACGAGAAGGTGCTGGCCATCGTGAACGCGCTGGTGGAGAACAAGGCCATCCGCGGCGACGAGGCCGGGC
 35 TGGTGTACAACGCGCTGCTGGAGCGCGTGGCCCGCTACAACAGCACCAACGTGCAGACGAACCTGGACCG
 CATGGTGAACGACGTGCGCGAGGCGGTGTGCGAGCGCGAGCGGTTCCACCGCGAGTCGAACCTGGGCTCC
 ATGGTGGCGCTGAACGCCTTCTGAGCACGCGAGCCCGCAACGTGCCCCGGGGCCAGGAGGACTACACCA
 ACTTCATCAGCGCGCTGCGGCTGATGGTGGCCGAGGTGCCCCAGAGCGAGGTGTACAGTCGGGGCCGGA
 CTACTTCTTCCAGACCAGTCGCCAGGGCTTGCAGACCGTGAACCTGAGCCAGGCTTTCAAGAACTTGCAG
 40 GGAAGTGTGGGGCGTGCAGGCCCGGTCGGGGACCGCGCGACGGTGTGAGCCTGCTGACGCCGAACCTCGC

GCCTGCTGCTGCTGCTGGTGGCGCCCTTCACGGACAGCGGCAGCGTGAGCCGCGACTCGTACCTGGGCTA
 CCTGCTTAACCTGTACCGCGAGGCCATCGGGCAGGCGCACGTGGACGAGCAGACCTACCAGGAGATCACC
 CACGTGAGCCGCGCGCTGGGCCAGGAGGACCCGGGCAACCTGGAGGCCACCCTGAACTTCCTGCTGACCA
 ACCGGTCGCAGAAGATCCCCCCCCAGTACGCGCTGAGCACCGAGGAGGAGCGCATCCTGCGCTACGTGCA
 5 GCAGAGCGTGGGGCTGTTCTGATGCAGGAGGGGGCCACGCCCAGCGCCGCGCTCGACATGACCGCGCGC
 AACATGGAGCCCAGCATGTACGCCCGCAACCGCCGTTTCATCAATAAGCTGATGGACTACTTGCATCGGG
 CGGCCGCCATGAACTCGGACTACTTTACCAACGCCATCTTGAACCCGCACTGGCTCCCGCCGCCGGGTT
 CTACACGGGCGAGTACGACATGCCCCACCCCAACGACGGGTTCTGTGGGATGACGTGGACAGCAGCGTG
 TTCTCGCCGCGTCCCACCACCACCGTGTGGAAGAAAGAGGGCGGGGACCGGCGGCCGTCTCGGCGCTGT
 10 CCGGTGCGCGGGTGCTGCCGCGCGGTGCCGAGGCCGCGCCAGCCCCCTTCCGAGCCTGCCCTTTTCGCT
 GAACAGCGTGCGCAGCAGCGAGCTGGGTGCGCTGACGCGGCCGCGCCTGCTGGGCGAGGAGGAGTACCTG
 AACGACTCCTTGTTGAGGCCCCGAGCGCGAAAAGAACTTCCCCAATAACGGGATAGAGAGCCTGGTGGACA
 AGATGAGCCGCTGGAAGACGTACGCGCACGAGCACAGGGACGAGCCCCGAGCTAGCAGCGCAGGCACCCG
 TAGACGCCAGCGGCACGACAGGCAGCGGGGTCTGGTGTGGGACGATGAGGATTCCGCCGACGACAGCAGC
 15 GTGTTGGACTTGGGTGGGAGTGGTGGTGGTAACCCGTTTCGCTCACTTGCGCCCCGTATCGGGCGCCTGA
 TGTAAGAATCTGAAAAATAAAAAACGGTACTCACCAAGGCCATGGCGACCAGCGTGCGTTCTTCTCTGTT
 GTTTGTAGTAGTATGATGAGGCGCGTGTACCCGAGGGTCTCTCTCCCTCGTACGAGAGCGTGATGCAGC
 AGGCGGTGGCGGCGGCGATGCAGCCCCCGCTGGAGGCGCCTTACGTGCCCCCGCGGTACCTGGCGCCTAC
 GGAGGGGCGGAACAGCATTCGTTACTCGGAGCTGGCACCCCTGTACGATACCACCCGGTGTACCTGGTG
 20 GACAACAAGTCGGCGGACATCGCCTCGCTGAACTACCAGAACGACCACAGCAACTTCCTGACCACCGTGG
 TGCAGAACACGATTTACCCCCACGGAGGCCAGCACCCAGACCATCAACTTTGACGAGCGCTCGCGGTG
 GGGCGGCCAGCTGAAAACCATCATGCACACCAACATGCCCAACGTGAACGAGTTCATGTACAGCAACAAG
 TTCAAGGCGCGGGTGATGGTCTCGCGCAAGACCCCCAACGGGGTCACAGTAACAGATGGTAGTCAGGACG
 AGCTGACCTACGAGTGGGTGGAGTTTGAGCTGCCCGAGGGCAACTTCTCGGTGACCATGACCATCGATCT
 25 GATGAACAACGCCATCATCGACAATACTTGGCGGTGGGGCGGCAGAACGGGGTGCTGGAGAGCGACATC
 GCGGTGAAGTTCGACACGCGCAACTTCCGGCTGGGTGGGACCCCGTGACCGAGCTGGTGATGCCGGGCG
 TGTACACCAACGAGGCCTTCCACCCCGACATCGTCTGCTGCCCGGCTGCGGCGTGGAATTCACCGAGAG
 CCGCCTCAGCAACCTGCTGGGCATCCGCAAGCGGCAGCCCTTCCAGGAGGGCTTCCAGATCCTGTACGAG
 GACCTGGAGGGGGGCAACATCCCCGCGCTCTTGATGTGAAGCTACGAGAAAAGCAAGGAGGATAGCA
 30 CCGCCGTGGCTACCGCCGCGACTGTGGCAGATGCCACTGTACACGAGGGCGATACATTCGCCACCCAGGC
 GGAGGAAGCAGCCGCCCTAGCGGCGACCGATGATAGTGAAAGTAAGATAGTTATCAAGCCGGTGGAGAAG
 GACAGCAAGGACAGGAGCTACAACGTTCTATCGGATGGAAAGAACACCGCCTACCGCAGCTGGTACCTGG
 CCTACAATAACGGCGACCCCGAGAAGGGCGTGCGCTCCTGGACGCTGCTACACCTCGGACGTCACCTG
 CGGCGTGGAGCAAGTCTACTGGTCGCTGCCCGACATGATGCAAGACCCGGTCACCTTCCGCTCCACGCGT
 35 CAAGTTAGCAACTACCCGGTGGTGGGCGCCGAGCTCCTGCCCGTCTACTCCAAGAGCTTCTTCAACGAGC
 AGGCCGTCTACTCGCAGCAGCTGCGCGCCTTACCTCGCTCACGCACGTCTTCAACCGCTTCCCCGAGAA
 CCAGATCCTCGTCCGCCCCGCCGCGCCACCATTACCACCGTCAGTGAAAACGTTCTGCTCTCACAGAT
 CACGGGACCCCTGCCGCTGCGCAGCAGTATCCGGGGAGTCCAGCGCGTGACCGTCACTGACGCCAGACGCC
 GCACCTGCCCCCTACGTCTACAAGGCCCTGGGCGTAGTCGCGCCGCGCGTCTCTCGAGCCGCACCTTCTA
 40 AAAAATGTCCATTCTCATCTCGCCAGTAATAACACCGGTTGGGGCCTGCGCGCGCCCAGCAAGATGTAC

GGAGGCGCTCGCCAACGCTCCACGCAACACCCCGTGCGCGTGCGCGGGCACTTCCGCGCTCCCTGGGGCG
 CCCTCAAGGGTCGCGTGCGCTCGCGCACCACCGTCGACGACGTGATCGACCAGGTGGTGGCCGACGCGCG
 CAACTACACGCCCCGCCGCCGCCGCCCTCCACCGTGAGCGCGTCATCGACAGCGTGGTGGCCGACGCG
 CGCCGGTACGCCCGCGCCAAGAGCCGGCGGGCGGCATCGCCCGCGGCACCGGAGCACCCCGCCATGC
 5 GCGCGGGCGGAGCCTTGCTGCGCAGGGCCAGGCGCACGGGACGCAGGGCCATGCTCAGGGCGGCCAGACG
 CGCGGCCTCCGGCAGCAGCAGCGCCGGCAGGACCCGCAGACGCGCGGCCACGGCGGGCGGCGGGCCATC
 GCCAGCATGTCCCGCCCCGCGGCGCGGCAACGTGTACTGGGTGCGCGACGCCGCCACCGGTGTGCGCGTGC
 CCGTGCGCACCCGCCCCCTCGCACTTGAAGATGCTGACTTCGCGATGTTGATGTGTCCCAGCGGCGAGG
 AGGATGTCCAAGCGCAAATACAAGGAAGAGATGCTCCAGGTCATCGCGCCTGAGATCTACGGCCCCGCGG
 10 CGGCGGTGAAGGAGGAAAGAAAGCCCCGCAAACCTGAAGCGGGTCAAAAAGGACAAAAAGGAGGAGGAAGA
 TGTGGACGGACTGGTGGAGTTTGTGCGCGAGTTGCCCCCGGGCGGCGGTGCAGTGGCGCGGGCGGAAA
 GTGAAACCGGTGCTGCGGCCCGGCACCACGGTGGTCTTACGCCCCGGCGAGCGTTCCGGCTCCGCCTCCA
 AGCGCTCCTACGACGAGGTGTACGGGGACGAGGACATCCTCGAGCAGGCGGCCGAGCGTCTGGGCGAGTT
 TGCTTACGGCAAGCGCAGCCGCCCGCGCCCTTGAAAGAGGAGGCGGTGTCCATCCCGCTGGACCACGGC
 15 AACCCACGCCGAGCCTGAAGCCGGTGACCCTGCAGCAGGTGCTGCCGAGCGCGGCCGCCGCGGGGCT
 TCAAGCGCGAGGGCGGCGAGGATCTGTACCCGACCATGCAGCTGATGGTGCCCAAGCGCCAGAAGCTGGA
 GGACGTGCTGGAGCACATGAAGGTGGACCCCGAGGTGCAGCCCGAGGTCAAGGTGCGGCCCATCAAGCAG
 GTGGCCCCGGGCCTGGGCGTGACACCGTGGACATCAAGATCCCCACGAGGCCATGGAAACGCAGACCG
 AGCCCGTGAAGCCAGCACCAGCACCATGGAGGTGCAGACGGATCCCTGGATGCCGGCGCCGGCTTCCAC
 20 CACCACTCGCCGAAGACGCAAGTACGGCGCGGCCAGCCTGCTGATGCCCAACTACGCGCTGCATCCTTCC
 ATCATCCCCACGCCGGGCTACCGCGGCACGCGCTTCTACCGCGGCTACAGCAGCCGCCCAAGACCACCA
 CCCGCCGCCCGCTCGCCGCACCCGCCGCAGCACCACCGCGACTTCCGCCGCCGCCTTGGTGCGGAGAGT
 GTACCGCAGCGGGCGTGAGCCTCTGACCCTGCCGCGCGCGCGCTACCACCCGAGCATCGCCATTTAACTC
 TGCCGTGCGCTCCTTGACAGATATGGCCCTCACATGCCGCCTCCGCGTCCCCATTACGGGTACCGAGGAA
 25 GAAAGCCGCGCCGTAGAAGGCTGACGGGGAACGGGCTGCGTCGCCATCACCACCGGCGGCGGCGGCCAT
 CAGCAAGCGGTTGGGGGGAGGCTTCCCTGCCCCGCGCTGATCCCCATCATCGCCGCGGCGATCGGGGCGATC
 CCCGGCATAGCTTCCGTGGCGGTGCAGGCCTCTCAGCGCCACTGAGACACAGCTTGAAAAATTTGTAATA
 AAAAAATGGACTGACGCTCCTGGTCCTGTGATGTGTGTTTTTAGATGGAAGACATCAATTTTTTCGTCCCT
 GGCACCGCGACACGGCACGCGGCCGTTTATGGGCACCTGGAGCGACATCGGCAACAGCCAACTGAACGGG
 30 GCGCCTTCAATTGGAGCAGTCTCTGGAGCGGGCTTAAGAATTTTCGGGTCCACGCTCAAAACCTATGGCA
 ACAAGGCGTGGAACAGCAGCACAGGGCAGGCGCTGAGGGAAAAGCTGAAAGAGCAGAACTTCCAGCAGAA
 GGTGGTCGATGGCCTGGCCTCGGGCATCAACGGGGTGGTGGACCTGGCCAACCAGGCCGTGCAGAAACAG
 ATCAACAGCCGCTGGACGCGGTCCC GCCCGCGGGGTCCGTGGAGATGCCCCAGGTGGAGGAGGAGCTGC
 CTCCCCCTGGACAAGCGCGGCGACAAGCGACCGCTCCCGACGCGGAGGAGACGCTGCTGACGCACACGGA
 35 CGAGCCGCCCCGTACGAGGAGGCGGTGAAACTGGGTCTGCCACCACGCGGCCCGTGGCGCCTCTGGCC
 ACCGGGGTGTGAAACCCAGCAGCAGCAGCAGCCAGCCCGCGACCCCTGGACTTGCTCCACCTCGCCCCCT
 CCACAGTGGCTAAGCCCCTGCCGCCGGTGGCCGTGCGCTGCGCGCCCCCGAGGCCGCCCGCCAGGCGAA
 CTGGCAGAGCACTCTGAACAGCATCGTGGGTCTGGGAGTGCAGAGTGTGAAGCGCCCGCGCTGCTATTAA
 AAGACACTGTAGCGCTTAACTTGCTTGTCTGTGTGTATATGTATGTCCGCCGACCAGAAGGAGGAGGAAG
 40 AGGCGCGCTCGCCGAGTTGCAAGATGGCCACCCCATCGATGCTGCCCCAGTGGGCGTACATGCACATCGCC

GGACAGGACGCTTCGGAGTACCTGAGTCCGGGTCTGGTGCAGTTCCGCCGCGCCACAGACACCTACTTCA
 GTCTGGGGAACAAGTTTAGGAACCCACGGTGGCACCACGCACGATGTGACCACCGACCGCAGCCAGCG
 GCTGACGCTGCGCTTCGTGCCCGTGGACCGCGAGGACAACACCTACTCGTACAAAGTGCCTACACGCTG
 GCCGTGGGCGACAACCGCGTGGTGGACATGGCCAGCACCTACTTTGACATCCGCGGCGTGCTGGATCGGG
 5 GCCCCAGCTTCAAACCCTACTCCGGCACC GCCTACAACAGCCTGGCTCCCAAGGGAGCGCCCAACACCTC
 ACAGTGGATAACCAAAGACAATGGAAGTATAAGACATACAGTTTTTGAAATGCTCCAGTCAGAGGATTG
 GACATTACAGAAGAGGGTCTCCAAATAGGAACCGATGAGTCAGGGGGTGAAAGCAAGAAAATTTTTGCAG
 AAAAAACCTATCAGCCTGAACCTCAGCTTGGAGATGAGGAATGGCATGATACTATTGGAGCTGAAGACAA
 GTATGGAGGCAGAGCGCTTAAACCTGCCACCAACATGAAACCTGCTATGGGTCTTTCGCCAAGCCAACT
 10 AATGCTAAGGGAGGTGAGGCTAAAAGCAGAACCAAGGACGATGGCACTACTGAGCCTGATATTGACATGG
 CCTTCTTTGACGATCGCAGTCAGCAAGCTAGTTTTAGTCCAGAACTTGTTTTGTATACTGAGAATGTGCA
 TCTGGACACCCCGGATACCCACATTATTTACAAACCTGGCACTGATGAAACAAGTTCTTCTTTCAACTTG
 GGTGAGCAGTCCATGCCCAACAGACCCAACTACATTGGCTTCAGAGACAACTTTATCGGGCTCATGTACT
 ACAACAGCACTGGCAATATGGGTGTACTGGCCGGTCAGGCCTCCCAGCTGAATGCTGTGGTGGACTTGCA
 15 GGACAGAAACACTGAACTGTCCTACCAGCTCTTGCTTGACTCTCTGGGTGACAGAACCAGGTATTTTCAGT
 ATGTGGAATCAGGCGGTGGACAGCTATGACCCCGATGTGCGCATTATTGAAAATCACGGTGTGGAGGATG
 AACTCCCCAACTATTGCTTCCCTTTGAATGGTGTGGGCTTTACAGATACATTCCAGGGAATTAAGGTAA
 AACTACAAATAACGGAACAGCAAATGCTACAGAGTGGGAATCTGATACCTCTGTCAATAATGCTAATGAG
 ATTGCCAAGGGCAATCCTTTTCGCCATGGAGATCAACATCCAGGCCAACCTGTGGCGGAACCTCCTCTACG
 20 CGAACGTGGCGCTGTACCTGCCGACTCCTACAAGTACACGCCGCCAACATCACGCTGCCACCAACAC
 CAACACCTACGATTACATGAACGGCCGCGTGGTGGCGCCCTCGCTGGTGGACGCCTACATCAACATCGGG
 GCGCGCTGGTCGCTGGACCCCATGGACAACGTCAACCCCTTCAACCACCACCGCAACGCGGGCCTGCGCT
 ACCGCTCCATGCTCCTGGGCAACGGGCGCTACGTGCCCTTCCACATCCAGGTGCCCCAAAAGTTTTTCGC
 CATCAAGAGCCTCCTGCTCCTGCCCGGTCTACACCTACGAGTGGAACCTCCGCAAGGACGTCAACATG
 25 ATCCTGCAGAGCTCCCTCGGCAACGACCTGCGCACGGACGGGGCCTCCATCGCCTTCACCAGCATCAACC
 TCTACGCCACCTTCTTCCCCATGGCGCACAACACCGCCTCCACGCTCGAGGCCATGCTGCGCAACGACAC
 CAACGACCAGTCCTTCAACGACTACCTCTCGGCGGCCAACATGCTCTACCCCATCCCGGCCAACGCCACC
 AACGTGCCCATCTCCATCCCCCTCGCGCAACTGGGCGGCCTTCCGCGGATGGTCTTTCACGCGCCTCAAGA
 CCCGCGAGACGCCCTCGCTCGGCTCCGGGTTCGACCCCTACTTCGTCTACTCGGGCTCCATCCCCTACCT
 30 CGACGGCACCTTCTACCTCAACCACACCTTCAAGAAGGTCTCCATCACCTTCGACTCCTCCGTGAGCTGG
 CCCGGCAACGACCGCCTCCTGACGCCCAACGAGTTTCGAAATCAAGCGCACCGTTCGACGGAGAGGGGTACA
 ACGTGGCCCAGTGCAACATGACCAAGGACTGGTTCCTGGTCCAGATGCTGGCCCACTACAACATCGGCTA
 CCAGGGCTTCTACGTGCCCCGAGGGCTACAAGGACCGCATGTACTCCTTCTTCCGCAACTTCCAGCCCATG
 AGCCGCCAGGTCGTGGACGAGGTCAACTACAAGGACTACCAGGCCGTACCCCTGGCCTACCAGCACAACA
 35 ACTCGGGCTTCGTGCGCTACCTCGCGCCACCATGCGCCAGGGCCAGCCCTACCCCGCCAACTACCCCTA
 CCCGCTCATCGGCAAGAGCGCCGTGCGCAGCGTCACCCAGAAAAAGTTCTCTGCGACCGGGTCATGTGG
 CGCATCCCCCTTCTCCAGCAACTTCATGTCCATGGGCGCGCTCACCGACCTCGGCCAGAACATGCTCTACG
 CCAACTCCGCCCACGCGCTAGACATGAATTTTGAAGTCGACCCCATGGATGAGTCCACCCCTTCTCTATGT
 TGTCTTCGAAGTCTTCGACGTGTCGAGTGCACCAGCCCCACCGCGGCGTCATCGAGGCCGTCTACCTG
 40 CGCACGCCCTTCTCGGCCGGCAACGCCACCACCTAAGCCTCTTGCTTCTTGCAAGATGACGGCCTGTGGC

TCCGGCGAGCAGGAGCTCAGGGCCATCCTCCGCGACCTGGGCTGCGGGCCCTACTTCCTGGGCACCTTCG
 ACAAGCGCTTCCC GGATTTCATGGCCCCGCACAAGCTGGCCTGCGCCATCGTCAACACGGCCGGCCGCGA
 GACCGGGGGCGAGCACTGGCTGGCCTTCGCCTGGAACCCGCGCACCCACACCTGCTACCTCTTCGACCCC
 TTCGGGTTCTCGGACGAGCGCCTCAAGCAGATCTACCAGTTCGAGTACGAGGGCCTGCTGCGCCGAGCG
 5 CCCTGGCCACCGAGGACCGCTGCGTCACCCTGGAAAAGTCCACCCAGACCGTGCAGGGTCCGCGCTCGGC
 CGCCTGCGGGCTCTTCTGCTGCATGTTCTGTCACGCCTTCGTGCACTGGCCCCGACCGCCCCATGGACAAG
 AACCCACCATGAACTTGCTGACGGGGGTGCCAACGGCATGCTCCAGTCGCCCCAGGTGGAACCCACCC
 TCGCCGCAACCAGGAGGCGCTCTACCGCTTCCTCAACGCCCCTCCGCTACTTTTCGCTCCCACCGCGC
 GCGCATCGAGAAGGCCACCGCCTTCGACCGCATGAATCAAGACATGTAAACTGTGTGTATGTGAATGCTT
 10 TATTCATAATAAACAGCACATGTTTATGCCACCTTCTCTGAGGCTCTGACTTTATTTAGAAATCGAAGGG
 GTTCTGCCGGCTCTCGGCGTGCCCCGCGGGCAGGATACGTTGCGGAACTGGTACTTTGGGCAGCCACTTG
 AACTCGGGGATCAGCAGCTTCGGCACGGGGAGGTGCGGGAACGAGTCGCTCCACAGCTTGCGCGTGAGTT
 GCAGGGCGCCCAGCAGGTGCGGCGCGGATATCTTGAAATCACAGTTGGGACCCGCGTTCTGCGCGCGAGA
 GTTGCGGTACACGGGGTTGCAGCACTGGAACACCATCAGGGCCGGGTGCTTCACGCTCGCCAGCACCGTC
 15 GCGTCGGTGATGCCCTCCACGTCCAGATCCTCGGCGTTGGCCATCCC GAAGGGGGTCATCTTGCAAGTCT
 GCCGCCCCATGCTGGGCACGCAGCCGGGCTTGTGGTTGCAATCGCAGTGCAGGGGGATCAGCATCATCTG
 GGCCTGCTCGGAGCTCATGCCCGGGTACATGGCCTTCATGAAAGCCTCCAGCTGGCGGAAGGCCTGCTGC
 GCCTTGCCGCCCTCGGTGAAGAAGACCCGCGAGGACTTGCTAGAGAACTGGTTGGTGCGCAGCCGGCGT
 CGTGACGCAGCAGCGCGCGTCTGTTGTTGGCCAGCTGCACCACGCTGCGCCCCCAGCGGTTCTGGGTGAT
 20 CTTGGCCCCGGTCGGGGTTCTCCTTCAGCGCGCGCTGCCCGTTCTCGCTCGCCACATCCATCTCGATCGTG
 TGCTCCTTCTGGATCATCACGGTCCCCTGTCAGGCACCGCAGCTTGCCCTCGGCTTCGGTGATCCGTGCA
 GCCACAGCGCGCAGCCGGTGCACTCCCAGTTCTTGTGGGCGATCTGGGAGTGCGAGTGACGAAGCCCTG
 CAGGAAGCGGCCCATCATCGCGGTGAGGGTCTTGTGCTGGTGAAGGTCAGCGGGATGCCGCGGTGCTCC
 TCGTTACATACAGGTGGCAGATGCGGCGGTACACCTCGCCCTGCTCGGGCATCAGCTGGAAGGCGGACT
 25 TCAGGTGCTCTCCACGCGGTACCGCTCCATCAGCAGCGTCATGACTTCCATGCCCTTCTCCCAGGCCGA
 AACGATCGGCAGGCTCAGGGGGTTCTTACCGTTGTCATCTTAGTCGCCGCCGCCGAGGTCAGGGGGTCCG
 TTCTCGTCCAGGTCTCAAACACTCGCTTGCCGTCTTCTCGGTGATGCGCACGGGGGGAAAGCTGAAGC
 CCACGGCCGCCAGCTCCTCCTCGGCCTGCCTTTTCGTCTCTGCTGTCTGGCTGATGTCTTGCAAAGGCAC
 ATGCTTGGTCTTGCGGGGTTTCTTTTTGGGCGGCAGAGGCGGCGGGGAGACGTGCTGGGCGAGCGCGAG
 30 TTCTCGCTCACCACGACTATTTCTTCTTCTTGGCCGTCTGTCGAGACCACGCGGCGGTAGGCATGCCTCT
 TCTGGGGCAGAGGCGGAGGCGACGGGCTCTCGCGGTTTCGGCGGGCGGCTGGCAGAGCCCCCTCCGCGTTC
 GGGGGTGCGCTCCTGGCGGCGCTGCTCTGACTGACTTCCTCCGCGGCCGGCCATTGTGTCTCCTAGGGA
 GCAAGCATGGAGACTCAGCCATCGTCGCCAACATCGCCATCTGCCCCCGCCGCCGCCGACGAGAACCAGC
 AGCAGCAGAAATGAAAGCTTAACCGCCCCGCGCCAGCCCCACCTCCGACGCGCGGCCCCAGACATGCA
 35 AGAGATGGAGGAATCCATCGAGATTGACCTGGGCTACGTGACGCCCCGCGGAGCACGAGGAGGAGCTGGCA
 GCGCGCTTTTCAGCCCCGGAAGAGAACCACCAAGAGCAGCCAGAGCAGGAAGCAGAGAGCGAGCAGAGCC
 AGGCTGGGCTCGAGCATGGCGACTACCTGAGCGGGGAGAGGACGTGCTCATCAAGCATCTGGCCCGCCA
 ATGCATCATCGTCAAGGATGCGCTGCTCGACCGCGCCGAGGTGCCCTCAGCGTGGCGGAGCTCAGCCGC
 GCCTACGAGCGCAACCTCTTCTCGCCGCGCGTGCCCCCAAGCGCCAGCCCAACGGCACCTGCGAGCCCA
 40 ACCCGCGCCTCAACTTCTACCCGGTCTTCGCGGTGCCCGAGGCCCTGGCCACCTACCACCTCTTTTTCAA

GAACCAAAGGATCCCCGTCTCCTGCCGCGCCAACCGCACCCGCGCCGACGCCCTGCTCAACCTGGGCCCC
 GCGCCCCGCTACCTGATATCGCCTCCTTGGAAGAGGTTCCCAAGATCTTCGAGGGTCTGGGCAGCGACG
 AGACTCGGGCCGCGAACGCTCTGCAAGGAAGCGGAGAGGAGCATGAGCACCACAGCGCCCTGGTGGAGTT
 GGAAGGCGACAACGCGCGCCTGGCGGTCTCAAGCGCACGGTCGAGCTGACCCACTTCGCCTACCCGGCG
 5 CTCAACCTGCCCCCAAGGTCATGAGCGCCGTCATGGACCAGGTGCTCATCAAGCGCGCCTCGCCCCCTCT
 CGGAGGAGGAGATGCAGGACCCCGAGAGCTCGGACGAGGGCAAGCCCGTGGTCAGCGACGAGCAGCTGGC
 GCGCTGGCTGGGAGCGAGTAGACCCCCCAGAGCCTGGAAGAGCGGCGCAAGCTCATGATGGCCGTGGTC
 CTGGTGACCGTGGAGCTGGAGTGTCTGCGCCGCTTCTTCGCCGACGCGGAGACCCTGCGCAAGGTCGAGG
 AGAACCTGCACTACCTCTTCAGGCACGGGTTCGTGCGCCAGGCCTGCAAGATCTCCAACGTGGAGCTGAC
 10 CAACCTGGTCTCCTACATGGGCATCCTGCACGAGAACCGCCTGGGGCAGAACGTGCTGCACACCACCCTG
 CGCGGGGAGGCCCGCCGCGACTACATCCGCGACTGCGTCTACCTGTACCTCTGCCACACCTGGCAGACGG
 GCATGGGCGTGTGGCAGCAGTGCCTGGAGGAGCAGAACCTGAAAGAGCTCTGCAAGCTCCTGCAGAAGAA
 CCTGAAGGCCCTGTGGACCGGGTTCGACGAGCGCACACCACCGCCTCGGACCTGGCCGACCTCATCTTCCCC
 GAGCGCCTGCGGCTGACGCTGCGCAACGGGCTGCCCCACTTTATGAGCCAAAGCATGTTGCAAAACTTTC
 15 GCTCTTTTCATCCTCGAACGCTCCGGGATCCTGCCCCGCCACCTGCTCCGCGCTGCCCTCGGACTTCGTGCC
 GCTGACCTTCCGCGAGTGCCCCCGCCGCTCTGGAGCCACTGCTACCTGCTGCGTCTGGCCAACCTACCTG
 GCCTACCACTCGGACGTGATCGAGGACGTCAGCGGCGAGGGTCTGCTCGAGTGCCACTGCCGCTGCAACC
 TCTGCACGCCGCACCGCTCCCTGGCCTGCAACCCCCAGCTGCTGAGCGAGACCAGATCATCGGCACCTT
 CGAGTTGCAAGGCCCGGCGAGGAGGGCAAGGGGGGTCTGAAACTCACCCCGGGGCTGTGGACCTCGGCC
 20 TACTTGCGCAAGTTCTGTGCCGAGGACTACCATCCCTTCGAGATCAGGTTCTACGAGGACCAATCCCAGC
 CGCCCAAGGCCGAGCTGTGCGCCTGCGTCATCACCCAGGGGGCCATCCTGGCCCAATTGCAAGCCATCCA
 GAAATCCCGCCAAGAATTTCTGTGAAAAAGGGCCACGGGGTCTACTTGGACCCCCAGACCGGAGAGGAG
 CTCAACCCAGCTTCCCCCAGGATGCCAGAGGAAGCAGCAAGAAGCTGAAAGTGGAGCTGCCGCTGCCG
 CCGGAGGATTTGGAGGAAGACTGGGAGAGCAGTCAGGCAGAGGAGGAGGAGATGGAAGACTGGGACAGCA
 25 CTCAGGCAGAGGAGGACAGCCTGCAAGACAGTCTGGAAGACGAGGTGGAGGAGGAGGCAGAGGAAGAAGC
 AGCCGCCGCCAGACCGTCTGCTCCTCGGCGGAGAAAGCAAGCAGCACGGATACCATCTCCGCTCCGGGTCCG
 GGTCTCGGCGGGCCGGGCCACAGTAGGTGGGACGAGACCGGGCGCTTCCCGAACCCACCCAGACCG
 GTAAGAAGGAGCGGCAGGGATACAAGTCTTGCGGGGGCACAAAACGCCATCGTCTCCTGCTTGCAAGC
 CTGCGGGGGCAACATCTCCTTCACCCGGCGCTACCTGCTCTTCCACCGCGGGGTGAACTTCCCCCGCAAC
 30 ATCTTGCAATTACTACCGTCACCTCCACAGCCCCCTACTACTGTTTCCAAGAAGAGGCAGAAACCCAGCAGC
 AGCAGAAAAACCAGCAGCAGCTAGAAAATCCACAGCGGCGGCGGCGGCAGGTGGAAGTACGAGGATCGCGGCGA
 ACGAGCCGGCGCAGACCCGGGAGCTGAGGAACCGGATCTTTCCACCCTCTATGCCATCTTCCAGCAGAG
 TCGGGGGCAGGAGCAGGAAGTCAAAGTCAAAGAACGTTCTCTGCGCTCGCTCACCCGCAGTTGTCTGTAT
 CACAAGAGCGAAGACCAACTTCAGCGCACTCTCGAGGACGCCGAGGCTCTCTTCAACAAGTACTGCGCGC
 35 TCACTCTTAAAGAGTAGCCCGCGCCCGCCACACACGGAAAAAGGCGGGAATTACGTCACCACCTGCGCC
 CTTTCGCCCCGACCATCATCATGAGCAAAGAGATTCCCACGCCTTACATGTGGAGCTACCAGCCCCAGATGG
 GCCTGGCCGCCGGCGCCGCCAGGACTACTCCACCCGCATGAACTGGCTCAGTGCCGGGCCCGCGATGAT
 CTCACGGGTGAATGACATCCGCGCCCGCCGAAACCAGATACTCCTAGAACAGTCAGCGATCACCGCCACG
 CCCCGCCATCACCTTAATCCGCGTAATTGGCCCGCCGCTGGTGTACCAGGAAATTCCCCAGCCCACGA
 40 CCGTACTACTTCCGCGAGACGCCAGGCCGAAGTCCAGCTGACTAACTCAGGTGTCCAGCTGGCCGGCGG

CGCCGCCCTGTGTCGTCACCGCCCCGCTCAGGGTATAAAGCGGCTGGTGATCCGAGGCAGAGGCACACAG
 CTC AACGACGAGGTGGTGAGCTCTTCGCTGGGTCTGCGACCTGACGGAGTCTTCCAACTCGCCGGATCGG
 GGAGATCTTCCTTCACGCCTCGTCAGGCCGTCTGACTTTGGAGAGTTTCGTCCTCGCAGCCCCGCTCGGG
 TGGCATCGGCACCTCTCCAGTTCGTGGAGGAGTTCACTCCCTCGGTCTACTTCAACCCCTTCTCCGGCTCC
 5 CCGGCCACTACCCGGACGAGTTCATCCCGAACTTCGACGCCATCAGCGAGTCGGTGGACGGCTACGATT
 GAATGTCCCATGGTGGCGCGGCTGACCTAGCTCGGCTTCGACACCTGGACCACTGCCGCCGCTTCCGCTG
 CTTGCTCGGGATCTCGCCGAGTTTGCCTACTTTGAGCTGCCCCGAGGAGCACCTCAGGGCCCCGGCCAC
 GGAGTGCGGATCATCGTCGAAGGGGGCCTCGACTCCACCTGCTTCGGATCTTCAGCCAGCGTCCGATCC
 TGGTCGAGCGCGAGCAAGGACAGACCCGTCTGACCCGTGACTGCATCTGCAACCACCCGGCCTGCATGA
 10 AAGTCTTTGTTGTCTGCTGTGTACTGAGTATAATAAAAGCTGAGATCAGCGACTACTCCGGACTTCCGTG
 TGTTCTCTGAATCCATCAACCAGTCCCTGTTCTTCACCGGGAACGAGACCGAGCTCCAGCTCCAGTGTAAG
 CCCCACAAGAAGTACCTCACCTGGCTGTTCCAGGGCTCCCCGATCGCCGTTGTCAACCACTGCGACAACG
 ACGGAGTCCTGCTGAGCGGCCCTGCCAACCTTACTTTTTTCCACCCGCAGAAGCAAGCTCCAGCTCTTCCA
 ACCCTTCTCCCCGGACCTATCAGTGCGTCTCGGGACCCTGCCATCACACCTTCCACCTGATCCCGAAT
 15 ACCACAGCGTCGCTCCCCGCTACTAACAACCAAACTACCCACCAACGCCACCGTCGCGACCTTTCTCTG
 AATCTAATACCACTACCCGAGGTGAGCTCCGAGGTCGACCAACCTCTGGGATTTACTACGGCCCCCTGGGA
 GGTGGTGGGGTTAATAGCGCTAGGCCTAGTTGTGGGTGGGCTTTTGGCTCTCTGCTACCTATACCTCCCT
 TGCTGTTCTGCTACTTAGTGCTGTGTTGCTGGTTTAAGAAATGGGGCAGATCACCTAGTGAGCTGCGG
 TGTGCTGGTGGCGGTGGTGCTTTCGATTGTGGGACTGGGCGGCGCGGCTGTAGTGAAGGAGAAGGCCGAT
 20 CCCTGCTTGCAATTTCAATCCCGACAAATGCCAGCTGAGTTTTTCAGCCCGATGGCAATCGGTGCGCGGTGC
 TGATCAAGTGCGGATGGGAATGCGAGAACGTGAGAATCGAGTACAATAACAAGACTCGGAACAATACTCT
 CGCGTCCGTGTGGCAGCCCCGGGACCCCGAGTGGTACACCGTCTCTGTCCCCGGTGCTGACGGCTCCCCG
 CGCACCGTGAATAATACTTTTCATTTTTTGCGCACATGTGCGACACGGTCATGTGGATGAGCAAGCAGTACG
 ATATGTGGCCCCCAGCAAGGAGAACATCGTGGTCTTCTCCATCGCTTACAGCCTGTGCACGGTGCTAAT
 25 CACCGCTATCGTGTGCCTGAGCATTACATGCTCATCGCTATTCGCCCCAGAAATAATGCCGAAAAAGAG
 AAACAGCCATAACACGTTTTTTTCACACACCTTGTTTTTACAGACAATGCGTCTGTAAATTTTTTAAACA
 TTGTGCTCAGTATTGCTTATGCCTCTGGCTATGCAAACATACAGAAAACCCTCTATGTAGGATCTGATGA
 TACACTAGAGGGTACCCAATCACAAGCTAGGGTTTCATGGTATTTTTTATAAAAGCTCAGATAATCCTATT
 ACTCTTTGCAAAGGTGATCAGGGGCGGACAACAAAGCCGCCTATCACATTTAGCTGTACCAGAACAAATC
 30 TCACGCTTTTCTCAATTACAAAACAATATGCTGGTATTTATTACAGTACAAACTTTTCATAGTGGGCAAGA
 TAAATATTATACCTGTTAAGGTAGAAAATCCTACCACTCCTAGAACTACCACCACCACCACCACCACC
 ACTACTGCGAAGCCCACTAAACCTAAAACTACCAAGAAAACCACTGTGAAAACCTACAACCTAGAACCACCA
 CAACTACAGAAACCACCACCAGCACAACACTTGCTGCAACTACACACACACACTGAGCTAACCTTACA
 GACCACTAATGATTTGATAGCCCTGTTGCAAAAGGGGGATAACAGCACCACTTCCAATGAGGAGATACCC
 35 AAATCCATGATTGGCATTATTGTTGCTGTAGTGGTGTGCATGTTGATCATCGCCTTGTGCATGGTGTACT
 ATGCCTTCTGCTACAGAAAGCACAGACTGAACGACAAGCTGGAACACTTACTAAGTGTTGAATTTTAATT
 TTTTAGAACCATGAAGATCCTAGGCCTTTTAGTTTTTTCTATCATTACCTCTGCTCTATGCAATTCTGAC
 AATGAGGACGTTACTGTGCTTGTGCGATCAAATTATACACTGAAAGGTCCAGCGAAGGGTATGCTTTCGT
 GGTATTGCTGGTTTGAAGTACACTGATCAAACCTGAGCTTTGCAATGCAATGAAAGGTCAAATACCAAC
 40 CTCAAAAATTAAACATAAATGCAATGGTACTGACTTAGTACTACTCAATATCACGAAATCATATGCTGGC

AGCTATTTCATGCCCTGGAGATGATGCTGAGAACATGATTTTTTACAAAGTAACTGTTGTTGATCCCACTA
 CTCCACCACCCACCACCACAACACTACTCACACCACACACACAGAACAAACACCAGAGGCAGCAGAAGCAGA
 GTTGGCCTTCCAGGTTACGGAGATTCTTTGCTGTCAATACCCCTACACCCGATCATCGGTGTCCGGGG
 CTGCTAGTCAGCGGCATTGTCGGTGTGCTTTTCGGGATTAGCAGTCATAATCATCTGCATGTTTCAATTTTG
 5 CTTGCTGCTATAGAAGGCTTTACCGACAAAAATCAGACCCACTGCTGAACCTCTATGTTTAATTTTTTCC
 AGAGCCATGAAGGCAGTTAGCGCTCTAGTTTTTTGTTCTTTGATTGGCATTGTTTTTTGCAATCCTATTA
 CTAGAGTTAGCTTTATTAAAGATGTGAATGTTACTGAGGGGGGCAATGTGACACTGGTAGGTGTAGAGGG
 TGCTAAAAACACCACCTGGACAAAATACCACCTTGGGTGGAAAGATATTTGCAATTGGAGTGTCACTGTG
 TACACATGTGAGGGAGTTAATCTTACCATTGTCAATGCCACCTCAGCTCAAAATGGTAGAATTCAGGAC
 10 AAAGTGTTAGTGTGACCAGTGATGGGTATTTTACCCAACATACTTTTATCTATGACGTTAAAGTCATACC
 ACTGCCTACGCCTAGCCACCTAGCACCCTACACAAACAACCCACACTACACAGACAACCCACATACAGT
 ACATCAAAATCAGCCTACCACCACTACAGCAGCAGAGGTTGCCAGCTCGTCTGGAGTTCAAGTGGCATT
 TGTGTTGTTGCCCCCATCTAGCAGTCCCCTGCTATTACCAATGAGCAGACTACTGCATTTTTTGTCCACTGT
 CGAGAGCCACACCACAGCTACCTCCAGTGCCTTCTCTAGCACCGCCAATCTCTCCTCGCTTTCTCTACA
 15 CCAATCAGTCCCGCTACTACTACTACCCCCGCTATTCTTCCCCTCCCCTGAAGCAAACAGACGGCGGCA
 TGCAATGGCAGATCACCCCTGCTCATTGTGATCGGGTGGTGCATCCTAGCCGTGTTGCTCTACTACATCTT
 CTGCCGCCGATTCCCAACGCGCACCGCAAGCCGGTCTACAAGCCCATCATTGTGCGGCAGCCGGAGCCG
 CTTTCAAGGTGGAAGGGGGTCTAAGGAATCTTCTCTTCTCTTTTACAGTATGGTGATTGAACTATGATTCT
 AGACAATCTTGATCACTATTCTTATCTGCCTCCTCCAAGTCTGTGCCACCCTCGCTCTGGTGGCCAACG
 20 CCAGTCCAGACTGTATTGGGCCCTTCGCCTCCTACGTGCTCTTTGCCTTCATCACCTGCATCTGCTGCTG
 TAGCATAGTCTGCCTGCTTATCACCTTCTTCCAGTTCATTGACTGGATCTTTGTGCGCATCGCCTACCTG
 CGCCACCACCCCCAGTACCGCGACCAGCGAGTGGCGCAGCTGCTCAGGCTCCTCTGATAAGCATGCGGGC
 TCTGCTACTTCTCGCGCTTCTGCTGTTAGTGCTCCCCCGTCCCGTTGACCCCCGGCCCCCCTCAGTCC
 CCGAGGAGGTCCGCAAATGCAAATTCGAAGAACCCTGGAAATTCCTCAAATGCTACCGCCAAAAATCAG
 25 ACATGCATCCCAGCTGGATCATGATCATTGGGATCGTGAACATTCTGGCCTGCACCCTCATCTCCTTTGT
 GATTTACCCCTGCTTTGACTTTGGTTGGAACCTCGCCAGAGGCGCTCTATCTCCCGCCTGAACCTGACACA
 CCACCACAGCAACCTCAGGCACACGCACTACCACCACCACAGCCTAGGCCACAATACATGCCCATATTAG
 ACTATGAGGCCGAGCCACAGCGACCCATGCTCCCCGCTATTAGTTACTTCAATCTAACCGGCGGAGATGA
 CTGACCCACTGGCCAACAACAACGTCAACGACCTTCTCCTGGACATGGACGGCCGCGCCTCGGAGCAGCG
 30 ACTCGCCCAACTTCGCATTTCGCCAGCAGCAGGAGAGAGCCGTCAAGGAGCTGCAGGACGGCATAGCCATC
 CACCAGTGCAAGAAAGGCATCTTCTGCCTGGTGAACAGGCCAAGATCTCCTACGAGGTACCCAGACCG
 ACCATCGCCTCTCCTACGAGCTCCTGCAGCAGCGCCAGAAGTTCACCTGCCTGGTGGAGTCAACCCCAT
 CGTCATCACCCAGCAGTCGGGCGATACCAAGGGGTGCATCCACTGCTCCTGCGACTCCCCGACTGCGCTC
 CACACTCTGATCAAGACCCTCTGCGGCCTCCGCGACCTCCTCCCCATGAACTAATCACCCACTTATCCAG
 35 TGAAATAAAAAAATAATCATTTGATTTGAAATAAAGATACAATCATATTGATGATTTGAGTTTAACAAAA
 ATAAAGAATCACTTACTTGAAATCTGATACCAGGTCTCTGTCCATATTTTCTGCCAACACCACCTCACTC
 CCCTCTTCCCAGCTCTGGTACTGCAGGCCCCGGCGGGCTGCAAACTTCCTCCACACGCTGAAGGGGATGT
 CAAATTCTCCTGCCCTCAATCTTCATTTTATCTTCTATCAGATGTCCAAAAAGCGCGTCCGGGTGGAT
 GATGACTTCGACCCCGTCTACCCCTACGATGCAGACAACGCACCGACCGTGCCCTTCATCAACCCCCCT
 40 TCGTCTCTTCAGATGGATTCCAAGAGAAGCCCCCTGGGGGTGTTGTCCCTGCGACTGGCCGACCCCGTCA

CACCAAGAACGGGGAAATCACCCCTCAAGCTGGGAGAGGGGTGGACCTCGACTCCTCGGGAAAACATCATC
 TCCAACACGGCCACCAAGGCCGCTGCCCCCTCTCAGTTTTTCCAACAACACCATTTCCCTTAACATGGATC
 ACCCCTTTTACACTAAAGATGGAAAATTAGCCTTACAAGTTTCTCCACCATTAAATATACTGAGAACAAG
 CATTCTAAACACACTAGCTTTAGGTTTTGGATCAGTTTTAGGACTCCGTGGCTCTGCCTTGGCAGTACAG
 5 TTAGTCTCTCCACTTACATTTGATACTGATGGAAACATAAAGCTTACCTTAGACAGAGGTTTGCATGTTA
 CAACAGGAGATGCAATTGAAAGCAACATAAGCTGGGCTAAAGGTTTAAAATTTGAAGATGGAGCCATAGC
 AACCAACATTGGAAATGGGTTAGAGTTTGAAGCAGTAGTACAGAAACAGGTGTGATGATGCTTACCCA
 ATCCAAGTTAACTTGGATCTGGCCTTAGCTTTGACAGTACAGGAGCCATAATGGCTGGTAACAAAGAAG
 ACGATAAACTCACTTTGTGGACAACACCTGATCCATCACCAAACTGTCAAATACTCGCAGAAAATGATGC
 10 AAACTAACACTTTGCTTGACTAAATGTGGTAGTCAAATACTGGCCACTGTGTGAGTCTTAGTTGTAGGA
 AGTGGAACCTAAACCCCATTAAGTGGCACCGTAAGCAGTGCTCAGGTGTTTCTACGTTTTGATGCAAACG
 GTGTTCTTTTAAACAGAACATTCTACACTAAAAAATACTGGGGGTATAGGCAGGGAGATAGCATAGATGG
 CACTCCATATGTCAATGCTGTAGGATTCATGCCCAATTTAAAGCTTATCCAAAGTCACAAAGTTCTACT
 ACTAAAAATAATATAGTAGGGCAAGTATACATGAATGGAGATGTTTCAAACCTATGCTTCTCACTATAA
 15 CCCTCAATGGTACTGATGACAGCAACAGTACATATTCAATGTCATTTTCATACACCTGGACTAATGGAAG
 CTATGTTGGAGCAACATTTGGAGCTAACTCTTATACCTTCTCCTACATCGCCCAAGAATGAATACTGTAT
 CCCACCCTGCATGCCCAACCTCCCCCACCTCTGTCTATATGGAACCTCTGAAACACAAAATAAAATAA
 AGTTCAAGTGTTTTATTGATTCAACAGTTTTACAGGATTCGAGCAGTTATTTTTCTCCACCCTCCCAGG
 ACATGGAATACACCACCCTCTCCCCCGCACAGCCTTGAACATCTGAATGCCATTGGTGATGGACATGCT
 20 TTTGGTCTCCACGTTCCACACAGTTTCAGAGCGAGCCAGTCTCGGGTCGGTCAGGGAGATGAAACCCTCC
 GGGCACTCCCGCATCTGCACCTCACAGCTCAACAGCTGAGGATTGTCCTCGGTGGTCGGGATCACGGTTA
 TCTGGAAGAAGCAGAAGAGCGGCGGTGGGAATCATAGTCCGCGAACGGGATCGGCCGGTGGTGTGCGATC
 AGGCCCCCGCAGCAGTCGCTGCCGCCGCGCTCCGTCAAGCTGCTGCTCAGGGGTCCGGGTCCAGGGACT
 CCCTCAGCATGATGCCACGGCCCTCAGCATCAGTCGTCTGGTGCGGCGGGCGCAGCAGCGCATGCGGAT
 25 CTCGCTCAGGTCGCTGCAGTACGTGCAACACAGGACCACCAGGTTGTTCAACAGTCCATAGTTCAACACG
 CTCCAGCCGAACTCATCGCGGGAAGGATGCTACCCACGTGGCCGTCTGACAGATCCTCAGGTAAATCA
 AGTGCGCCCCCTCCAGAACACGCTGCCCATGTACATGATCTCCTTGGGCATGTGGCGGTTCCACCACCTC
 CCGGTACCACATCACCTCTGGTTGAACATGCAGCCCCGGATGATCCTGCGGAACACAGGGCCAGCACC
 GCCCCGCCCCGCGCATGCAGCGAAGAGACCCCGGGTCCCGGCAATGGCAATGGAGGACCCACCGCTCGTACC
 30 CGTGATCATCTGGGAGCTGAACAAGTCTATGTTGGCACAGCACAGGCACACGCTCATGCATCTCTTCAG
 CACTCTCAGTCTCTCGGGGTCAAACCATATCCAGGGCACGGGAACTCTTGAGGACAGCGAAGCCC
 GCAGAACAGGGCAATCCTCGCACATAACTTACATTGTGCATGGACAGGGTATCGCAATCAGGCAGCACCG
 GGTGATCCTCCACCAGAGAAGCGCGGGTCTCGGTCTCCTCACAGCGTGTAAGGGGGCCGGCCGATACGG
 GTGATGGCGGGACGCGGCTGATCGTGTTCGCGACCGTGTGATGATGAGTTGCTTTTCGGACATTTTCGTA
 35 CTTGCTGAAGCAGAACCTGGTCCGGGCGCTGCACACCGATCGCCGGCGGGTCTCGGCGCTTGAACGC
 TCGGTGTTGAAGTTGTAAAACAGCCACTCTCTCAGACCGTGCAGCAGATCTAGGGCCTCAGGAGTGATGA
 AGATCCCATCATGCCTGATGGCTCTGATCACATCGACCACCGTGGAATGGGCCAGACCCAGCCAGATGAT
 GCAATTTTGTGGGTTTCGGTGACGGCGGGGAGGGAAGAACAGGAAGAACCATGATTAACCTTTTAATCC
 AAACGGTCTCGGAGCACTTCAAATGAAGGTGCGGAGATGGCACCTCTCGCCCCCGCTGTGTTGGTGGA
 40 AAATAACAGCCAGGTCAAAGGTGATACGGTTCTCGAGATGTTCCACGGTGGCTTCCAGCAAAGCCTCCAC

GCGCACATCCAGAAACAAGACAATAGCGAAAGCGGGAGGGTTCTCTAATTCCTCAATCATCATGTTACAC
 TCCTGCACCATCCCCAGATAATTTTTCATTTTCCAGCCTTGAATGATTCGAACTAGTTCTTGAGGTAAAT
 CCAAGCCAGCCATGATAAAGAGCTCGCGCAGAGCGCCCTCCACCGGCATTCTTAAGCACACCCTCATAAT
 TCCAAGATATTCTGCTCCTGGTTCACCTGCAGCAGATTGACAAGCGGGATATCAAAATCTCTGCCGCGAT
 5 CCCTGAGCTCCTCCCTCAGCAATAACTGTAAGTACTCTTTCATATCCTCTCCGAAATTTTGTAGCCATAGG
 ACCCCCAGGAATAAGAGAAGGGCAAGCCACATTACAGATAAACCGAAGTCCCCCCCAGTGAGCATTGCCA
 AATGTAAGATTGAAATAAGCATGCTGGCTAGACCCGGTGATATCTTCCAGATAACTGGACAGAAAATCGG
 GCAAGCAATTTTAAAGAAAATCAACAAAAGAAAAATCTTCCAGGTGCACGTTTAGGGCCTCGGGAACAAC
 GATGGAGTAAGTGCAAGGGGTGCGTTCCAGCATGGTTAGTTAGCTGATCTGTAAAAAACAATAAA
 10 ACATTAAACCATGCTAGCCTGGCGAACAGGTGGGTAAATCGTTCTCTCCAGCACCAGGCAGGCCACGGGG
 TCTCCGGCGCGACCCTCGTAAAAATTGTCGCTATGATTGAAAACCATCACAGAGAGACGTTCCCGGTGGC
 CGGCGTGAATGATTGAGAAGAAGCATAACCCCCGGAACATTGGAGTCCGTGAGTGAAAAAAGCGGCC
 GAGGAAGCAATGAGGCACTACAACGCTCACTCTCAAGTCCAGCAAAGCGATGCCATGCGGATGAAGCACA
 AAATTTTTCAGGTGCGTAAAAAATGTAATTACTCCCTCCTGCACAGGCAGCGAAGCTCCCGATCCCTCCA
 15 GATACACATACAAAGCCTCAGCGTCCATAGCTTACCGAGCGGCAGCAGCAGCGGCACACAACAGGCGCAA
 GAGTCAGAGAAAAGACTGAGCTCTAACCTGTCCGCCGCTCTCTGCTCAATATATAGCCCCAGATCTACA
 CTGACGTAAAGGCCAAAGTCTAAAAATACCCGCCAAATAATCACACACGCCCAGCACACGCCCAGAAACC
 GGTGACACACTCAAAAAAATACGCGCACTTCTCAAACGCCCAAATGCGGTCATTTCCGGGTTCACAG
 CTACGTCATCAAAACACGACTTTCAAATTCCGTGACCGTTAAAAACGTCACCCGCCCCGCCCTAACGG
 20 TCGCCGCTCCCGCAGCCAATCAGCGCCCCGCATCCCCAAATTCAAACAGCTCATTTGCATATTAACGCGC
 ACCAAAAGTTTGAGGTATATTATTGATGATG

SEQ ID NO: 3 Polynucleotide sequence encoding the CASI promoter

GGAGTTCGCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAA
 25 TAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACT
 GCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC
 CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCTTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTA
 CCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCCTCCCCACCCCCAATTTTGTATTTA
 TTTATTTTTTAATTATTTTGTGTCAGCGATGGGGGCGGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGG
 30 GAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCTTTTAT
 GGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCTCCCTATCAGTGATAGAGATCTCCCTATCAGTGAT
 AGAGATCGTCGACGAGCTCGCGGCGGGCGGGAGTCGCTGCGCGCTGCCTTCGCCCCGTGCCCGCTCCGCCGCCGCC
 TCGCGCCGCCCGCCCCGCTCTGACTGACCGGTTACTAAAACAGGTAAGTCCGGCCTCCGCGCGGGTTTTGGCGC
 CTCCCGCGGGCGCCCCCTCTCACGGCGAGCGCTGCCACGTGACGAGGCGCAGCGAGCGTCTGATCCTTCC
 35 GCGCGGACGCTCAGGACAGCGGCCCGCTGCTCATAAGACTCGGCCTTAGAACCCAGTATCAGCAGAAGGACATTTT
 AGGACGGGACTTGGGTGACTCTAGGGCACTGGTTTTCTTTCCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTC
 TCGGCGATTCTGCGGAGGGATCTCCGTGGGGCGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTT
 TTTTTTCTACAGGTCTTGGGTGACGAACAG

40 SEQ ID NO: 4 Polynucleotide sequence encoding ChAd155/RSV

CATCATCAATAATATACCTTATTTTGGATTGAAGCCAATATGATAATGAGATGGGCGGGCGCGGGGCGG
 GGCGCGGGGCGGGAGGCGGGTTTGGGGGCGGGCCGGCGGGCGGGCGGGTGTGGCGGAAGTGGACTTT
 GTAAGTGTGGCGGATGTGACTTGCTAGTGCCGGGCGCGGTAAAAGTGACGTTTTCCGTGCGCGACAAC
 GCCCCCGGGAAGTGACATTTTTCCCGCGGTTTTTACCGGATGTTGTAGTGAATTTGGGCGTAACCAAGT
 5 AAGATTTGGCCATTTTCGCGGGA AAACTGAAACGGGGAAAGTGAAATCTGATTAATTTTTCGTTAGTCA
 TACCGCGTAATATTTGTCTAGGGCCGAGGGACTTTGGCCGATTACGTGGAGGACTCGCCCAGGTGTTTT
 TTGAGGTGAATTTCCGCGTTCCGGGTCAAAGTCTGCGTTTTATTATTATAGGATATCCCATTCATACG
 TTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGAT
 TATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGC
 10 TTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATA
 ATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACG
 GTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATG
 ACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACA
 TCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTTGGCAGTACATCAATGGGCGTGGATAGC
 15 GGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTTTTGGCACCAAA
 ATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCATGACGCAAATGGGCGGTAGGCGTGTA
 CGGTGGGAGGTCTATATAAGCAGAGCTCTCCCTATCAGTGATAGAGATCTCCCTATCAGTGATAGAGA
 TCGTCGACGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCA
 TAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGT
 20 GCCAAGAGTGAGATCTTCCGTTTATCTAGGTACCAGATATCGCCACCATGGAAGTGTGATCCTGAAG
 GCCAACGCCATCACCACCATCCTGACCGCCGTGACCTTCTGCTTCGCCAGCGGCCAGAACATCACCAG
 GGAATTCTACCAGAGCACCTGTAGCGCCGTGAGCAAGGGCTACCTGAGCGCCCTGAGAACCGGCTGGT
 ACACCAGCGTGATCACCATCGAGCTGAGCAACATCAAAGAAAACAAGTGAACGGCACCGACGCCAA
 AGTGAAGCTGATCAAGCAGGAACTGGACAAGTACAAGAACGCCGTGACCGAGCTGCAGCTGCTGATG
 25 CAGAGCACCCCCGCCACCAACAACCGGGCCAGACGGGAGCTGCCCCGGTTCATGAACTACACCCTGA
 ACAACGCCAAAAAGACCAACGTGACCCTGAGCAAGAAGCGGAAGCGGCGGTTCTCTGGGCTTTCTGCT
 GGGCGTGGGCAGCGCCATTGCCAGCGGCGTGGCCGTGTCTAAGGTGCTGCACCTGGAAGGCGAAGTG
 AACAAGATCAAGAGCGCCCTGCTGAGCACCAACAAGGCCGTGGTGTCCCTGAGCAACGGCGTGAGCG
 TGCTGACCAGCAAGGTGCTGGATCTGAAGAACTACATCGACAAGCAGCTGCTGCCCATCGTGAACAAG
 30 CAGAGCTGCAGCATCAGCAACATCGAGACAGTGATCGAGTTCCAGCAGAAGAACAACCGGCTGCTGG
 AAATCACCCGGGAGTTCAGCGTGAACGCCGGCGTGACCACCCCTGTGTCCACCTACATGCTGACCAAC
 AGCGAGCTGCTGAGCCTGATCAACGACATGCCCATCACCACGACCAGAAAAAGCTGATGAGCAACA
 ACGTGCAGATCGTGCGGCAGCAGAGCTACTCCATCATGTCCATCATCAAAGAAGAGGTGCTGGCCTAC
 GTGGTGCAGCTGCCCCGTGACGGCGTGATCGACACCCCTGCTGGAAGCTGCACACCAGCCCCCTGTG
 35 CACCACCAACACCAAAGAGGGCAGCAACATCTGCCTGACCCGGACCGACAGAGGCTGGTACTGCGAC
 AACGCCGGCAGCGTGTCTTTTCCACAGGCCGAGACATGCAAGGTGCAGAGCAACCGGGTGTCTG
 CGACACCATGAACAGCCTGACCCTGCCCTCCGAAGTGAACCTGTGCAACGTGGACATCTTCAACCCCA

AGTACGACTGCAAGATCATGACCTCCAAGACCGACGTGTCCAGCTCCGTGATCACCTCCCTGGGCGCC
 ATCGTGTCTGCTACGGCAAGACCAAGTGCACCGCCAGCAACAAGAACCGGGGCATCATCAAGACCTT
 CAGCAACGGCTGCGACTACGTGTCCAACAAGGGGGTGGACACCGTGTCCGTGGGCAACACCCTGTACT
 ACGTGAACAAACAGGAAGGCAAGAGCCTGTACGTGAAGGGCGAGCCCATCATCAACTTCTACGACCC
 5 CCTGGTGTTCCTCAGCGACGAGTTCGACGCCAGCATCAGCCAGGTGAACGAGAAGATCAACCAGAGC
 CTGGCCTTCATCCGGAAGTCCGACGAGCTGCTGCACAATGTGAATGCCGGCAAGTCCACCACCAACCG
 GAAGCGGAGAGCCCCTGTGAAGCAGACCCTGAACTTCGACCTGCTGAAGCTGGCCGGCGACGTGGAG
 AGCAATCCCGGCCCTATGGCCCTGAGCAAAGTGAACTGAACGATACACTGAACAAGGACCAGCTGC
 TGTCCAGCAGCAAGTACACCATCCAGCGGAGCACCGGCGACAGCATCGATACCCCCAACTACGACGT
 10 GCAGAAGCACATCAACAAGCTGTGCGGCATGCTGCTGATCACAGAGGACGCCAACCACAAGTTCACC
 GGCCTGATCGGCATGCTGTACGCCATGAGCCGGCTGGGCCGGGAGGACACCATCAAGATCCTGCGGG
 ACGCCGGCTACCACGTGAAGGCCAATGGCGTGGACGTGACCACACACCGGCAGGACATCAACGGCAA
 AGAAATGAAGTTCGAGGTGCTGACCCTGGCCAGCCTGACCACCGAGATCCAGATCAATATCGAGATCG
 AGAGCCGGAAGTCCTACAAGAAAATGCTGAAAGAAATGGGCGAGGTGGCCCCCGAGTACAGACACGA
 15 CAGCCCCGACTGCGGCATGATCATCCTGTGTATCGCCGCCCTGGTGATCACAAAGCTGGCCGCTGGCG
 ACAGATCTGGCCTGACAGCCGTGATCAGACGGGCCAACAATGTGCTGAAGAACGAGATGAAGCGGTA
 CAAGGGCCTGCTGCCCAAGGACATTGCCAACAGCTTCTACGAGGTGTTGAGAAGTACCCCCACTTCA
 TCGACGTGTTCTGTCACCTTCGGCATTGCCCAGAGCAGCACCGAGGGCGGCTCCAGAGTGGAGGGCATC
 TTCGCCGGCCTGTTTCATGAACGCCTACGGCGCTGGCCAGGTGATGCTGAGATGGGGCGTGCTGGCCAA
 20 GAGCGTGAAGAACATCATGCTGGGCCACGCCAGCGTGCAGGCCGAGATGGAACAGGTGGTGGAGGTG
 TACGAGTACGCCAGAAGCTGGGCGGAGAGGCCGGCTTCTACCACATCCTGAACAACCCTAAGGCCTC
 CCTGCTGTCCCTGACCCAGTTCCCCCACTTCTCCAGCGTGGTGCTGGGAAATGCCGCCGGACTGGGCAT
 CATGGGCGAGTACCGGGGACCCCCAGAAACCAGGACCTGTACGACGCCGCCAAGGCCTACGCCGAG
 CAGCTGAAAGAAAACGGCGTGATCAACTACAGCGTGCTGGACCTGACCGCTGAGGAACTGGAAGCCA
 25 TCAAGCACCAGCTGAACCCCAAGGACAACGACGTGGAGCTGGGAGGCGGAGGATCTGGCGGCGGAGG
 CATGAGCAGACGGAACCCCTGCAAGTTCGAGATCCGGGGGCCACTGCCTGAACGGCAAGCGGTGCCAC
 TTCAGCCACAATACTTCGAGTGGCCCCCTCATGCTCTGCTGGTGCGGCAGAACTTCATGCTGAACCGG
 ATCCTGAAGTCCATGGACAAGAGCATCGACACCCTGAGCGAGATCAGCGGAGCCGCCGAGCTGGACA
 GAACCGAGGAATATGCCCTGGGCGTGGTGGGAGTGCTGGAAAGCTACATCGGCTCCATCAACAACAT
 30 CACAAAGCAGAGCGCCTGCGTGGCCATGAGCAAGCTGCTGACAGAGCTGAACAGCGACGACATCAAG
 AAGCTGAGGGACAACGAGGAACTGAACAGCCCCAAGATCCGGGTGTACAACACCGTGATCAGCTACA
 TTGAGAGCAACCGCAAGAACAACAAGCAGACCATCCATCTGCTGAAGCGGCTGCCCCGCCGACGTGCT
 GAAAAAGACCATCAAGAACACCCTGGACATCCACAAGTCCATCACCATCAACAATCCCAAAGAAAGC
 ACCGTGTCTGACACCAACGATCACGCCAAGAACAACGACACCCTGATGAGCGGCCGCGATCTGCTG
 35 TGCCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCCTTCCTTGACCCTGGAAGGTGCCAC
 TCCCACTGTCTTTTCTTAATAAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCT
 GGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGA

TGC GGTGGGCTCTATGGCCGATCAGCGATCGCTGAGGTGGGTGAGTGGGCGTGGCCTGGGGTGGTCAT
 GAAAATATATAAGTTGGGGGTCTTAGGGTCTCTTTATTTGTGTTGCAGAGACCGCCGGAGCCATGAGC
 GGGAGCAGCAGCAGCAGCAGTAGCAGCAGCGCCTTGATGGCAGCATCGTGAGCCCTTATTTGACGA
 CGCGGATGCCCCACTGGGCCGGGGTGCGTCAGAATGTGATGGGCTCCAGCATCGACGGCCGACCCGTC
 5 CTGCCCCGAAATTCCGCCACGCTGACCTATGCGACCGTCGCGGGGACGCCGTTGGACGCCACCGCCGC
 CGCCGCCGCCACCGCAGCCGCCCTCGGCCGTGCGCAGCCTGGCCACGGACTTTGCATTCTTGGGACCAC
 TGGCGACAGGGGCTACTTCTCGGGCCGCTGCTGCCGCCGTTTCGCGATGACAAGCTGACCGCCCTGCTG
 GCGCAGTTGGATGCGCTTACTCGGGAAGTGGGTGACCTTTCTCAGCAGGTCATGGCCCTGCGCCAGCA
 GGTCTCCTCCCTGCAAGCTGGCGGGAATGCTTCTCCACAAATGCCGTTTAAGATAAATAAAACCAGA
 10 CTCTGTTTGGATTAAAGAAAAGTAGCAAGTGCATTGCTCTCTTTATTTTCATAATTTTCCGCGCGGATA
 GGCCCTAGACCAGCGTTCTCGGTGCTTGAGGGTGGCGGTGTATCTTCTCCAGGACGTGGTAGAGGTGGC
 TCTGGACGTTGAGATACATGGGCATGAGCCCGTCCCGGGGGTGGAGGTAGCACCACTGCAGAGCTTCA
 TGCTCCGGGGTGGTGTGTAGATGATCCAGTCGTAGCAGGAGCGCTGGGCATGGTGCCTAAAAATGTC
 CTTACAGCAGCAGGCCGATGGCCAGGGGGAGGCCCTTGGTGTAAGTGTTTACAAAACGGTTAAGTTGGG
 15 AAGGGTGCATTCGGGGAGAGATGATGTGCATCTTGGACTGTATTTTATAGATTGGCGATGTTTCCGCCCA
 GATCCCTTCTGGGATTTCATGTTGTGCAGGACCACCAGTACAGTGTATCCGGTGCATTGGGGAATTTGT
 CATGCAGCTTAGAGGGAAAAGCGTGGAAGAACTTGAGACGCCTTTGTGGCCTCCAGATTTTCCATG
 CATTCGTCCATGATGATGGCAATGGGCCCGCGGGAGGCAGCTTGGGCAAAGATATTTCTGGGGTCGCT
 GACGTCGTAGTTGTGTTCCAGGGTGAGGTCGTACATAGGCCATTTTACAAAGCGCGGGCGGAGGGTGC
 20 CCGACTGGGGGATGATGGTCCCCTCTGGCCCTGGGGCGTAGTTGCCCTCGCAGATCTGCATTTCCCAG
 GCCTTAATCTCGGAGGGGGGAATCATATCCACCTGCGGGGCGATGAAGAAAACGGTTTCCGGAGCCG
 GGGAGATTAACTGGGATGAGAGCAGGTTTCTAAGCAGCTGTGATTTTCCACAACCGGTGGGCCCATAA
 ATAACACCTATAACCGGTTGCAGCTGGTAGTTTAGAGAGCTGCAGCTGCCGTCTCGCCGAGGAGGGG
 GGCCACCTCGTTGAGCATGTCCCTGACGCGCATGTTCTCCCCGACCAGATCCGCCAGAAGGCGCTCGC
 25 CGCCCAGGGACAGCAGCTCTTGCAAGGAAGCAAAGTTTTTTCAGCGGCTTGAGGCCGTCCGCCGTGGGC
 ATGTTTTTTCAGGGTCTGGCTCAGCAGCTCCAGGCGGTCCCAGAGCTCGGTGACGTGCTCTACGGCATCT
 CTATCCAGCATATCTCTCGTTTCGCGGGTTGGGGCGACTTTCGCTGTAGGGCACCAAGCGGTGGTCGT
 CCAGCGGGGCCAGAGTCATGTCCTCCATGGGCGCAGGGTCCTCGTCAGGGTGGTCTGGGTACAGGTG
 AAGGGGTGCGCTCCGGGCTGAGCGCTTGCCAAGGTGCGCTTGAGGCTGGTTCTGCTGGTGTGAAGCG
 30 CTGCCGGTCTTCGCCCTGCGCGTCGGCCAGGTAGCATTTGACCATGGTGTGATAGTCCAGCCCCCTCCGC
 GGCGTGTCCCTTGCGCGCAGCTTGCCCTTGAGAGTGGCGCCGCACGAGGGGCAGAGCAGGCTCTTGA
 GCGCGTAGAGCTTGGGGGCGAGGAAGACCGATTTCGGGGGAGTAGGCGTCCGCGCCGAGACCCCGCA
 CACGGTCTCGCACTCCACCAGCCAGGTGAGCTCGGGGCGCGCCGGGTCAAAAACCAGGTTTCCCCCAT
 GCTTTTTGATGCGTTTCTTACCTCGGGTCTCCATGAGGTGGTGTCCCCGCTCGGTGACGAAGAGGCTGT
 35 CCGTGTCTCCGTAGACCGACTTGAGGGGTCTTTTCTCCAGGGGGGTCCCTCGGTCTTCTCGTAGAGGA
 ACTCGGACCACTCTGAGACGAAGGCCCGCGTCCAGGCCAGGACGAAGGAGGCTATGTGGGAGGGGTA
 GCGGTGCTTGTCCACTAGGGGGTCCACCTTCTCCAAGGTGTGAAGACACATGTGCGCTTCTCGGCGTC

CAGGAAGGTGATTGGCTTGTAGGTGTAGGCCACGTGACCGGGGGTTCCTGACGGGGGGGTATAAAAG
 GGGGTGGGGGCGCGCTCGTCGTCCTCTTCCGCATCGCTGTCTGCGAGGGCCAGCTGCTGGGGTGA
 GTATTCCCTCTCGAAGGCGGGCATGACCTCCGCGCTGAGGTTGTCAGTTTCCAAAAACGAGGAGGATT
 TGATGTTACCTGTCCCGAGGTGATACCTTTGAGGGTACCCGCGTCCATCTGGTCAGAAAACACGATCT
 5 TTTTATTGTCCAGCTTGGTGGCGAACGACCCGTAGAGGGCGTTGGAGAGCAGCTTGGCGATGGAGCGC
 AGGGTCTGGTTCTTGTCCCTGTGCGCGCGCTCCTTGGCCGCGATGTTGAGCTGCACGTACTCGCGCGCG
 ACGCAGCGCCACTCGGGGAAGACGGTGGTGCCTCGTCGGGCACCAGGCGCACGCGCCAGCCGCGGT
 TGTGCAGGGTGACCAGGTCCACGCTGGTGGCGACCTCGCCGCGCAGGCGCTCGTTGGTCCAGCAGAGA
 CGGCCGCCCTTGCAGAGCAGAAGGGGGGAGGGGGTTCGAGCTGGGTCTCGTCCGGGGGGTCCGCGT
 10 CCACGGTGAAAACCCCGGGGCGCAGGCGCGCGTCAAGTAGTCTATCTTGCAACCTTGCATGTCCAGC
 GCCTGTGTCAGTCGCGGGGCGCGAGCGCGCGCTCGTAGGGGTTGAGCGGCGGGCCCCAGGGCATGG
 GGTGGGTGAGTGCAGAGGCGTACATGCCGCAGATGTCATAGACGTAGAGGGGCTCCCGCAGGACCCC
 GATGTAGGTGGGTAGCAGCGGCCCGCGCGATGCTGGCGCGCACGTAGTCATACAGCTCGTGCGAG
 GGGGCGAGGAGGTGCGGGGCCAGGTTGGTGGCGGGGCGCTCCGCGCGGAAGACGATCTGCCTGA
 15 AGATGGCATGCGAGTTGGAAGAGATGGTGGGGCGCTGGAAGACGTTGAAGCTGGCGTCCCTGCAGGCC
 GACGGCGTCGCGCACGAAGGAGGCGTAGGAGTCGCGCAGCTTGTGTACCAGCTCGGCGGTGACCTGC
 ACGTCGAGCGCGCAGTAGTCGAGGGTCTCGCGGATGATGTCATATTTAGCCTGCCCTTCTTTTCCAC
 AGCTCGCGGTTGAGGACAACTCTTCGCGGTCTTTCCAGTACTCTTGGATCGGGAAACCGTCCGGTTCC
 GAACGGTAAGAGCCTAGCATGTAGAACTGGTTGACGGCCTGGTAGGCGCAGCAGCCCTTCTCCACGGG
 20 GAGGGCGTAGGCCTGCGCGGCCCTTGGCGAGCGAGGTGTGGGTGAGGGCGAAGGTGTCCCTGACCATG
 ACTTTGAGGTACTGGTGCTTGAAGTCGAGTCGTCGAGCCGCCCGCTCCAGAGCGAGAAGTCGGT
 GCGCTTCTTGAGCGGGGGTTGGGCAGAGCGAAGGTGACATCGTTGAAGAGGATTTTGCCCGCGCGG
 GGCATGAAGTTGCGGGTGATGCGGAAGGGCCCCGGCACTTCAGAGCGGTTGTTGATGACCTGGGCGG
 CGAGCACGATCTCGTCGAAGCCGTTGATGTTGTGGCCACGATGTAGAGTTCCAGGAAGCGGGGCCG
 25 CCCTTTACGGTGGGCAGCTTCTTTAGCTCTTCGTAGGTGAGCTCCTCGGGCGAGGCGAGGCCGTGCTCG
 GCCAGGGCCCAGTCCGCGAGGTGCGGGTGTCTCTGAGGAAGGACTTCCAGAGGTGCGGGGCCAGGA
 GGGTCTGCAGGCGGTCTCTGAAGTCTGAACTGGCGGCCACGGCCATTTTTTCGGGGGTGATGCAG
 TAGAAGGTGAGGGGGTCTTGCTGCCAGCGGTCCCAGTCGAGCTGCAGGGCGAGGTGCGCGCGGGCGG
 TGACCAGGCGCTCGTCGCCCCGAATTTTCATGACCAGCATGAAGGGCACGAGCTGCTTTCCGAAGGCC
 30 CCCATCCAAGTGTAGGTCTCTACATCGTAGGTGACAAAGAGGCGCTCCGTGCGAGGATGCGAGCCGAT
 CGGGAAGAACTGGATCTCCCGCCACCAGTTGGAGGAGTGGCTGTTGATGTGGTGGAAGTAGAAGTCCC
 GTCGCCGGGCCGAACACTCGTGCTGGCTTTTGTAAGAGCGAGCGCAGTACTGGCAGCGCTGCACGGGC
 TGTACCTCATGCACGAGATGCACCTTTCGCCCCGCGCACGAGGAAGCCGAGGGGAAATCTGAGCCCCC
 GCCTGGCTCGCGGCATGGCTGGTTCTTCTACTTTGGATGCGTGTCCGTCTCCGTCTGGCTCCTCGAG
 35 GGGTGTTACGGTGGAGCGGACCACCGCGCGAGCCGCAGGTCCAGATATCGGCGCGCGGCGGT
 CGGAGTTTGATGACGACATCGCGCAGCTGGGAGCTGTCCATGGTCTGGAGCTCCCGCGGCGGCGGAG
 GTCAGCCGGGAGTTCTTGCAAGTTCACCTCGCAGAGTCGGGCCAGGGCGCGGGGCAGGTCTAGGTGGT

ACCTGATCTCTAGGGGCGTGTTGGTGGCGGCGTCGATGGCTTGCAGGAGCCCCGAGCCCCGGGGGGCG
 ACGACGGTGCCCCGCGGGGTGGTGGTGGTGGTGGCGGTGCAGCTCAGAAGCGGTGCCGCGGGCGGGC
 CCCCCGAGGTAGGGGGGGCTCCGGTCCCGCGGGCAGGGGCGGCAGCGGCACGTCCGGCGTGAGCGCG
 GGCAGGAGTTGGTGTCTGTGCCCGAGGTTGCTGGCGAAGGCGACGACGCGGCGGTTGATCTCCTGGAT
 5 CTGGCGCCTCTGCGTGAAGACGACGGGCCCGGTGAGCTTGAACCTGAAAGAGAGTTTCGACAGAATCA
 ATCTCGGTGTCATTGACCGCGGCCCTGGCGCAGGATCTCCTGCACGTCTCCCGAGTTGTCTTGGTAGGCG
 ATCTCGGCCATGAACTGCTCGATCTCTTCTCCTGGAGGTCTCCGCGTCCGGCGCGTTCCACGGTGGCC
 GCCAGGTCGTTGGAGATGCGCCCCATGAGCTGCGAGAAGGCGTTGAGTCCGCCCTCGTTCCAGACTCG
 GCTGTAGACCACGCCCCCTGGTCATCGCGGGCGCGCATGACCACCTGCGCGAGGTTGAGCTCCACGT
 10 GCCGCGCAAGACGGCGTAGTTGCGCAGACGCTGGAAGAGGTAGTTGAGGGTGGTGGCGGTGTGCTC
 GGCCACGAAGAAGTTCATGACCCAGCGGCGCAACGTGGATTGTTGATGTCCCCAAGGCCTCCAGCC
 GTTCCATGGCCTCGTAGAAGTCCACGGCGAAGTTGAAAACTGGGAGTTGCGCGCCGACACGGTCAAC
 TCCTCCTCCAGAAGACGGATGAGCTCGGCGACGGTGTGCGGCACCTCGCGCTCGAAGGCTATGGGGAT
 CTCTTCTCCGCTAGCATCACACCTCCTCCTCTTCTCCTCTTCTGACATTCCATGATGGCTTCTCCT
 15 CTTCGGGGGGTGGCGGCGGCGGCGGTGGGGGAGGGGGCGCTCTGCGCCGGCGGCGGCGCACCGGGAG
 GCGGTCCACGAAGCGCGCGATCATCTCCCCGCGGCGGCGGCGCATGGTCTCGGTGACGGCGGCGCGT
 TCTCCCGGGGGCGCAGTTGGAAGACGCCGCCGGACATCTGGTGCTGGGGCGGGTGGCCGTGAGGCAG
 CGAGACGGCGCTGACGATGCATCTCAACAATTGCTGCGTAGGTACGCCGCCGAGGGACCTGAGGGAG
 TCCATATCCACCGGATCCGAAAACCTTTCGAGGAAGGCGTCTAACCAGTCGCAGTCGCAAGGTAGGCT
 20 GAGCACCGTGGCGGGCGGCGGGGGGTGGGGGAGTGTCTGGCGGAGGTGCTGCTGATGATGTAATTG
 AAGTAGGCGGACTTGACACGGCGGATGGTCGACAGGAGCACCATGTCCTTGGGTCCGGCCTGCTGGAT
 GCGGAGGCGGTTCGGCTATGCCCCAGGCTTCGTTCTGGCATCGGCGCAGGTCCTTGATAGTAGTCTTGCAT
 GAGCCTTTCACCGGCACCTCTTCTCCTTCTTCTGCTTCTTCCATGTCTGCTTCGGCCCTGGGGCGG
 CGCCGCGCCCCCTGCCCCCATGCGCGTGACCCCGAACCCCTGAGCGGTTGGAGCAGGGCCAGGTC
 25 GGCGACGACGCGCTCGGCCAGGATGGCCTGCTGCACCTGCGTGAGGGTGGTTTGGAAGTCATCCAAGT
 CCACGAAGCGGTGGTAGGCGCCCGTGTGATGGTGTAGGTGCAGTTGGCCATGACGGACCAAGTTGACG
 GTCTGGTGGCCCGGTTGCGACATCTCGGTGTACCTGAGTCGCGAGTAGGCGCGGGAGTCGAAGACGTA
 GTCGTTGCAAGTCCGCACCAGGTAAGGTAGCCACCAGGAAGTGCAGGCGGCGGCTGGCGGTAGAGG
 GGCCAGCGCAGGGTGGCGGGGGCTCCGGGGGCCAGGTCTTCCAGCATGAGGCGGTGGTAGGCGTAGA
 30 TGTACCTGGACATCCAGGTGATACCCGCGGCGGTGGTGGAGGCGCGCGGGAAGTCGCGCACCCGGTTC
 CAGATGTTGCGCAGGGGCAGAAAGTGCTCCATGGTAGGCGTGCTCTGTCCAGTCAGACGCGCGCAGTC
 GTTGATACTCTAGACCAGGGAAAACGAAAGCCGGTCAGCGGGCACTCTTCCGTGGTCTGGTGAATAGA
 TCGCAAGGGTATCATGGCGGAGGGCCTCGGTTTCGAGCCCCGGGTCCGGGGCCGGACGGTCCGCCATGAT
 CCACGCGGTTACCGCCCGCGTGTGCAACCCAGGTGTGCGACGTGAGACAACGGTGGAGTGTTCTTTT
 35 GGCGTTTTTCTGGCCGGGCGCCGGCGCCGCGTAAGAGACTAAGCCGCGAAAGCGAAAGCAGTAAGTG
 GCTCGCTCCCGTAGCCGAGGGATCCTTGCTAAGGGTTGCGTTGCGGCGAACCCCGGTTGCAATCCC
 GTACTCGGGCCGCGCGGACCCGCGGCTAAGGTGTTGGATTGGCCTCCCCCTCGTATAAAGACCCCGCT

TGCGGATTGACTCCGGACACGGGGACGAGCCCCTTTTATTTTGGCTTTCCCCAGATGCATCCGGTGCTG
 CGGCAGATGCGCCCCCGCCCCAGCAGCAGCAACAACACCAGCAAGAGCGGCAGCAACAGCAGCGGG
 AGTCATGCAGGGCCCCCTCACCCACCCTCGGCGGGCCGGCCACCTCGGCGTCCGCGGCCGTGTCTGGC
 GCCTGCGGCGGGCGGGGGGGCCGGCTGACGACCCCCGAGGAGCCCCCGGGCGCAGGGCCAGACACT
 5 ACCTGGACCTGGAGGAGGGCGAGGGCCTGGCGCGGCTGGGGGCGCCGTCTCCCGAGCGCCACCCGCG
 GGTGCAGCTGAAGCGCGACTCGCGCGAGGCGTACGTGCCTCGGCAGAACCTGTTACAGGGACCGCGCG
 GGCGAGGAGCCCGAGGAGATGCGGGACAGGAGGTTACGCGCAGGGCGGGAGCTGCGGCAGGGGCTG
 AACCGCGAGCGGCTGCTGCGCGAGGAGGACTTTGAGCCCCGACGCGCGGACGGGGATCAGCCCCGCGC
 GCGCGCACGTGGCGGCCGCCGACCTGGTGACGGCGTACGAGCAGACGGTGAACCAGGAGATCAACTT
 10 CCAAAAGAGTTTCAACAACCACGTGCGCACGCTGGTGGCGCGCGAGGAGGTGACCATCGGGCTGATG
 CACCTGTGGGACTTTTGTAAAGCGCGCTGGTGCAGAACCCCAACAGCAAGCCTCTGACGGCGCAGCTGTT
 CCTGATAGTGCAGCACAGCAGGGACAACGAGGCGTTTAGGGACGCGCTGCTGAACATCACCGAGCCC
 GAGGGTTCGGTGGCTGCTGGACCTGATTAACATCCTGCAGAGCATAGTGGTGCAGGAGCGCAGCCTGA
 GCCTGGCCGACAAGGTGGCGGCCATCAACTACTCGATGCTGAGCCTGGGCAAGTTTTACGCGCGCAAG
 15 ATCTACCAGACGCCGTACGTGCCCATAGACAAGGAGGTGAAGATCGACGGTTTTTACATGCGCATGGC
 GCTGAAGGTGCTCACCTGAGCGACGACCTGGGCGTGTACCGCAACGAGCGCATCCACAAGGCCGTG
 AGCGTGAGCCGGCGGCGCGAGCTGAGCGACCGCGAGCTGATGCACAGCCTGCAGCGGGCGCTGGCGG
 GCGCCGGCAGCGGCGACAGGGAGGCGGAGTCTACTTCGATGCGGGGGCGGACCTGCGCTGGGCGCC
 CAGCCGGCGGGCCCTGGAGGGCCGCGGGGGTCCGCGAGGACTATGACGAGGACGGCGAGGAGGATGA
 20 GGAGTACGAGCTAGAGGAGGGCGAGTACCTGGACTAAACCGCGGGTGGTGTTCGGGTAGATGCAAG
 ACCCGAACGTGGTGGACCCGGCGCTGCGGGCGGCTCTGCAGAGCCAGCCGTCCGGCCTTAACCTCTCA
 GACGACTGGCGACAGGTCATGGACCGCATCATGTGCTGACGGCGCGTAACCCGGACGCGTTCCGGCA
 GCAGCCGCAGGCCAACAGGCTCTCCGCCATCCTGGAGGCGGTGGTGCCTGCGCGCTCGAACCCACGC
 ACGAGAAGGTGCTGGCCATAGTGAACGCGCTGGCCGAGAACAGGGCCATCCGCCCGGACGAGGCCGG
 25 GCTGGTGTACGACGCGCTGCTGCAGCGCGTGGCCCGCTACAACAGCGGCAACGTGCAGACCAACCTG
 GACCGGCTGGTGGGGGACGTGCGCGAGGCGGTGGCGCAGCGCGAGCGCGCGGATCGGCAGGGCAACC
 TGGGCTCCATGGTGGCGCTGAATGCCTTCCTGAGCACGCAGCCGGCCAACGTGCCGCGGGGGCAGGA
 AGACTACACCAACTTTGTGAGCGCGCTGCGGCTGATGGTGACCGAGACCCCCAGAGCGAGGTGTACC
 AGTCGGGCCCCGACTACTTCTTCCAGACCAGCAGACAGGGCCTGCAGACGGTGAACCTGAGCCAGGCT
 30 TTCAAGAACCTGCGGGGGCTGTGGGGCGTGAAGGCGCCACCGGCGACCGGGCGACGGTGTCCAGCC
 TGCTGACGCCCAACTCGCGCCTGCTGCTGCTGCTGATCGCGCCGTTACGGACAGCGGCAGCGTGTCC
 CGGGACACCTACCTGGGGCACCTGCTGACCTGTACCGCGAGGCCATCGGGCAGGCGCAGGTGGACG
 AGCACACCTTCCAGGAGATCACAGCGTGAGCCGCGCGCTGGGGCAGGAGGACACGAGCAGCCTGGA
 GGCGACTCTGAACCTGCTGACCAACCGGCGGCAGAAGATTCCCTCGCTGCACAGCCTGACCTCCG
 35 AGGAGGAGCGCATCTTGCGCTACGTGCAGCAGAGCGTGAGCCTGAACCTGATGCGCGACGGGGTGAC
 GCCAGCGTGGCGCTGGACATGACCGCGCGCAACATGGAACCGGGCATGTACGCCGCGCACCGGCCCT
 TACATCAACCGCCTGATGGACTACCTGCATCGCGCGGCGGCCGTGAACCCCGAGTACTTTACCAACGC

CATCCTGAACCCGCACTGGCTCCCGCCGCCCGGGTTCTACAGCGGGGGCTTCGAGGTCCCGGAGACCA
 ACGATGGCTTCCTGTGGGACGACATGGACGACAGCGTGTCTCCCCGCGGCCGCAGGCGCTGGCGGAA
 GCGTCCCTGCTGCGTCCCAAGAAGGAGGAGGAGGAGGAGGCGAGTCGCCGCCGCGGCAGCAGCGGCG
 TGGCTTCTCTGTCCGAGCTGGGGGCGGCAGCCGCCGCGCGCCCCGGGTCCCTGGGCGGCAGCCCCTTT
 5 CCGAGCCTGGTGGGGTCTCTGCACAGCGAGCGCACCAACCCGCCCTCGGCTGCTGGGCGAGGACGAGTA
 CCTGAATAACTCCCTGCTGCAGCCGGTGCGGGAGAAAAACCTGCCTCCCGCCTTCCCCAACAACGGGA
 TAGAGAGCCTGGTGGACAAGATGAGCAGATGGAAGACCTATGCGCAGGAGCACAGGGACGCGCCTGC
 GCTCCGGCCGCCACGCGGCGCCAGCGCCACGACCGGCAGCGGGGGCTGGTGTGGGATGACGAGGAC
 TCCGCGGACGATAGCAGCGTGCTGGACCTGGGAGGGAGCGGCAACCCGTTGCGGCACCTGCGCCCCC
 10 GCCTGGGGAGGATGTTTTAAAAAAAAAAAAAAAAAAGCAAGAAGCATGATGCAAAAATTAAATAAAA
 CTCACCAAGGCCATGGCGACCGAGCGTTGGTTTCTTGTGTTCCCTTCAGTATGCGGCGCGCGCGATGT
 ACCAGGAGGGACCTCCTCCCTCTTACGAGAGCGTGGTGGGCGCGGCGGCGGCGGCCCTCTTCTCCC
 TTTGCGTCGCAGCTGCTGGAGCCGCCGTACGTGCCCTCCGCGCTACCTGCGGCCCTACGGGGGGGAGAAA
 CAGCATCCGTTACTCGGAGCTGGCGCCCCTGTTGACACCAACCCGGGTGTACCTGGTGGACAACAAGT
 15 CGGCGGACGTGGCCTCCCTGAACTACCAGAACGACCACAGCAATTTTTTGACCACGGTCATCCAGAAC
 AATGACTACAGCCCGAGCGAGGCCAGCACCCAGACCATCAATCTGGATGACCGGTCGCACTGGGGCG
 GCGACCTGAAAACCATCCTGCACACCAACATGCCCAACGTGAACGAGTTCATGTTACCAATAAGTTC
 AAGGCGCGGGTGATGGTGTGCGGCTCGCACACCAAGGAAGACCGGGTGGAGCTGAAGTACGAGTGGG
 TGGAGTTCGAGCTGCCAGAGGGCAACTACTCCGAGACCATGACCATTGACCTGATGAACAACGCGATC
 20 GTGGAGCACTATCTGAAAGTGGGCAGGCAGAACGGGGTCTGGAGAGCGACATCGGGGTCAAGTTCG
 ACACCAGAACTTCCGCCTGGGGCTGGACCCCGTGACCGGGCTGGTTATGCCCGGGGTGTACACCAAC
 GAGGCCTTCCATCCCGACATCATCCTGCTGCCCGGCTGCGGGGTGGACTTCACTTACAGCCGCCTGAG
 CAACCTCCTGGGCATCCGCAAGCGGCAGCCCTTCCAGGAGGGCTTCAGGATCACCTACGAGGACCTGG
 AGGGGGGCAACATCCCCGCGCTCCTCGATGTGGAGGCCCTACCAGGATAGCTTGAAGGAAAATGAGGC
 25 GGGACAGGAGGATACCGCCCCCGCCGCTCCGCGCCGCGCCGAGCAGGGCGAGGATGCTGCTGACACC
 GCGGCCGCGGACGGGGCAGAGGCCGACCCCGCTATGGTGGTGGAGGCTCCCGAGCAGGAGGAGGACA
 TGAATGACAGTGCGGTGCGCGGAGACACCTTCGTACCCGGGGGAGGAAAAGCAAGCGGAGGCCGA
 GGCCGCGGCCGAGGAAAAGCAACTGGCGGCAGCAGCGGCGGCGGCGGCGTTGGCCGCGGCGGAGGC
 TGAGTCTGAGGGGACCAAGCCCGCCAAGGAGCCCGTGATTAAGCCCCTGACCGAAGATAGCAAGAAG
 30 CGCAGTTACAACCTGCTCAAGGACAGCACCAACACCGCGTACCGCAGCTGGTACCTGGCCTACAATA
 CGGCGACCCGTCGACGGGGGTGCGCTCCTGGACCCTGCTGTGCACGCCGACGTGACCTGCGGCTCGG
 AGCAGGTGTACTGGTCGCTGCCCCGACATGATGCAAGACCCCGTGACCTCCGCTCCACGCGGCAGGTC
 AGCAACTTCCCGGTGGTGGGCGCCGAGCTGCTGCCCGTGCACTCCAAGAGCTTCTACAACGACCAGGC
 CGTCTACTCCAGCTCATCCGCCAGTTACCTCTCTGACCCACGTGTTCAATCGCTTTTCTGAGAACCA
 35 GATTCTGGCGCGCCCGCCCCGCCCCACCATCACACCGTCAGTGAAAACGTTCTGCTCTCACAGATC
 ACGGGACGCTACCGCTGCGCAACAGCATCGGAGGAGTCCAGCGAGTGACCGTTACTGACGCCAGACG
 CCGCACCTGCCCTACGTTTACAAGGCCTTGGGCATAGTCTCGCCGCGCGTCCCTTCCAGCCGCACTTT

TTGAGCAACACCACCATCATGTCCATCCTGATCTCACCCAGCAATAACTCCGGCTGGGGACTGCTGCG
 CGCGCCAGCAAGATGTTCCGAGGGGCGAGGAAGCGTTCCGAGCAGCACCCCGTGCGCGTGCGCGGG
 CACTTCCGCGCCCCCTGGGGAGCGCACAAACGCGGCCGCGCGGGGCGCACCAACCGTGACGACGCCA
 TCGACTCGGTGGTGGAGCAGGCGCGCAACTACAGCCCCGCGGTCTCTACCGTGACGCGGCCATCCAG
 5 ACCGTGGTGCAGGGGCGCGCGGCGGTACGCCAAGCTGAAGAGCCGCCGGAAGCGCGTGCCCCGCCGCC
 ACCGCCGCCGACCCGGGGCCCGCCGCAAACGCGCCGCCGCGGCCCTGCTTCGCCGGGCCAAGCGCAC
 GGGCCGCCGCGCCGCCATGAGGGCCGCGCGCCGCTTGCCCGCCGGCATCACCGCCGCCACCATGGCCC
 CCCGTACCCGAAGACGCGCGGCCGCCGCCGCCGCCGCCGCCGCCATCAGTGACATGGCCAGCAGGCGCCG
 GGGCAACGTGTACTGGGTGCGCGACTCGGTGACCGGCACGCGCGTGCCCGTGCGCTTCCGCCCCCGC
 10 GGACTTGAGATGATGTGAAAAACAACACTGAGTCTCCTGCTGTTGTGTGTATCCCAGCGGCGGGCGG
 GCGCGCAGCGTCATGTCCAAGCGCAAAATCAAAGAAGAGATGCTCCAGGTCGTCGCGCCGAGATCT
 ATGGGCCCCCGAAGAAGGAAGAGCAGGATTCGAAGCCCCGCAAGATAAAGCGGGTCAAAAAGAAAA
 AGAAAGATGATGACGATGCCGATGGGGAGGTGGAGTTCCTGCGCGCCACGGCGCCAGGCGCCCCGT
 GCAGTGGAAGGGCCGGCGCGTAAAGCGCGTCTGCGCCCCGGCACCGCGGTGGTCTTACGCCCGGC
 15 GAGCGCTCCACCCGACTTTCAAGCGCGTCTATGACGAGGTGTACGGCGACGAAGACCTGCTGGAGCA
 GGCCAACGAGCGCTTCGGAGAGTTTGCTTACGGGAAGCGTCAGCGGGCGCTGGGGAAGGAGGACCTG
 CTGGCGCTGCCGCTGGACCAGGGCAACCCACCCCACTGCTGAAGCCCGTGACCCTGCAGCAGGTGCT
 GCCGAGCAGCGCACCCCTCCGAGGCGAAGCGGGGTCTGAAGCGCGAGGGCGGGGACCTGGCGCCCACC
 GTGCAGCTCATGGTGCCCAAGCGGCAGAGGCTGGAGGATGTGCTGGAGAAAATGAAAGTAGACCCCG
 20 GTCTGCAGCCGGACATCAGGGTCCGCCCCATCAAGCAGGTGGCGCCGGGCCTCGGCGTGACACCGTG
 GACGTGGTCATCCCCACCGGCAACTCCCCCGCCGCCGCCACCACTACCGCTGCCTCCACGGACATGGA
 GACACAGACCGATCCCGCCGCAGCCGCAGCCGCAGCCGCCGCCGCGACCTCCTCGGCGGAGGTGCAG
 ACGGACCCCTGGCTGCCGCCGGCGATGTCAGCTCCCCGCGCGCGTCGCGGGCGCAGGAAGTACGGCG
 CCGCCAACGCGCTCTGCCCCGAGTACGCCTTGTCATCCTTCCATCGCGCCACCCCCGGCTACCGAGGCT
 25 ATACCTACCGCCCGCGAAGAGCCAAGGGTTCCACCCGCCGTCCCCGCCGACGCGCCGCCGCCACCACC
 CGCCGCCGCCGCCGAGACGCCAGCCCGCACTGGCTCCAGTCTCCGTGAGGAAAGTGCGCGCGGACG
 GACACACCCTGGTGCTGCCAGGGCGCGCTACCACCCAGCATCGTTTAAAAGCCTGTTGTGGTTCTTG
 CAGATATGGCCCTCACTTGCCGCTCCGTTTCCCGGTGCCGGGATACCGAGGAGGAAGATCGCGCCGC
 AGGAGGGGTCTGGCCGGCCGCGGCCTGAGCGGAGGCAGCCGCCGCGCGCACCGGCGGCGACGCGCCA
 30 CCAGCCGACGCATGCGCGGCGGGGTGCTGCCCCTGTTAATCCCCCTGATCGCCGCGGCGATCGGCGCC
 GTGCCCCGGATCGCTCCGTGGCCTTGCAAGCGTCCAGAGGCATTGACAGACTTGCAAACCTTGCAAA
 TATGGAAAAAAAACCCCAATAAAAAAGTCTAGACTCTCACGCTCGCTTGGTCTGTGACTATTTTGT
 AGAATGGAAGACATCAACTTTGCGTCGCTGGCCCCGCGTCACGGCTCGCGCCCGTTCTGGGACACTG
 GAACGATATCGGCACCAGCAACATGAGCGGTGGCGCCTTCAGTTGGGGCTCTCTGTGGAGCGGCATTA
 35 AAAGTATCGGGTCTGCCGTTAAAAATTACGGCTCCCGGGCCTGGAACAGCAGCACGGGCCAGATGTTG
 AGAGACAAGTTGAAAGAGCAGAACTTCCAGCAGAAGGTGGTGGAGGGCCTGGCCTCCGGCATCAACG
 GGGTGGTGGACCTGGCCAACCAGGCCGTGCAGAATAAGATCAACAGCAGACTGGACCCCCGGCCGCC

GGTGGAGGAGGTGCCGCCGGCGCTGGAGACGGTGTCCCCCGATGGGCGTGCGGAGAAGCGCCCCGCG
 CCCGATAGGGAAGAGACCACTCTGGTCACGCAGACCGATGAGCCGCCCCCGTATGAGGAGGCCCTGA
 AGCAAGGTCTGCCACCACGCGGCCCATCGCGCCCATGGCCACCGGGGTGGTGGGCCGCCACACCCCC
 GCCACGCTGGACTTGCCTCCGCCCGCCGATGTGCCGCAGCAGCAGAAGGCGGCACAGCCGGGCCCGC
 5 CCGCGACCGCCTCCCGTTCCCTCCGCCGGTCTCTGCGCCGCGCGGCCAGCGGCCCCCGCGGGGGGGT
 GCGAGGCACGGCAACTGGCAGAGCAGCTGAACAGCATCGTGGGTCTGGGGGTGCGGTCCGTGAAGC
 GCCGCCGATGCTACTGAATAGCTTAGCTAACGTGTTGTATGTGTGTATGCGCCCTATGTCGCCGCCAGA
 GGAGCTGCTGAGTCGCCGCCGTTCCGCGCGCCACCACCACCGCCACTCCGCCCCCTCAAGATGGCGACC
 CCATCGATGATGCCGCAGTGGTCGTACATGCACATCTCGGGCCAGGACGCCTCGGAGTACCTGAGCCC
 10 CGGGCTGGTGCAGTTCGCCCCGCGCCACCGAGAGCTACTTCAGCCTGAGTAACAAGTTTAGGAACCCCA
 CGGTGGCGCCACGCACGATGTGACCACCGACCGGTCTCAGCGCCTGACGCTGCGGTTTATTCCCGTG
 GACCGCGAGGACACCGCGTACTCGTACAAGGCGCGGTTACCCCTGGCCGTGGGCGACAACCGCGTGCT
 GGACATGGCCTCCACCTACTTTGACATCCGCGGGGTGCTGGACCGGGGTCCCCTTTCAAGCCCTACTC
 TGGCACCGCCTACAACCTCCCTGGCCCCCAAGGGCGCTCCCAACTCCTGCGAGTGGGAGCAAGAGGAA
 15 ACTCAGGCAGTTGAAGAAGCAGCAGAAGAGGAAGAAGAAGATGCTGACGGTCAAGCTGAGGAAGAG
 CAAGCAGCTACCAAAAAGACTCATGTATATGCTCAGGCTCCCCCTTTCTGGCGAAAAAATTAGTAAAGA
 TGGTCTGCAAATAGGAACGGACGCTACAGCTACAGAACAAAAACCTATTTATGCAGACCCTACATTCC
 AGCCCGAACCCCAAATCGGGGAGTCCCAGTGGAATGAGGCAGATGCTACAGTCGCCGGCGGTAGAGT
 GCTAAAGAAATCTACTCCCATGAAACCATGCTATGGTTCTATGCAAGACCCACAAATGCTAATGGAG
 20 GTCAGGGTGTACTAACGGCAAATGCCCAGGGACAGCTAGAATCTCAGGTTGAAATGCAATTCTTTTCA
 ACTTCTGAAAACGCCCGTAACGAGGCTAACAAACATTCAGCCCAAATTTGGTGTGTATAGTGAGGATGT
 GCACATGGAGACCCCGGATACGCACCTTTCTTACAAGCCCGCAAAAAGCGATGACAATTCAAAAATCA
 TGCTGGGTGAGCAGTCCATGCCAACAGACCTAATTACATCGGCTTCAGAGACAACCTTTATCGGCCTC
 ATGTATTACAATAGCACTGGCAACATGGGAGTGCTTGCAAGTCAAGGCTCTCAGTTGAATGCAGTGGT
 25 GGACTTGCAAGACAGAAACACAGAACTGTCCTACCAGCTCTTGCTTGATTCCATGGGTGACAGAACCA
 GATACTTTTCCATGTGGAATCAGGCAGTGGACAGTTATGACCCAGATGTTAGAATTATTGAAAATCAT
 GGAAGTGAAGACGAGCTCCCCAACTATTGTTTCCCTCTGGGTGGCATAAGGGGTAAGTACACTTACCA
 GGCTGTAAAACCAACAATGGCAATAACGGGGGGCCAGGTGACTTGGACAAAAGATGAACTTTTGCA
 GATCGCAATGAAATAGGGGTGGGAAACAATTTGCTATGGAGATCAACCTCAGTGCCAACCTGTGGA
 30 GAACTTCCTGTACTCCAACGTGGCGCTGTACCTACCAGACAAGCTTAAGTACAACCCCTCCAATGTG
 GACATCTCTGACAACCCCAACACCTACGATTACATGAACAAGCGAGTGGTGGCCCCGGGGCTGGTGGGA
 CTGCTACATCAACCTGGGCGCGCGCTGGTCGCTGGACTACATGGACAACGTCAACCCCTTCAACCACC
 ACCGCAATGCGGGCCTGCGCTACCGCTCCATGCTCCTGGGCAACGGGCGCTACGTGCCCTTCCACATC
 CAGGTGCCCCAGAAGTTCTTTGCCATCAAGAACCTCCTCCTCCTGCCGGGCTCCTACACCTACGAGTGG
 35 AACTTCAGGAAGGATGTCAACATGGTCCTCCAGAGCTCTCTGGGTAACGATCTCAGGGTGGACGGGGC
 CAGCATCAAGTTCGAGAGCATCTGCCTCTACGCCACCTTCTTCCCCATGGCCCACAACACGGCCTCCAC
 GCTCGAGGCCATGCTCAGGAACGACACCAACGACCAGTCCTTCAATGACTACCTCTCCGCCGCCAACA

TGCTCTACCCCATACCCGCCAACGCCACCAACGTCCCCATCTCCATCCCCTCGCGCAACTGGGCGGCCT
 TCCGCGGCTGGGCCTTCAACCGCCTCAAGACCAAGGAGACCCCTCCCTGGGCTCGGGATTTCGACCCC
 TACTACACCTACTCGGGCTCCATTCCCTACCTGGACGGCACCTTCTACCTCAACCACACTTTCAAGAAG
 GTCTCGGTCACCTTCGACTCCTCGGTCAGCTGGCCGGGCAACGACCGTCTGCTACCCCCAACGAGTTC
 5 GAGATCAAGCGCTCGGTCGACGGGGAGGGCTACAACGTGGCCCAGTGCAACATGACCAAGGACTGGT
 TCCTGGTCCAGATGCTGGCCAACTACAACATCGGCTACCAGGGCTTCTACATCCCAGAGAGCTACAAG
 GACAGGATGTACTCCTTCTTCAGGAACTTCCAGCCCATGAGCCGGCAGGTGGTGGACCAGACCAAGTA
 CAAGGACTACCAGGAGGTGGGCATCATCCACCAGCACAACTCGGGCTTCGTGGGCTACCTCGCCCC
 CCACCATGCGCGAGGGACAGGCCTACCCCGCCAACTTCCCCTATCCGCTCATAGGCAAGACCGCGGTC
 10 GACAGCATCACCCAGAAAAAGTTCTCTGCGACCGCACCCCTCTGGCGCATCCCCTTCTCCAGCAACTTC
 ATGTCCATGGGTGCGCTCTCGGACCTGGGCCAGAACTTGCTCTACGCCAACTCCGCCCCACGCCCTCGA
 CATGACCTTCGAGGTCGACCCCATGGACGAGCCCACCCCTTCTCTATGTTCTGTTTGAAGTCTTTGACGT
 GGTCCGGGTCCACCAGCCGCACCGCGGCGTCATCGAGACCGTGTACCTGCGTACGCCCTTCTCGGCCG
 GCAACGCCACCACCTAAAGAAGCAAGCCGCAGTCATCGCCGCTGCATGCCGTGCGGTTCACCGAGC
 15 AAGAGCTCAGGGCCATCGTCAGAGACCTGGGATGCGGGCCCTATTTTTTGGGCACCTTCGACAAGCGC
 TTCCCTGGCTTTGTCTCCCCACACAAGCTGGCCTGCGCCATCGTCAACACGGCCGGCCGCGAGACCGG
 GGGCGTGCACTGGCTGGCCTTCGCCTGGAACCCGCGCTCCAAAACATGCTTCCTCTTTGACCCCTTCGG
 CTTTTTCGGACCAGCGGCTCAAGCAAATCTACGAGTTCGAGTACGAGGGCTTGCTGCGTCGCAGCGCCA
 TCGCCTCTCGCCCGACCGCTGCGTCACCCCTCGAAAAGTCCACCCAGACCGTGCAGGGGCCCCGACTCG
 20 GCCGCTGCGGTCTCTTCTGCTGCATGTTTCTGCACGCCTTTGTGCACTGGCCTCAGAGTCCCATGGAC
 CGCAACCCCAACCATGAACTTGCTGACGGGGGTGCCAACTCCATGCTCCAGAGCCCCCAGGTTCGAGCC
 CACCCTGCGCCGCAACCAGGAGCAGCTCTACAGCTTCTTGAGCGCCACTCGCCTTACTTCCGCCGCC
 ACAGCGCACAGATCAGGAGGGCCACCTCCTTCTGCCACTTGCAAGAGATGCAAGAAGGGTAATAACG
 ATGTACACACTTTTTTTCTCAATAAATGGCATCTTTTTATTTATACAAGCTCTCTGGGGTATTCAATTTCC
 25 CACCACCACCCGCCGTTGTGCCATCTGGCTCTATTTAGAAATCGAAAGGGTTCTGCCGGGAGTCGCC
 GTGCGCCACGGGCAGGGACACGTTGCGATACTGGTAGCGGGTGCCCCACTTGAACCTCGGGCACCACCA
 GGCAGAGGCAGCTCGGGGAAGTTTTGCTCCACAGGCTGCGGGTCAGCACCAGCGGTTTCATCAGGTCG
 GCGCCGAGATCTTGAAGTCGAGTTGGGGCCGCCGCCCTGCGCGCGGAGTTGCGGTACACCGGGTT
 GCAGCACTGGAACACCAACAGCGCCGGGTGCTTACGCTGGCCAGCACGCTGCGGTTCGAGATCAGC
 30 TCGGCGTCCAGGTCTTCCGCGTTGCTCAGCGCGAACGGGGTCATCTTGGGCACTTGCCGCCCCAGGAA
 GGGCGCGTGCCCCGTTTTCGAGTTGCAGTCGCAGCGCAGCGGGATCAGCAGGTGCCCGTGCCCGGACT
 CGGCGTTGGGGTACAGCGCGCGCATGAAGGCCTGCATCTGGCGGAAGGCCATCTGGGCCTTGCGCCCC
 TCCGAGAAGAACATGCCGCAAGACTTGCCCGAGAACTGGTTTTCGGGGCAGCTGGCGTTCGTGCAGGC
 AGCAGCGCGCGTCGGTGTTGGCGATCTGCACCACGTTGCGCCCCCACCAGTTCTTACGATCTTGGCCT
 35 TGGACGATTGCTCCTTCAGCGCGCGCTGCCCCGTTCTCGCTGGTCACATCCATCTCGATCACATGTTCTT
 TGTTACCATGCTGCTGCCGTGCAGACACTTCAGCTCGCCCTCCGTCTCGGTGCAGCGGTGCTGCCACA
 GCGCGCAGCCCGTGGGCTCGAAAGACTTGTAGGTACCTCCGCGAAGGACTGCAGGTACCCCTGCAAA

AAGCGGCCCATCATGGTCACGAAGGTCTTGTGCTGCTGAAGGTCAGCTGCAGCCCCGCGGTGCTCCTC
 GTTCAGCCAGGTCTTGCACACGGCCGCCAGCGCCTCCACCTGGTCGGGCAGCATCTTGAAGTTCACCTT
 CAGCTCATTCTCCACGTGGTACTTGTCCATCAGCGTGC GCGCCGCTCCATGCCCTTCTCCCAGGCCGA
 CACCAGCGGCAGGCTCACGGGGTTCTTACCATCACCGTGGCCGCCGCTCCGCCGCGCTTTCGCTTTC
 5 CGCCCCGCTGTTCTCTTCTCTTCTCTCTCTCTCTCGCCGCCGCCACTCGCAGCCCCCGCACCACGGGG
 TCGTCTTCTCTGCAGGCGCTGCACCTTGCCTTGGCGTTGGCGCCCTGCTTGATGCGCACGGGCGGGTTG
 CTGAAGCCCACCATCACAGCGCGGCCTCTTCTTGCTCGTCTCTCGTGTCCAGAATGACCTCCGGGGAG
 GGGGGGTTGGTCATCCTCAGTACCGAGGCACGCTTCTTTTTCTTCTCTGGGGGCGTTTCGCCAGCTCCGCG
 GCTGCGGCCGCTGCCGAGGTGAAGGCCGAGGGCTGGGCGTGCGCGGCACCAGCGCTCCTGCGAGC
 10 CGTCTCTGTCCTCCTCGGACTCGAGACGGAGGCGGGCCCGCTTCTTCGGGGGCGCGCGGGGCGGCGGA
 GGCGGCGGCGCGACGGAGACGGGGACGAGACATCGTCCAGGGTGGGTGGACGGCGGGCCGCGCCG
 CGTCCGCGCTCGGGGGTGGTCTCGCGCTGGTCTCTTCCCGACTGGCCATCTCCCACTGCTCCTTCTCCT
 ATAGGCAGAAAGAGATCATGGAGTCTCTCATGCGAGTCGAGAAGGAGGAGGACAGCCTAACCGCCCC
 CTCTGAGCCCTCCACCACCGCCGCCACCACCGCCAATGCCGCCGCGGACGACGCGCCACCGAGACCA
 15 CCGCCAGTACCACCTCCCCAGCGACGCACCCCCGCTCGAGAATGAAGTGCTGATCGAGCAGGACCCG
 GGTTTTGTGAGCGGAGAGGAGGATGAGGTGGATGAGAAGGAGAAGGAGGAGGTGCGCCGCTCAGTGC
 CAAAAGAGGATAAAAAGCAAGACCAGGACGACGCAGATAAGGATGAGACAGCAGTCGGGCGGGGGA
 ACGBAAGCCATGATGCTGATGACGGCTACCTAGACGTGGGAGACGACGTGCTGCTTAAGCACCTGCAC
 CGCCAGTGCGTCATCGTCTGCGACGCGCTGCAGGAGCGCTGCGAAGTGCCCTGGACGTGGCGGAGGT
 20 CAGCCGCGCCTACGAGCGGCACCTCTTCGCGCCGCACGTGCCCCCAAGCGCCGGGAGAACGGCACCT
 GCGAGCCCAACCCGCGTCTCAACTTCTACCCGGTCTTCGCGGTACCCGAGGTGCTGGCCACCTACCAC
 ATCTTTTTTCCAAACTGCAAGATCCCCCTCTCCTGCCGCGCCAACCGCACCCGCGCCGACAAAACCCTG
 ACCCTGCGGCAGGGCGCCACATACCTGATATCGCCTCTCTGGAGGAAGTGCCCAAGATCTTCGAGGG
 TCTCGGTGCGGACGAGAAACGGGCGGCGAACGCTCTGCACGGAGACAGCGAAAACGAGAGTCACTCG
 25 GGGGTGCTGGTGGAGCTCGAGGGCGACAACGCGCGCCTGGCCGTACTCAAGCGCAGCATAGAGGTCA
 CCCACTTTGCCTACCCGGCGCTCAACCTGCCCCCAAGGTGATGAGTGTGGTCATGGGCGAGCTCATC
 ATGCGCCGCGCCAGCCCCTGGCCGCGGATGCAAACTTGCAAGAGTCCTCCGAGGAAGGCCTGCCCCG
 GGTACGCGACGAGCAGCTGGCGCGCTGGCTGGAGACCCGCGACCCCGCGCAGCTGGAGGAGCGGCGC
 AAGTCATGATGGCCGCGGTGCTGGTACCGTGGAGCTCGAGTGTCTGCAGCGCTTCTTCGCGGACCC
 30 CGAGATGCAGCGCAAGCTCGAGGAGACCCTGCACTACACCTTCCGCCAGGGCTACGTGCGCCAGGCCT
 GCAAGATCTCCAACGTGGAGCTCTGCAACCTGGTCTCTACCTGGGCATCCTGCACGAGAACC GCCTC
 GGGCAGAACGTCTCTGCACTCCACCCTCAAAGGGGAGGCGCGCCGCGACTACATCCGCGACTGCGCCTA
 CCTCTTCTCTGCTACACCTGGCAGACGGCCATGGGGGTCTGGCAGCAGTGCCTGGAGGAGCGCAACC
 TCAAGGAGCTGGAAAAGCTCCTCAAGCGCACCCCTCAGGGACCTCTGGACGGGCTTCAACGAGCGCTCG
 35 GTGGCCGCGCGCTGGCGGACATCATCTTTCCCGAGCGCCTGCTCAAGACCCTGCAGCAGGGCCTGCC
 CGACTTCACCAGCCAGAGCATGCTGCAGAACTTCAGGACTTTCATCCTGGAGCGCTCGGGCATCCTGC
 CGGCCACTTGCTGCGCGCTGCCAGCGACTTCGTGCCCATCAAGTACAGGGAGTGCCCGCCGCGCTC

TGGGGCCACTGCTACCTCTTCCAGCTGGCCAACTACCTCGCCTACCACTCGGACCTCATGGAAGACGT
 GAGCGGCGAGGGCCTGCTCGAGTGCCACTGCCGCTGCAACCTCTGCACGCCCCACCGCTCTCTAGTCT
 GCAACCCGCAGCTGCTCAGCGAGAGTCAGATTATCGGTACCTTCGAGCTGCAGGGTCCCTCGCCTGAC
 GAGAAGTCCGCGGCTCCAGGGGCTGAAACTCACTCCGGGGGCTGTGGACTTCCGCTACCTACGCAAATT
 5 TGTACCTGAGGACTACCACGCCCACGAGATCAGGTTCTACGAAGACCAATCCCGCCCGCCCAAGGCGG
 AGCTCACCGCCTGCGTCATACCCAGGGGCACATCCTGGGCCAATTGCAAGCCATCAACAAAGCCCCG
 CGAGAGTTCTTGCTGAAAAAGGGTCGGGGGGTGTACCTGGACCCCCAGTCCGGCGAGGAGCTAAACC
 CGCTACCCCCCGCCGCCGCCAGCAGCGGGACCTTGCTTCCAGGATGGCACCCAGAAAGAAGCAGC
 AGCCGCCGCCGCCGCCGAGCCATACATGCTTCTGGAGGAAGAGGAGGAGGACTGGGACAGTCAGGC
 10 AGAGGAGGTTTCGGACGAGGAGCAGGAGGAGATGATGGAAGACTGGGAGGAGGACAGCAGCCTAGA
 CGAGGAAGCTTCAGAGGCCGAAGAGGTGGCAGACGCAACACCATCGCCCTCGGTTCGAGCCCCCTCG
 CCGGGGCCCTGAAATCCTCCGAACCCAGCACCAGCGCTATAACCTCCGCTCCTCCGGCGCCGGCGCC
 ACCCGCCCGCAGACCCAACCGTAGATGGGACACCACAGGAACCGGGGTCGGTAAGTCCAAGTGCCCG
 CCGCCGCCACCGCAGCAGCAGCAGCAGCAGCGCCAGGGCTACCGCTCGTGCGCGGGCACAAGAACG
 15 CCATAGTCGCCTGCTTGCAAGACTGCGGGGGCAACATCTCTTTCGCCCCGCCGCTTCCTGCTATTCCACC
 ACGGGGTCGCCTTTCCCCGCAATGTCCTGCATTACTACCGTCATCTCTACAGCCCCCTACTGCAGCGGCG
 ACCCAGAGGCGGCAGCGGCAGCCACAGCGGCGACCACCACCTAGGAAGATATCCTCCGCGGGCAAGA
 CAGCGGCAGCAGCGGCCAGGAGACCCGCGGCAGCAGCGGCGGGAGCGGTGGGCGCACTGCGCCTCTC
 GCCCAACGAACCCCTCTCGACCCGGGAGCTCAGACACAGGATCTTCCCCACTTTGTATGCCATCTTCCA
 20 ACAGAGCAGAGGCCAGGAGCAGGAGCTGAAAATAAAAAACAGATCTCTGCGCTCCCTCACCCGCAGC
 TGTCTGTATCACAAAAGCGAAGATCAGCTTCGGCGCACGCTGGAGGACGCGGAGGCACTCTTCAGCAA
 ATACTGCGCGCTCACTCTTAAAGACTAGCTCCGCGCCCTTCTCGAATTTAGGCGGGAGAAAACCTACGT
 CATCGCCGGCCGCCGCCAGCCGCCCAGCCGAGATGAGCAAAGAGATTCCCACGCCATACATGTGG
 AGCTACCAGCCGAGATGGGACTCGCGGCGGGAGCGGGCCAGGACTACTCCACCCGCATGAACTACA
 25 TGAGCGCGGGACCCACATGATCTCACAGGTCAACGGGATCCGCGCCCAGCGAAACCAAATACTGCT
 GGAACAGGCGGCCATCACCGCCACGCCCCGCCATAATCTCAACCCCCGAAATTGGCCCCGCCGCCCTCG
 TGTACCAGGAAACCCCTCCGCCACCACCGTACTACTTCCGCGTGACGCCAGGCCGAAGTCCAGATG
 ACTAACTCAGGGGCGCAGCTCGCGGGCGGCTTTCGTACGGGGCGCGGCCGCTCCGACCAGGTATAAG
 ACACCTGATGATCAGAGGCCGAGGTATCCAGCTCAACGACGAGTCGGTGAGCTCTTCGCTCGGTCTCC
 30 GTCCGACGGAACTTTCCAGCTCGCCGGATCCGGCCGCTCTTCGTTACGCCCCGCCAGGCGTACCTG
 ACTCTGCAGACCTCGTCCTCGGAGCCCCGCTCCGGCGGCATCGGAACCTCCAGTTCGTGGAGGAGTT
 CGTGCCCTCGGTCTACTTCAACCCCTTCTCGGGACCTCCCGGACGCTACCCCGACCAGTTCATTCCGAA
 CTTTGACGCGGTGAAGGACTCGGCGGACGGCTACGACTGAATGTCAGGTGTGAGGCAGAGCAGCTTC
 GCCTGAGACACCTCGAGCACTGCCGCCGCCACAAGTGCTTCGCCCCGCGTTCTGGTGAGTTCTGCTACT
 35 TTCAGTACCCGAGGAGCATACCGAGGGGGCCGGCGCACGGCGTCCGCCTGACCACCCAGGGCGAGGT
 TACCTGTTCCCTCATCCGGGAGTTTACCCTCCGTCCCCTGCTAGTGAGGAGCGGGAGCGGGGTCCCTGTGT
 CCTAACTATCGCCTGCAACTGCCCTAACCCTGGATTACATCAAGATCTTTGCTGTCATCTCTGTGCTGA

GTTTAATAAACGCTGAGATCAGAATCTACTGGGGCTCCTGTCGCCATCCTGTGAACGCCACCGTCTTCA
 CCCACCCCGACCAGGCCAGGCCGAACCTCACCTGCGGTCTGCATCGGAGGGCCAAGAAGTACCTCACC
 TGGTACTTCAACGGCACCCCTTTGTGGTTTACAACAGCTTCGACGGGGACGGAGTCTCCCTGAAAGA
 CCAGCTCTCCGGTCTCAGCTACTCCATCCACAAGAACACCACCCCTCCAACCTCTTCCCTCCCTACCTGCC
 5 GGAACCTACGAGTGCGTCACCGGCCGCTGCACCCACCTCACCCGCTGATCGTAAACCAGAGCTTTC
 CGGAACAGATAACTCCCTCTTCCCCAGAACAGGAGGTGAGCTCAGGAAACTCCCCGGGGACCAGGG
 CGGAGACGTACCTTCGACCCTTGTGGGGTTAGGATTTTTTATTACCGGGTTGCTGGCTCTTTAATCAA
 AGTTTCCTTGAGATTTGTTCTTCTCTACGTGTATGAACACCTCAACCTCCAATAACTCTACCCCTTC
 TTCGGAATCAGGTGACTTCTCTGAAATCGGGCTTGGTGTGCTGCTTACTCTGTTGATTTTTTCTTATC
 10 ATACTCAGCCTTCTGTGCCTCAGGCTCGCCGCTGCTGCGCACACATCTATATCTACTGCTGGTTGCTC
 AAGTGCAGGGGTCGCCACCCAAGATGAACAGGTACATGGTCCTATCGATCCTAGGCCTGCTGGCCCTG
 GCGGCCTGCAGCGCCGCCAAAAAAGAGATTACCTTTGAGGAGCCCGCTTGCAATGTAACCTTTCAAGCC
 CGAGGGTGACCAATGCACCACCTCGTCAATGCGTTACCAATCATGAGAGGCTGCGCATCGACTACA
 AAAACAAAACCTGGCCAGTTTTCGGTCTATAGTGTGTTTACGCCCGGAGACCCCTCTAACTACTCTGTCA
 15 CCGTCTTCCAGGGCGGACAGTCTAAGATATTCAATTACACTTTCCCTTTTTATGAGTTATGCGATGCGG
 TCATGTACATGTCAAAACAGTACAACCTGTGGCCTCCCTCTCCCCAGGCGTGTGTGGAAAATACTGGG
 TCTTACTGCTGTATGGCTTTCGCAATCACTACGCTCGCTCTAATCTGCACGGTGCTATACATAAAATTC
 AGGCAGAGGCGAATCTTTATCGATGAAAAGAAAATGCCTTGATCGCTAACACCGGCTTTCTATCTGCA
 GAATGAATGCAATCACCTCCCTACTAATCACCACCACCTCCTTGCGATTGCCCATGGGTTGACACGA
 20 ATCGAAGTGCCAGTGGGGTCCAATGTACCATGGTGGGCCCCGCCGCAATTCCACCCTCATGTGGGA
 AAAATTTGTCCGCAATCAATGGGTTCATTTCTGCTCTAACCGAATCAGTATCAAGCCCAGAGCCATCTG
 CGATGGGCAAAATCTAACTCTGATCAATGTGCAAATGATGGATGCTGGGTACTATTACGGGCAGCGGG
 GAGAAATCATTAATTACTGGCGACCCCAAGGACTACATGCTGCATGTAGTCGAGGCACTTCCCACT
 ACCACCCCACTACCACCTCTCCACCACCACCACCTACTACTACTACTACTACTACTACTACTACT
 25 ACCACTACCGCTGCCCCGCATACCCGCAAAAGCACCATGATTAGCACAAAGCCCCCTCGTGCTCACTC
 CCACGCCGGCGGGCCCATCGGTGCGACCTCAGAAACCACCGAGCTTTGCTTCTGCCAATGCACTAACG
 CCAGCGCTCATGAACTGTTTCGACCTGGAGAATGAGGATGTCCAGCAGAGCTCCGCTTGCTGACCCAG
 GAGGCTGTGGAGCCCGTTGCCCTGAAGCAGATCGGTGATTCAATAATTGACTCTTCTTCTTTGCCACT
 CCCGAATACCCTCCCGATTCTACTTTCCACATCAGGGTACCAAAGACCCTAACCTCTCTTTCTACCTG
 30 ATGCTGCTGCTCTGTATCTCTGTGGTCTCTTCCGCGCTGATGTTACTGGGGATGTTCTGCTGCCTGATCT
 GCCGCAGAAAGAGAAAAGCTCGCTCTCAGGGCCAACCACTGATGCCCTTCCCCTACCCCCCGGATTTT
 GCAGATAACAAGATATGAGCTCGCTGCTGACACTAACCGCTTTACTAGCCTGCGCTCTAACCTTGTCG
 CTTGCGACTCGAGATTCCACAATGTCACAGCTGTGGCAGGAGAAAATGTTACTTTCAACTCCACGGCC
 GATACCCAGTGGTCGTGGAGTGGCTCAGGTAGCTACTTAACTATCTGCAATAGCTCCACTTCCCCCGGC
 35 ATATCCCCAACCAAGTACCAATGCAATGCCAGCCTGTTACCCCTCATCAACGCTTCCACCCTGGACAAT
 GGACTCTATGTAGGCTATGTACCCTTTGGTGGGCAAGGAAAGACCCACGCTTACAACCTGGAAGTTGCG
 CCAGCCCAGAACCCTACCCAAGCTTCTCCACCACCACCACCACCACCACCACCATCACCAGCAGCAGCA

GCAGCAGCAGCCACAGCAGCAGCAGCAGATTATTGACTTTGGTTTTGGCCAGCTCATCTGCCGCTACC
 CAGGCCATCTACAGCTCTGTGCCCCGAAACCACTCAGATCCACCGCCCAGAAACGACCACCGCCACCAC
 CCTACACACCTCCAGCGATCAGATGCCGACCAACATCACCCCTTGGCTCTTCAAATGGGACTTACAA
 GCCCCACTCCAAAACAGTGGATGCCGGCCGAGGTCTCCGCCCTCGTCAATGACTGGGCGGGGCTGGGA
 5 ATGTGGTGGTTCGCCATAGGCATGATGGCGCTCTGCCTGCTTCTGCTCTGGCTCATCTGCTGCCTCCAC
 CGCAGGCGAGCCAGACCCCCATCTATAGACCCATCATTGTCCTGAACCCCGATAATGATGGGATCCA
 TAGATTGGATGGCCTGAAAAACCTACTTTTTTCTTTTACAGTATGATAAATTGAGACATGCCTCGCATT
 TTCTTGACATGTTCTTCTCCACCTTTTCTGGGGTGTCTACGCTGGCCGCTGTGTCTCACCTGGAGG
 TAGACTGCCTCTCACCTTCACTGTCTACCTGCTTTACGGATTGGTCAACCTCACTCTCATCTGCAGCCT
 10 AATCACAGTAATCATCGCCTTCATCCAGTGCATTGATTACATCTGTGTGCGCCTCGCATACTTCAGACA
 CCACCCGAGTACCGAGACAGGAACATTGCCCAACTTCTAAGACTGCTCTAATCATGCATAAGACTGT
 GATCTGCCTTCTGATCCTCTGCATCCTGCCACCCCTCACCTCCTGCCAGTACACCACAAAATCTCCGCG
 CAAAAGACATGCCCTCTGCCGCTTCACCAACTGTGGAATATACCCAAATGCTACAACGAAAAGAGCG
 AGCTCTCCGAAGCTTGGCTGTATGGGGTTCATCTGTGTCTTAGTTTTCTGCAGCACTGTCTTTGCCCTCAT
 15 AATCTACCCCTACTTTGATTTGGGATGGAACGCGATCGATGCCATGAATTACCCACCTTTCCCGCACC
 CGAGATAATTCCACTGCGACAAGTTGTACCCGTTGTCGTTAATCAACGCCCCCATCCCTACGCCCAC
 TGAAATCAGCTACTTTAACCTAACAGGCGGAGATGACTGACGCCCTAGATCTAGAAATGGACGGCATC
 AGTACCGAGCAGCGTCTCCTAGAGAGGCGCAGGCAGGCGGCTGAGCAAGAGCGCCTCAATCAGGAGC
 TCCGAGATCTCGTTAACCTGCACCACTGCAAAAAGAGGCATCTTTTGTCTGGTAAAGCAGGCCAAAAGTC
 20 ACCTACGAGAAGACCGGCAACAGCCACCGCCTCAGTTACAAATTGCCACCCAGCGCCAGAAGCTGG
 TGCTCATGGTGGGTGAGAATCCCATCACCGTCACCCAGCACTCGGTAGAGACCGAGGGGTGTCTGCAC
 TCCCCCTGTGCGGGTCCAGAAGACCTCTGCACCCTGGTAAAGACCCTGTGCGGTCTCAGAGATTTAGT
 CCCCTTTAACTAATCAAACACTGGAATCAATAAAAAGAATCACTTACTTAAATCAGACAGCAGGTCT
 CTGTCCAGTTTATTACAGCAGCACCTCCTTCCCCCTCCTCCAACTCTGGTACTCCAAACGCCCTTCTGGCG
 25 GCAAACCTTCCTCCACACCCTGAAGGGAATGTCAGATTCTTGCTCCTGTCCCTCCGCACCCACTATCTTC
 ATGTTGTTGCAGATGAAGCGCACCAAAACGTCTGACGAGAGCTTCAACCCCGTGTACCCCTATGACAC
 GGAAAGCGGCCCTCCCTCCGTCCCTTTCCTCACCCCTCCCTTCGTGTCTCCCGATGGATTCCAAGAAAG
 TCCCCCGGGGTCTGTCTCTGAACCTGGCCGAGCCCCCTGGTCACTTCCCACGGCATGCTCGCCCTGAA
 AATGGGAAGTGGCCTCTCCCTGGACGACGCTGGCAACCTCACCTCTCAAGATATCACACCGCTAGCC
 30 CTCCCCCTCAAAAAACCAAGACCAACCTCAGCCTAGAAACCTCATCCCCCTAACTGTGAGCACCTCA
 GGCGCCCTCACCGTAGCAGCCGCCGCTCCCCCTGGCGGTGGCCGGCACCTCCCTCACCATGCAATCAGA
 GGCCCCCTGACAGTACAGGATGCAAACTCACCTGGCCACCAAAGGCCCCCTGACCGTGTCTGAAG
 GCAAACCTGGCCTTGCAAACATCGGCCCCGCTGACGGCCGCTGACAGCAGCACCTCACAGTCAGTGCC
 ACACCACCCCTTAGCACAAGCAATGGCAGCTTGGGTATTGACATGCAAGCCCCCATTTACACCACCAA
 35 TGGAAAACCTAGGACTTAACTTTGGCGCTCCCCCTGCATGTGGTAGACAGCCTAAATGCACTGACTGTAG
 TTAAGTGGCCAAGGTCTTACGATAAACGGAACAGCCCTACAAACTAGAGTCTCAGGTGCCCTCAACTAT
 GACACATCAGGAAACCTAGAATTGAGAGCTGCAGGGGGTATGCGAGTTGATGCAAATGGTCAACTTA

TCCTTGATGTAGCTTACCCATTTGATGCACAAAACAATCTCAGCCTTAGGCTTGGACAGGGACCCCTGT
 TTGTTAACTCTGCCCACAACCTTGGATGTAACTACAACAGAGGCCTCTACCTGTTACATCTGGAAATA
 CCAAAAAGCTAGAAGTTAATATCAAAACAGCCAAGGGTCTCATTTATGATGACACTGCTATAGCAATC
 AATGCGGGTGATGGGCTACAGTTTGACTCAGGCTCAGATACAAATCCATTAAAAACTAAACTTTGGATT
 5 AGGACTGGATTATGACTCCAGCAGAGCCATAATTGCTAAACTGGGAACTGGCCTAAGCTTTGACAACA
 CAGGTGCCATCACAGTAGGCAACAAAAATGATGACAAGCTTACCTTGTGGACCACACCAGACCCATCC
 CCTAACTGTAGAATCTATTTCAGAGAAAGATGCTAAATTCACACTTGTTTTGACTAAATGCGGCAGTCA
 GGTGTTGGCCAGCGTTTCTGTTTTATCTGTAAAAGGTAGCCTTGCGCCCATCAGTGGCACAGTAACTAG
 TGCTCAGATTGTCCTCAGATTTGATGAAAATGGAGTTCTACTAAGCAATTCTTCCCTTGACCCTCAATA
 10 CTGGAACCTACAGAAAAGGTGACCTTACAGAGGGCACTGCATATACCAACGCAGTGGGATTTATGCCCA
 ACCTCACAGCATACCCAAAAACACAGAGCCAACTGCTAAAAGCAACATTGTAAGTCAGGTTTACTTG
 AATGGGGACAAATCCAAACCCATGACCCTCACCATTACCCTCAATGGAACCTAATGAAACAGGAGATG
 CCACAGTAAGCACTTACTCCATGTCATTCTCATGGAAGTGAATGGAAGTAATTACATTAATGAAACG
 TTCCAAACCAACTCCTTCACCTTCTCCTACATCGCCCAAGAATAAAAAGCATGACGCTGTTGATTTGAT
 15 TCAATGTGTTTCTGTTTTATTTTCAAGCACAACAAAATCATTCAAGTCATTCTTCCATCTTAGCTTAATA
 GACACAGTAGCTTAATAGACCCAGTAGTGCAAAGCCCCATTCTAGCTTATACTAGTGGAGAAGTACT
 CGCCTACATGGGGGTAGAGTCATAATCGTGCATCAGGATAGGGCGGTGGTGTCTGCAGCAGCGCGCGA
 ATAACTGCTGCCGCCGCCGCTCCGTCCTGCAGGAATACAACATGGCAGTGGTCTCCTCAGCGATGAT
 TCGCACC GCCCGCAGCATAAGGCGCCTTGTCTCCGGGCACAGCAGCGCACCCCTGATCTCACTTAAAT
 20 CAGCACAGTAACTGCAGCACAGCACCACAATATTGTTCAAAATCCCACAGTGCAAGGCGCTGTATCCA
 AAGCTCATGGCGGGGACCACAGAACCCACGTGGCCATCATACCACAAGCGCAGGTAGATTAAAGTGGC
 GACCCCTCATAAACACGCTGGACATAAACATTACCTCTTTTGGCATGTTGTAATTCACCACCTCCCGGT
 ACCATATAAACCTCTGATTAAACATGGCGCCATCCACCACCATCCTAAACCAGCTGGCCAAAACCTGC
 CCGCCGGCTATACACTGCAGGGAACCGGGACTGGAACAATGACAGTGGAGAGCCCAGGACTCGTAAC
 25 CATGGATCATCATGCTCGTCATGATATCAATGTTGGCACAACACAGGCACACGTGCATACACTTCCTC
 AGGATTACAAGCTCCTCCCGCGTTAGAACCATATCCCAGGGAACAACCCATTCTGAATCAGCGTAAA
 TCCCACACTGCAGGGAAGACCTCGCACGTAACCTACGTTGTGCATTGTCAAAGTGTTACATTCGGGCA
 GCAGCGGATGATCCTCCAGTATGGTAGCGCGGGTTTCTGTCTCAAAAGGAGGTAGACGATCCCTACTG
 TACGGAGTGCGCCGAGACAACCGAGATCGTGTTGGTCGTAGTGTGCATGCCAAATGGAACGCCGGACGT
 30 AGTCATATTTCTGAAGTCTTAGATCTCTCAACGCAGCACCAGCACCAACACTTCGCAGTGTAAGG
 CCAAGTGCCGAGAGAGTATATATAGGAATAAAAAGTGACGTAAACGGGCAAAGTCCAAAAAACGCC
 AGAAAAACCGCACGCGAACCTACGCCCCGAAACGAAAGCCAAAAAACACTAGACACTCCCTTCCGGC
 GTCAACTTCCGCTTTCCACGCTACGTCACTTGCCCCAGTCAAACAACTACATATCCCGAACTTCCAA
 GTCGCCACGCCAAAACACCGCCTACACCTCCCCGCCCGCCGGCCGCCCCCAACCCGCCTCCCGCC
 35 CCGCGCCCCGCCCGCGCCGCCCATCTCATTATCATATTGGCTTCAATCCAAAATAAGGTATATTATTG
 ATGATG

SEQ ID NO: 5 RSV F0 Δ TM-N-M2-1 amino acid sequence

MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDA
 KVKLIKQELDKYKNAVTELQLLMQSTPATNNRRELPRFMNYTLNNAKKTNTVLSKKRKRRLGFLGVLG
 GSAIASGVAVSKVLHLEGEVNIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNIYDKQLLPVINKQSCSISNI
 5 ETVIEFQQKNNRLLLEITREFSVNAGVTTTPVSTYMLTNSELLSLNDMPITNDQKKLMSNNVQIVRQQSYSIMSI
 IKEEVLAYVVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQS
 NRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIKTF
 SNGCDYVSNKGVDTVSVGNTLYYVVKQEGKSLYVKGEPIINFYDPLVFPSEDFDASISQVNEKINQSLAFIR
 KSDELLHNVNAGKSTTNRRRAPVKQTLNFDLLKLAGDVESNPGPMALSKVKLNDTLNKDQLLSSSKYTI
 10 QRSTGDSIDTPNYDVQKHINKLCGMILLITEDANHKFTGLIGMLYAMSRLGREDTIKILRDAGYHVKANGVD
 VTTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYYKKMLKEMGEVAPEYRHDSPDCGMILCIAALVIT
 KLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANS
 FYEVFEKYPHFIDVFVHFGLAQSSSTRGGSRVGEIFAGLFMNAYGAGQVMLRWGVLAHSVKNIMLGHASVQ
 AEMEQVVEVYEYAQKLGGEGAFYHILNPNKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYD
 15 AAKAYAEQLKENGVINYSVLDLTAEELAEIAKHQLNPKDNDVELGGGGSGGGGMSRRNPCKFEIRGHCLNG
 KRCHFSHNYFEWPPHALLVRQNFMLNRILKSMDKSIDTLSEISGAAELDRTEEYALGVVGVLESYIGSINNIT
 KQSACVAMSKLLTELNSDDIKLRDNEELNSPKIRVYNTVISYIESNRKNNKQTIHLLKRLPADVLKKTIKN
 TLDIHSITINNPKESTVSDTNDHAKNNDTT

20 SEQ ID NO: 6 Polynucleotide sequence encoding the enhanced hCMV promoter

CCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTG
 ACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
 GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATG
 ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC
 25 CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
 CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
 ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGATAGCGGTTTGACTCACGGGGATTTCCAAG
 TCTCCACCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACA
 ACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGGCGAAGCGCTCCCTAT
 30 CAGTGATAGAGATCTCCCTATCAGTGATAGAGATCGTCGACGAGCTCGCGGCGGGCGGGAGTCGCTGCGCGCTG
 CCTTCGCCCCGTGCCCCGCTCCGCGCCGCTCGCGCCGCCCCGGCTCTGACTGACCGCGTTACTAAAC
 AGGTAAGTCCGGCCTCCGCGCCGGGTTTTGGCGCCTCCGCGGGCGCCCCCTCCTCACGGCGAGCGCTGCCAC
 GTCAGACGAAGGGCGCAGCGAGCGTCCTGATCCTTCGCCCCGACGCTCAGGACAGCGGCCGCTGCTCATAAG
 ACTCGGCCTTAGAACCCCAAGTATCAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTT
 35 TTCTTTCCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGGATCTCCGTGGGG

CGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTTTTTTTTTCTACAGGTCCTGGGTGACGAA
CAG

SEQ ID NO: 7 Polynucleotide sequence encoding the hCMV NM2 bghpolyA

5 **cassette**
CCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTG
ACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
GCGTTACATAACTTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATG
ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC
10 CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
CCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCTTACTTGGCAGTACATCTACGTATTAGTCATCGCT
ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAG
TCTCCACCCCATTGACGTCAATGGGAGTTTGTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACA
ACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCCCTATC
15 AGTGATAGAGATCTCCCTATCAGTGATAGAGATCGTCGACGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAG
ACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCA
TTGGAACGCGGATTCCCCGTGCCAAGAGTGA
GATCTTCCGTTTATCTAGGTACCAGATATCGCCACCATGGCCC
TGAGCAAAGTGAAAAGTGAACGATACACTGAACAAGGACCAGCTGCTGTCCAGCAGCAAGTACACCATCCAGCGG
AGCACCGGCGACAGCATCGATACCCCCAACTACGACGTGCAGAAGCACATCAACAAGCTGTGCGGCATGCTGCT
20 GATCACAGAGGACGCCAACCACAAGTTCACCGGCCTGATCGGCATGCTGTACGCCATGAGCCGGCTGGGCCGGG
AGGACACCATCAAGATCCTGCGGGACGCCGGCTACCACGTGAAGGCCAATGGCGTGGACGTGACCACACACCGG
CAGGACATCAACGGCAAAGAAATGAAGTTCGAGGTGCTGACCCTGGCCAGCCTGACCACCGAGATCCAGATCAA
TATCGAGATCGAGAGCCGGAAGTCTACAAGAAAATGCTGAAAGAAATGGGCGAGGTGGCCCCCGAGTACAGAC
ACGACAGCCCCGACTGCGGCATGATCATCCTGTGTATCGCCGCCCTGGTGATCACAAAGCTGGCCGCTGGCGAC
25 AGATCTGGCCTGACAGCCGTGATCAGACGGGCCAACAATGTGCTGAAGAACGAGATGAAGCGGTACAAGGGCCT
GCTGCCCAAGGACATTGCCAACAGCTTCTACGAGGTGTTGAGAAGTACCCCCACTTCATCGACGTGTTCTGTC
ACTTCGGCATTGCCCAGAGCAGCACCAGAGGCGGCTCCAGAGTGGAGGGCATCTTCGCCGGCCTGTTTCATGAAC
GCCTACGGCGCTGGCCAGGTGATGCTGAGATGGGGCGTGCTGGCCAAGAGCGTGAAGAACATCATGCTGGGCCA
CGCCAGCGTGCAGGCCGAGATGGAACAGGTGGTGGAGGTGTACGAGTACGCCCAGAAGCTGGGCGGAGAGGCCG
30 GCTTCTACCACATCCTGAACAACCCTAAGGCCTCCCTGCTGTCCCTGACCCAGTTCCCCCACTTCTCCAGCGTG
GTGCTGGGAAATGCCGCCGACTGGGCATCATGGGCGAGTACCGGGGCACCCCCAGAAACCAGGACCTGTACGA
CGCCGCCAAGGCCTACGCCGAGCAGCTGAAAGAAAACGGCGTGATCAACTACAGCGTGCTGGACCTGACCGCTG
AGGAACTGGAAGCCATCAAGCACCAGCTGAACCCCAAGGACAACGACGTGGAGCTGGGAGGCGGAGGATCTGGC
GGCGGAGGCATGAGCAGACGGAACCCCTGCAAGTTCGAGATCCGGGGCCACTGCCTGAACGGCAAGCGGTGCCA
35 CTTACGCCACAATACTTTCGAGTGGCCCCCTCATGCTCTGCTGGTGCGGCAGAACTTCATGCTGAACCGGATCC
TGAAGTCCATGGACAAGAGCATCGACACCCTGAGCGAGATCAGCGGAGCCGCCGAGCTGGACAGAACCAGGAA

TATGCCCTGGGCGTGGTGGGAGTGCTGGAAAGCTACATCGGCTCCATCAACAACATCACAAAGCAGAGCGCCTG
 CGTGGCCATGAGCAAGCTGCTGACAGAGCTGAACAGCGACGACATCAAGAAGCTGAGGGACAACGAGGAAGTGA
 ACAGCCCCAAGATCCGGGTGTACAACACCGTGATCAGCTACATTGAGAGCAACCGCAAGAACAACAAGCAGACC
 ATCCATCTGCTGAAGCGGCTGCCCCGCCGACGTGCTGAAAAAGACCATCAAGAACACCCTGGACATCCACAAGTC
 5 CATCACCATCAACAATCCCAAAGAAAGCACCGTGTCTGACACCAACGATCACGCCAAGAACAACGACACCACCT
 GATGAGCGGCCGCGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCTTCCTT
GACCCTGGAAGGTGCCACTCCCCTGTCTTTCCTAATAAAATGAGGAAATGCATCGCATTGTCTGAGTAGGT
GTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCT
GGGGATGCGGTGGGCTCTATGG

10

CMV Promoter sequence: bold

Transgene sequence NM2: Italic

bghpolyA PolyA signal: italic+ underline

15

SEQ ID NO: 8 NM2 protein sequence

MALSKVKLNDTLNKDQLLSSSKYTIQRSTGDSIDTPNYDVQKHINKLCGMLLITEDANHKFTGLIGMLYAMSRL
 GREDTIKILRDAGYHVKANGVDTVTHRQDINGKEMKFEVLTLASLTTEIQINIEIESRKSYYKMLKEMGEVAPE
 YRHDS PDCGMIILCIAALVITKLAAGDRSGLTAVIRRANNVLKNEMKRYKGLLPKDIANSFYEVFEKYPHFIDV
 20 FVHFGLIAQSSTRGGSRVEGIFAGLFMNAYGAGQVMLRWGLAKSVKNIMLGHASVQAEMEQQVEVYEYAQKLGG
 EAGFYHILNPNKASLLSLTQFPHFSSVVLGNAAGLGIMGEYRGTPRNQDLYDAAKAYAEQLKENGVINYSVLDL
 TAELEAIAKHQLNPKDNDVELGGGSGGGGMSRRNPCKFEIRGHCLNGKRCHFShNYFEWPPHALLVRQNFMLN
 RILKSMDKSIDTLSEISGAAELDRTEEYALGVVGVLESYIGSINNITKQSACVAMSKLLTELNSDDIKKLRDNE
 ELNSPKIRVYNTVISYIESNRKNNKQTIHLLKRLPADVLKKTIKNTLDIHKSITINNPKESTVSDTNDHAKNND
 25 TT

SEQ ID NO: 9 Polynucleotide sequence encoding the hCMV F0 WPRE bghpolyA cassette

CCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTG
 30 ACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCC
 GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCATTGACGTCAATAATG
 ACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGC
 CCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCG
 CCTGGCATTATGCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCT
 35 ATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAG

TCTCCACCCCATTGACGTCAATGGGAGTTTGTGTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACA
 ACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGGCGAAGCGCTCCCTAT
 CAGTGATAGAGATCTCCCTATCAGTGATAGAGATCGTCGACGAGCTCGCGGGCGGGCGGGAGTCGCTGCGCGCTG
 CCTTCGCCCCGTGCCCCGCTCCGCCGCCGCTCGCGCGCGCGCCCCGGCTCTGACTGACCGCGTTACTAAAAC
 5 AGGTAAGTCCGGCCTCCGCGCCGGGTTTGGCGCCTCCGCGGGGCGCCCCCTCCTCACGGCGAGCGCTGCCAC
 GTCAGACGAAGGGCGCAGCGAGCGTCTGATCCTTCCGCCCGGACGCTCAGGACAGCGGCCGCTGCTCATAAG
 ACTCGGCCTTAGAACCCCACTATCAGCAGAAGGACATTTTAGGACGGGACTTGGGTGACTCTAGGGCACTGGTT
 TTCTTTCCAGAGAGCGGAACAGGCGAGGAAAAGTAGTCCCTTCTCGGCGATTCTGCGGAGGGATCTCCGTGGGG
 CGGTGAACGCCGATGATGCCTCTACTAACCATGTTTCATGTTTTCTTTTTTTTTCTACAGGTCCTGGGTGACGAA
 10 CAGGATATCGCCACCATGGAACGCTGATCCTGAAGGCCAACGCCATCACCACCATCCTGACCGCCGTGACCTT
 CTGCTTCGCCAGCGGCCAGAACATCACCAGAGGAATTCTACCAGAGCACCTGTAGCGCCGTGAGCAAGGGCTACC
 TGAGCGCCCTGAGAACCGGCTGGTACACCAGCGTGATCACCATCGAGCTGAGCAACATCAAAGAAAACAAGTGC
 AACGGCACCAGACGCCAAAGTGAAGCTGATCAAGCAGGAAGTGGACAAGTACAAGAACGCCGTGACCGAGCTGCA
 GCTGCTGATGCAGAGCACCCCCGCCACCAACAACCGGGCCAGACGGGAGCTGCCCCGGTTCATGAACCTACACCC
 15 TGAACAACGCCAAAAAGACCAACGTGACCCTGAGCAAGAAGCGGAAGCGGCGGTTCTGGGCTTTCTGCTGGGC
 GTGGGCAGCGCCATTGCCAGCGGCGTGGCCGTGTCTAAGGTGCTGCACCTGGAAGGCGAAGTGAACAAGATCAA
 GAGCGCCCTGCTGAGCACCAACAAGGCCGTGGTGTCCCTGAGCAACGGCGTGAGCGTGCTGACCAGCAAGGTGC
 TGGATCTGAAGAACTACATCGACAAGCAGCTGCTGCCCATCGTGAACAAGCAGAGCTGCAGCATCAGCAACATC
 GAGACAGTGATCGAGTTCCAGCAGAAGAACAACCGGCTGCTGGAAATCACCCGGGAGTTCAGCGTGAACGCCGG
 20 CGTGACCACCCCTGTGTCCACCTACATGCTGACCAACAGCGAGCTGCTGAGCCTGATCAACGACATGCCATCA
 CCAACGACCAGAAAAAGCTGATGAGCAACAACGTGCAGATCGTGCGGCAGCAGAGCTACTCCATCATGTCCATC
 ATCAAAGAAGAGGTGCTGGCCTACGTGGTGCAGCTGCCCCCTGTACGGCGTGATCGACACCCCTGCTGGAAGCT
 GCACACCAGCCCCCTGTGCACCACCAACACCAAAAGAGGGCAGCAACATCTGCCTGACCCGGACCGACAGAGGCT
 GGTACTGCGACAACGCCGGCAGCGTGTCAATCTTTCCACAGGCCGAGACATGCAAGGTGCAGAGCAACCGGGTG
 25 TTCTGCGACACCATGAACAGCCTGACCCTGCCCTCCGAAGTGAACCTGTGCAACGTGGACATCTTCAACCCCCA
 GTACGACTGCAAGATCATGACCTCCAAGACCGACGTGTCCAGCTCCGTGATCACCTCCCTGGGCGCCATCGTGT
 CCTGCTACGGCAAGACCAAGTGCACCGCCAGCAACAAGAACCGGGGCATCATCAAGACCTTCAGCAACGGCTGC
 GACTACGTGTCCAACAAGGGGGTGGACACCGTGTCCGTGGGCAACACCTGTACTACGTGAACAAACAGGAAGG
 CAAGAGCCTGTACGTGAAGGGCGAGCCATCATCAACTTCTACGACCCCTGGTGTCCCCAGCGACGAGTTCTG
 30 ACGCCAGCATCAGCCAGGTGAACGAGAAGATCAACCAGAGCCTGGCCTTCATCCGGAAGTCCGACGAGCTGCTG
 CACAATGTGAATGCCGGCAAGTCCACCACCAACTGATGAGCGGCCATCTAATCAACCTCTGGATTACAAAATTT
GTGAAAGATTGACTGGTATTCTTAACCTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTG
TATCATGCTATTGCTTCCCGTATGGCTTTTCATTTTCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGA
GGAGTTGTGGCCCGTTGTGAGGCAACGTGGCGTGGTGTGCACTGTGTTTGTGACGCAACCCCACTGGTTGGG
 35 GCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACCTCATC
GCCGCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCGCTGGTGTGTGCGGGAA

ATCATCGTCCTTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCC
CTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGC
CTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCTCCCCGCC*TGCGGCCGCGATCTGCTGTGCCTTCTA*
GTTGCCAGCCATCTGTTGTTTGGCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCCTGTCTT
 5 *TCCTAATAAAATGAGGAAATGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGTGGGGTGGGGCA*
GGACAGCAAGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG

Enhanced CMV Promoter sequence: bold

Transgene sequence F0: Italic

10 **WPRE sequence: underlined bold**

bghpolyA PolyA signal: italic+ underline

SEQ ID NO: 10 F0 protein sequence

15 MELLILKANAIITILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDA
 KVKLIKQELDKYKNAVTELQLLMQSTPATNNRARELPRFMNYTLNNAKKTNTLSKKRKRRLGFLLGVS
 ASGVAVSKVLHLEGEVNIKSALLSTNKAVVSLNGVSVLTSKVLDLKNYIDKQLLPVNVKQSCSISNIETVIE
 FQQKNNRLLLEITREFSVNAGVTTPVSTYMLTNSSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEV
 LAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDGRWYCDNAGSVSFFPQAETCKVQSNRVFCDTM
 20 NSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIKTFSGNCDYVSN
 KGVDTVSVGNTLYYVKNQEGKSLYVKGEPIINFYDPLVFPSEFDASISQVNEKINQSLAFIRKSDELLHNVA
 GKSTTN

SEQ ID NO: 11 Amino acid sequence of a flexible linker

25 Gly-Gly-Gly-Ser-Gly-Gly-Gly

SEQ ID NO: 12 Amino acid sequence of a flexible linker

Gly-Gly-Gly-Ser-Gly-Gly-Gly

30

CLAIMS

1. A simian adenoviral vector comprising two expression cassettes, wherein each expression
5 cassette comprises a transgene and a promoter, and wherein the first expression cassette is
inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is
inserted in a region of the adenoviral vector that is compatible with vector replication.
2. A simian adenoviral vector comprising two expression cassettes, wherein each expression
10 cassette comprises a transgene and a promoter, and wherein the first expression cassette is
inserted in the E1 region of the simian adenoviral vector, and the second expression cassette is
inserted in the E3 region, between the stop codons of L5 and E4 (the "HE1" region) or between
the end of the ITR and the cap site of E4 mRNA (the "HE2" region) of the simian adenoviral vector.
- 15 3. The simian adenoviral vector of Claim 2, wherein the second expression cassette is
inserted in the E3 region of the simian adenoviral vector.
4. The simian adenoviral vector of Claim 2, wherein the second expression cassette is
inserted in the HE1 region of the simian adenoviral vector.
- 20 5. The simian adenoviral vector of Claim 2, wherein the second expression cassette is
inserted in the HE2 region of the simian adenoviral vector.
6. The simian adenoviral vector of any preceeding claim, wherein the vector is a chimpanzee
25 adenoviral vector.
7. The simian adenoviral vector of any preceeding claim, wherein the vector is an
adenovirus.
- 30 8. The simian adenoviral vector of Claim 7, wherein the vector is ChAd155.
9. The simian adenoviral vector of Claim 7, wherein the vector is ChAd83.

10. The simian adenoviral vector of any preceeding claim, wherein the first expression cassette comprises a human CMV or an enhanced human CMV promoter.

11. The simian adenoviral vector of any preceeding claim, wherein the second expression cassette comprises a human CMV or an enhanced human CMV promoter.

12. The simian adenoviral vector of Claim 10 or 11, wherein the enhanced hCMV promoter has a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity to SEQ ID NO: 6.

13. The simian adenoviral vector of any one of Claims 10 to 12, wherein, the promoter comprises or consists of a nucleic acid sequence of SEQ ID NO: 6.

14. The simian adenoviral vector of any preceeding claim, wherein the first and second expression cassettes comprise different promoters.

15. The simian adenoviral vector of any preceeding claim, wherein the adenoviral vector is capable of infecting a mammalian cell.

16. The simian adenoviral vector of any preceeding claim, wherein the first and/or second expression cassette further comprises a posttranscriptional regulatory element.

17. The simian adenoviral vector of claim 16, wherein the posttranscriptional regulatory element is a Woodchuck Hepatitis Postranscriptional Regulatory Element.

18. A composition comprising a simian adenoviral vector of any preceding claim and a pharmaceutically acceptable excipient.

19. A simian adenoviral vector or composition according to any preceding claim for use as a medicament.

20. A simian adenoviral vector or composition according to any preceding claim for use as a vaccine.


21. A simian adenoviral vector or composition according to any preceding claim for the therapy or prophylaxis of a disease.

22. A method of inducing an immune response in a subject comprising administering the
5 simian adenoviral vector or composition according to any preceding claim to the subject.


1/27

FIG. 1


(i) RC1



(ii) RC3:




(iii) RC2:




2/27

FIG. 2A




3/27

FIG. 2B




4/27

FIG. 3A



5/27


FIG. 3B




6/27

FIG. 4

(a)




(b)



7/27


FIG. 5



8/27


FIG. 5

(c)




9/27

FIG. 6




10/27

FIG. 7




11/27

FIG. 8




12/27

FIG. 9




13/27

FIG. 10




14/27

FIG. 11




15/27

FIG. 12A




16/27

FIG. 12B




17/27

FIG. 13A




18/27

FIG. 13B




19/27

FIG. 14A




20/27

FIG. 14B




21/27

FIG. 15A




22/27

FIG. 15B




23/27

FIG. 15C




24/27

FIG. 16A




25/27

FIG. 16B



26/27

FIG. 17



27/27

FIG.18




FIG. 7

